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ABSTRACT  
 
Background In England there is a comprehensive framework of tobacco 
control policies to reduce smoking-related harm. Policy evaluation helps to 
ascertain how policies may be improved so that they have the greatest 
impact; ineffective policies can be dropped or improved, while effective 
policies can be kept and improved further in order to optimise their impact. 
The evaluation of tobacco control policy requires high quality and timely 
data on smoking and smoking cessation behaviour. Time series analysis 
(TSA) is a robust way of evaluating policy, as it takes existing trends into 
account, but requires frequently collected data in large samples over long 
time periods. 
The aims of this thesis were to investigate the suitability of a range 
of existing data sources for evaluating the impact of tobacco control 
policies in England on quitting behaviour, validate potentially suitable 
measures, and use validated measures to evaluate the impact of recent 
tobacco control initiatives in England using TSA. 
Methods A range of data sources which provide information on smoking 
cessation behaviour were analysed to determine their adequacy for 
evaluating tobacco control policies, and previously unvalidated measures 
were validated. Different approaches to TSA ± interrupted time series 
analysis and multiple time series analysis - were employed to evaluate the 
impact of the introduction of a new smoking cessation medication, 
varenicline, the broadening of the indications for nicotine replacement 
therapy (NRT) to include people with cardiovascular disease and 
adolescents, and the effect of anti-tobacco mass media campaigns on 
quitting behaviour.  
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Results Two key indicators of quitting behaviour are quit attempts and 
smoking prevalence; however, there are currently no frequently collected 
data from large enough samples covering a long time period on these 
measures. Survey data are generally not suitable for policy evaluation 
because they are infrequently carried out and often have small sample 
sizes, making it difficult to detect small and transient changes in 
behaviour. In contrast, routine sources of data such as electronic medical 
records data are often frequently collected in large samples over long time 
periods. A validation study showed that primary care data from The Health 
Improvement Network are an accurate source of data on prescribing of 
smoking cessation medication. Time series analyses of these data showed 
that both the introduction of varenicline, and the broadening of the 
indications for NRT, did not increase rates of prescribing for smoking 
cessation medication. Another study found that tobacco control mass 
media campaigns appear to be more effective at triggering quitting 
behaviour than pharmaceutical company NRT campaigns. 
Conclusions Although there are significant gaps in the existing data 
available, there are some high quality time series data which can be used 
to evaluate the impact of tobacco control policies in England. There is a 
need for regular collection of data on key indicators of quitting behaviour, 
and the use of time series analysis in policy evaluation can play a vital role 
in strengthening the evidence for the effectiveness of policies, both in 
tobacco control, and in other areas of public health. The time series studies 
in this thesis suggest that recent changes to the availability of 
pharmacological smoking cessation aids have not had a significant impact 
on public health, and that recent cuts in tobacco control advertising are 
likely to have reduced quitting behaviour.  
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CHAPTER 1:  INTRODUCTION
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1.1 The health costs of smoking 
Smoking killed 100 million people worldwide in the twentieth 
century.1 If current trends in smoking persist, smoking will kill one billion 
people in the 21st century.2  
Cigarette smoking is the cause of approximately one in five deaths 
in Britain, which equated to an estimated 106,000 deaths per year 
between 1998 and 2002.3, 4 Half of all regular smokers, and possibly as 
many as two thirds, will die as a result of their addiction.2 The proportional 
impact of smoking is greatest in younger age groups and in men. One in 
three deaths in males aged 35±64 is caused by smoking.3  A 35 year old 
male smoker shortens his life expectancy by approximately seven years; 
the corresponding figure for women is six years.3 
The list of diseases demonstrated to be caused by smoking 
continues to lengthen. Recent reports about the health consequences of 
smoking have added diseases for which there was previously weak or no 
evidence to the list.5, 6 This section summarises the diseases caused by 
smoking. 
1.1.1 Cancer 
Cancer is the most common cause of death in the UK, causing one 
in four deaths.7 More than one in three people are diagnosed with cancer 
at some point in their life.7 In 2009, over 260,000 people in England were 
diagnosed with cancer.8 Relative survival for many cancers is very poor. 
For example, the 10 year relative survival rate for lung cancer in England 
and Wales has been estimated to be 5.3%.9 
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Smoking increases the risk of cancer mortality between two- and 
fourfold and in 2007 around 28% of over 155,000 cancer deaths in the UK 
were attributed to smoking.10,11 Smoking has been shown to increase the 
risk of 19 cancers; these associations are summarised for the most 
common of these cancers below.12  
Lung  
Lung cancer is the most common form of cancer; there were over 
33,000 new diagnoses of lung cancer in England in 2009.8 Smoking causes 
84% of lung cancer.3, 7 Around a quarter of lung cancers in non-smokers 
are caused by passive smoking.7 Smokers are 10 times more likely to die 
from lung cancer than non-smokers.10 In heavy smokers the risks are even 
higher: they are 15 to 25 times more likely to die from lung cancer  than 
non-smokers.10  
Bladder 
There were over 6000 newly diagnosed cases of bladder cancer in 
men in England in 2009, and nearly 2500 in women.8 Smoking more than 
doubles the risk of dying from bladder cancer, and causes nearly 30% of 
deaths caused by the disease.13, 14 
Pancreas 
Pancreatic cancer is a rapidly fatal form of cancer accounting for 
approximately 3% of all cancers in England and Wales.7  There were nearly 
7000 new cases of pancreatic cancer in England in the year 2009.8 Current 
smokers are approximately twice as likely to die from pancreatic cancer as 
never smokers.13, 14 
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Oesophagus 
There were over 6500 new registrations of oesophageal cancer in 
England in 2009.8 This type of cancer is strongly associated with smoking, 
which, when combined with alcohol, has a multiplicative effect.7 At 10%, 
the survival rate for oesophageal cancer is extremely low, although it has 
trebled since the early 1970s.9  
Stomach 
In 1980 stomach cancer was the most common cancer in the world; 
its incidence has declined substantially in recent decades.7 Current 
smokers are approximately twice as likely as non-smokers to get stomach 
cancer.15-18 
Kidney 
There were nearly 6500 new diagnoses of kidney cancer in England 
in 2009.8 Smoking has been identified as a major risk factor for renal cell 
carcinoma and cancer of the renal pelvis. Current smokers are 50% more 
likely to get kidney cancer than non-smokers.19 The risk is higher in heavy 
smokers, who double their risk of kidney cancer compared with non-
smokers.20 
Bowel 
Bowel (colorectal) cancer is the third most common cancer in men, 
after prostate and lung cancer, and the fourth most common in women in 
England. In 2009 approximately 30,000 new cases of bowel cancer were 
diagnosed in England.8 
The association between bowel cancer and smoking has only 
recently been demonstrated, as early studies suggested that smoking was 
not an important risk factor. However, there is an increasing body of 
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evidence, which has been able to take account of the long lag from the 
exposure to smoking to the onset of the disease, and the fact that 
colorectal cancer is common in non-smokers as well as smokers, which 
suggests that smoking is associated with both colon and rectal cancers.5 
Lip, Mouth and Pharynx 
In 2009 there were around 3500 and 2000 new cases of cancers of 
the lip, mouth and pharynx in men and women in England respectively.8 
Pharyngeal cancer is relatively rare, but highly associated with 
smoking: Smokers have a sevenfold increased risk of cancer of the 
pharynx compared with non-smokers.19 The risk of oral cancers is 
increased more than threefold by smoking.19 
1.1.2 Cardiovascular Disease 
In 2005 there were about 100,000 deaths from coronary heart 
disease (CHD), 58,000 from stroke and 50,000 deaths from other types of 
cardiovascular disease (CVD) in the UK, accounting for over a third of all 
deaths.21 Cigarette smoking significantly increases the risk of CVD, as well 
as aggravating existing CVD conditions.13, 22 Smoking causes one in seven 
deaths from heart disease.23  The risk of CVD increases with increased 
exposure; however, even very light smokers have a much higher risk of 
CVD than non-smokers.24-27 
Overall, smokers are 70% more likely to die from CHD than non-
smokers.28 Heavy smokers are almost three times as likely to die from 
CHD than non-smokers.28  
The risk of sudden cardiac death is two to four times higher in 
smokers than non-smokers. 28 The risk of sudden cardiac death increases 
with the number of cigarettes smoked per day.28 
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 Current smokers also have a two- to fourfold increased relative risk 
of stroke compared with non-smokers.29, 30 People who smoke 40 or more 
cigarettes per day are nearly twice as likely to die from stroke than those 
who smoke fewer than 10 cigarettes per day.29 
1.1.3 Respiratory Disease 
In 2007 there were nearly 80,000 deaths from respiratory disease 
in the UK, including approximately 30,000 deaths from COPD.11 Of all 
deaths from respiratory disease, 34% were attributable to smoking.11 
It has been estimated that 25% of smokers develop clinically 
significant COPD, and up to 40% develop some symptoms associated with 
the disease.31 However, it has also been suggested that most long-term 
smokers probably get COPD, but that it is often not sufficiently severe to 
be diagnosed, or that its diagnosis is missed if patients die from another 
disease, such as heart disease.32 An estimated 69% of COPD deaths in 
men in the UK, and 77% in women, are attributable to smoking.11 
However, in the USA up to 80-90% of COPD deaths have been estimated 
to be due to smoking.33   
Smoking is also associated with other respiratory diseases, such as 
pneumonia (twofold risk in smokers compared with non-smokers, and 
threefold risk in heavy and long-term smokers) and tuberculosis (threefold 
risk in smokers compared with non-smokers).34, 35 
1.1.4 Passive smoking 
Smoking does not only pose a threat to smokers themselves, but 
also to those who are exposed to their second-hand (SHS) smoke. It has 
been estimated that in 2003 11,000 adults in the UK died as a result of 
passive smoking in the home, and a further 617 from the effects of passive 
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smoking at work.36 Because the majority of passive smoking-related 
deaths occur within the home, legislation prohibiting smoking in public 
places, which was introduced in the UK in 2006 and 2007, has only a 
limited, albeit an important effect on the prevention of deaths due to 
passive smoking. In particular, it is unable to protect a group that is 
particularly vulnerable to the effects of passive smoking: children. In 
children, passive smoking leads to over 165,000 new episodes of disease, 
300,000 primary care contacts, 9500 hospital admissions, at least 200 
cases of bacterial meningitis, and about 40 sudden infant deaths each 
year.37  
1.1.5 Smoking in pregnancy 
3DVVLYHVPRNLQJLVQRWWKHRQO\PHDQVE\ZKLFKDSHUVRQ¶VVPRNLQJ
can harm others. Smoking in pregnancy can cause harm to the unborn 
child. Maternal smoking has been associated with low birth weight (which, 
in turn, can lead to neo- and perinatal health problems), premature birth, 
congenital malformations, spontaneous abortion and perinatal mortality. 37-
39 Passive smoking in pregnancy is also associated with increased risk of 
stillbirth and congenital malformation.40 The children of mothers who 
smoke in pregnancy have an increase in risk of sudden infant death 
syndrome (SIDS), as well as a higher risk of respiratory illness and otitis 
media.38, 41, 42  Exposure to secondhand smoke in early childhood also 
increases the risk of respiratory illness, otitis media and sore throats.43, 44 
1.2 The economic costs of smoking 
1.2.1 Individual costs 
Smoking is associated with economic costs, as well as a public 
health burden. Smoking addiction comes with a heavy financial burden for 
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the individual smoker. Smoking 20 cigarettes per day costs between £1600 
and £1800 per year.45 
More deprived smokers spend a higher proportion of their income 
on smoking than better off smokers. In 2008, the poorest 10% of 
households spent an average of 2.21% of their weekly expenditure on 
cigarettes; for the richest 10% the corresponding figure was 0.35%.46  
1.2.2 Costs to society 
The cost of smoking to the taxpayer is also considerable. In the UK, 
the treatment of smoking-related disease has been estimated to cost the 
National Health Service (NHS) £5.2 billion per year.47 The cost of treating 
childhood illnesses caused by passive smoking has been estimated at £410 
million per year.48 An estimated 34 million days are lost to absenteeism 
resulting from smoking-related disease in England and Wales per year.48 It 
has been suggested that the societal costs of smoking in the UK outweigh 
the income from tobacco taxation.49 
1.3  Trends in smoking in the UK 
There has been relatively slow decline in smoking prevalence in the 
UK since the mid-1990s. The prevalence of cigarette smoking fell rapidly in 
the 1970s and early 80s, from 45% in 1974 to 35% in 1982. The rate of 
decline was much slower until the mid-1990s, when it levelled off at 
approximately 27%. Since the start of the 2000s, there has been an 
annual decline of around one percentage point. In 2009, 21% of British 
adults smoked.50 
1.3.1 By sex 
Historically, in Britain, cigarette smoking has been higher in men 
than in women; in 1974, the prevalence of smoking in men was 51%, 
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while in women it was 41%.51 However, the gap in prevalence between 
men and women has narrowed over recent decades; in 2009, the General 
Lifestyle Survey (GLF) found that 22% of men in the UK were smokers, 
compared with 20% of women, but the difference was not statistically 
significant.50  
1.3.2 By age 
Since the early 1990s, the prevalence of smoking has been highest 
in adults aged 20-24. In 2009, however, the prevalence in this group was 
26%, and very similar in 25-49 year olds, at 25%.50 Adult smoking 
prevalence is lowest in those over 60, at 14%.50 
Most smokers begin smoking as teenagers. The prevalence of self-
reported regular smoking (at least one cigarette per week) among 11-15 
year olds in England was 5% in 2010.52 This has declined since the start of 
the decade, when prevalence in this group was 10%.52 The prevalence of 
smoking in this age group rapidly increases with age. In 2010, smoking 
prevalence in 13 year olds was 5%; in 15 year olds, it was 17%.52 
1.3.3 By socioeconomic status 
There is a marked social gradient in the prevalence of smoking. In 
2009, the prevalence of cigarette smoking in manual groups was 26%, 
compared with 16% in non-manual groups.50 Smoking is the largest 
identified cause of social inequalities in health, and recent reduction in 
smoking prevalence has occurred predominantly in the more 
socioeconomically advantaged.53 As a result, socioeconomic disparity in 
smoking prevalence and the prevalence of smoking-related mortality and 
morbidity has grown.39   
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1.3.4 In pregnancy 
Survey data suggest that the rate of smoking in pregnancy has 
fallen in recent years, but a substantial proportion of mothers continue to 
SXW WKHLU XQERUQ FKLOG¶V KHDOWK DW ULVN E\ VPRNLQJ ,Q the 2010 Infant 
Feeding Survey (IFS) 26% of mothers in the UK reported smoking in the 
year before or during pregnancy, although evidence suggests that this 
survey, which lacks a biochemical measure to validate smoking status, 
underestimates the true level.54, 55 The survey found that 12% of expectant 
mothers continued to smoke throughout their pregnancy. Data on smoking 
status at the time of delivery (SSATOD) from the Department of Health 
also suggest that the IFS figures are underestimates: according to these 
data, 13.5% of mothers were smoking at delivery.54 The IFS estimated 
that the percentage of mothers smoking throughout pregnancy in the UK 
fell from 20% to 12% between 2000 and 2010.54  
The survey also found that in the UK, 40% of mothers in routine 
and manual occupations smoked before or during pregnancy, compared 
with 14% in managerial and professional occupations.54 20% of mothers in 
routine and manual occupations smoked throughout pregnancy.54 Young 
mothers were also more likely to smoke during pregnancy: 35% of 
mothers aged 20 and under smoked throughout pregnancy.54  
1.3.5 Awareness and attitudes 
Around two thirds to three quarters of smokers in Britain say that 
they want to quit smoking.56 However, less WKDQDTXDUWHUVD\WKH\µYHU\
PXFK¶ZDQWWRGRVR56 In Britain, 77% of smokers say they intend to stop 
smoking at some point, yet only 12% say they intend to do so in the next 
month.56 
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The majority (85%) of smokers who want to stop smoking have at 
least one health reason for wanting to quit.57 Nonetheless, survey 
LQIRUPDWLRQ DERXW VPRNHUV¶ NQRZOHGJH DV WR WKH KHDOWK ULVNV RI VPRNLQg 
suggests that the limited intention of British smokers to quit smoking may 
be attributable to a lack of awareness of the specific risks of smoking. A 
significant proportion of smokers in the UK continue to be unaware of the 
extent of the risks associated with smoking. Only 39% think smoking is the 
biggest cause of premature deaths in the UK, compared with 48% of ex-
smokers.56 10% are not aware that smoking causes heart disease and 
30% do not know it causes stroke.56 There is therefore a continued need to 
warn of the dangers of smoking in the UK. 
1.4  The importance of smoking cessation 
1.4.1 Individual gains 
The health benefits of stopping smoking are overwhelming; 
smoking cessation adds years to life, regardless of the age at which people 
quit.2, 58 Cessation at age 60, 50, 40, or 30 years has been estimated to 
improve life expectancy by approximately 3, 6, 9, or 10 years respectively 
and, although the risk of some smoking-related diseases tends not to 
return to the level of lifelong non-smokers, the risk in long-term quitters is 
similar to that in never smokers.2, 59  
4XLWWLQJ VPRNLQJ GHFUHDVHV DQ LQGLYLGXDO¶V ULVN RI OXQJ FDQFHU
compared with continuing smokers. The risk is reduced regardless of the 
age at which people quit, but the risk reduction is increased if the smoker 
stops at a younger age, as demonstrated in Figure 1-1.60 
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Figure 1-1. Effects of stopping smoking at various ages on the 
cumulative risk (%) of death from lung cancer up to age 75, at 
death rates for men in United Kingdom in 1990 
 
Source: Peto et al. (2000)60 
  
13 
 
 
The risk of other cancers also decreases after people have quit 
smoking, and tends to decrease towards the risk of never-smokers over 
time, although for many cancers the risk never returns to the level of that 
in never-smoker. For example, the risks of lip, mouth and pharyngeal 
cancers decrease with time after cessation, although it can take two 
decades for the risk to return to close to that of never-smokers. Smoking 
cessation reduces the risk of pancreatic, kidney and bladder cancer, as well 
as stomach cancer and laryngeal cancer.16, 18, 59 The evidence of the 
decrease in risk for some other cancers is inconsistent or inadequate.59 
 
Smoking cessation also rapidly leads to a decrease in the risk of 
CHD. This risk continues to decline, albeit slowly, after the first year 
following cessation, and reaches a level comparable to that in never-
smokers around 15 years after cessation.59 Quitting smoking also reduces 
the risk of other types of cardiovascular disease including cerebrovascular 
disease, peripheral arterial disease and aortic aneurysm.59 For example, 
the risk of stroke decreases significantly two years after quitting; after five 
years, quitters have the same lower risk of stroke as never smokers.29 
 
Quitting smoking is important for respiratory health, both for 
patients with and without existing respiratory disease. Smoking cessation 
is vital in preventing and decreasing the progression of COPD and 
respiratory symptoms.61-63 In people without respiratory disease, smoking 
cessation has been shown to improve lung function by  5% within just a 
few months of quitting and reduces the risk of a first-time COPD 
diagnosis.6, 64  
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1.4.2 Population gains 
The population level effects of the reduced health risk in individuals 
who quit smoking are substantial. As demonstrated by Figure 1-2, unless 
current smokers quit, tobacco deaths will rise dramatically worldwide in the 
next 50 years. If adult consumption halves by 2020, tobacco deaths will 
continue to rise, but at a much lower rate. Further to this, getting current 
smokers to quit now will reap benefits more quickly than preventing young 
people from taking up smoking; the vast majority of the projected 
smoking-related deaths worldwide for the first half of the current century 
are those of current smokers.65  
Increasing the rate at which smokers stop smoking and remain 
abstinent is a fundamental aim of tobacco policy in the UK and elsewhere, 
and, in industrialised countries is proposed as the most important means of 
reducing morbidity and premature death over the next 20 years.2  
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Figure 1-2. Estimated cumulative tobacco deaths 1950±2050 with 
different intervention strategies 
 
 
Peto and others estimate 60 million tobacco deaths between 1950 and 
2000 in developed countries. The figure estimates an additional 10 million 
between 1990 and 2000 in developing countries. It assumes no tobacco 
deaths before 1990 in developing countries and minimal tobacco deaths 
worldwide before 1950. Projections for deaths from 2000 are based on 
Peto (personal communication [1998]). Sources: Peto, Richard and others. 
1994. Mortality from Smoking in Developed Countries 1950±2000. Oxford 
University Press; and Peto, Richard, personal communication. 
 
Source: World Bank ± Curbing the Epidemic (1999) 65  
1.5  The development of tobacco control policy in the UK 
The previous sections have outlined the importance of encouraging 
smokers to quit and preventing new smokers from starting to smoke. 
These are the primary aims of tobacco control policy. It also aims to 
reduce exposure to environmental tobacco smoke (ETS) and smoking-
related health inequalities. In the UK, tobacco control policy is primarily 
determined by the government, with additional influence in terms of both 
policy and legislation from the European Union and the Framework 
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Convention on Tobacco Control. The role of each of these in shaping 
tobacco control policy in the UK is described in this section. 
1.5.1 Government tobacco control policy in the UK 
In 1998 the UK government published the first White Paper on 
tobacco control, µSmoking Kills¶.66 It defined a strategy which has shaped 
the comprehensive set of tobacco control policies implemented in the UK 
since then. The majority of the decrease in smoking prevalence in the UK 
in thHSDVWGHFDGHLVDWWULEXWHGWRµ6PRNLQJ.LOOV¶. Its objectives were to: 
x Reduce smoking in children and young people 
x Help adults to stop smoking 
x Reduce smoking in manual groups as a step towards reducing 
inequalities 
x Offer particular help to pregnant smokers 
It detailed a range of policy measures, most of which were 
implemented and remain in place today. These included: 
x A ban on tobacco advertising and sponsorship  
x Tobacco taxes rises 
x Enforcement of under-age sales 
x Reducing point-of-sale tobacco advertising  
x Introducing smoking cessation services 
x Facilitating access to smoking cessation medication 
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Devolution since 1998 means that tobacco control policy is largely 
dealt with separately in England, Scotland, Wales and Northern Ireland, 
although some policy areas related to tobacco control, such as taxation, 
remain the responsibility of the UK government. However, µSmoking Kills¶ 
related to the whole of the UK, and as such many of the same steps to 
reduce the burden of smoking have been taken throughout the UK, albeit 
at somewhat different times. 
,Q0DUFKDQHZWREDFFRFRQWUROVWUDWHJ\µ$7REDFFR&RQWURO
3ODQIRU(QJODQG¶ZDVSXEOLVKHG67 It committed to:  
x implementing legislation to end tobacco displays in shops 
x looking at whether the plain packaging of tobacco products 
could be an effective way to reduce the number of young 
people who take up smoking and to support adult smokers who 
want to quit, and consulting on options by the end of the year 
x continuing to defend tobacco legislation against legal challenges 
by the tobacco industry, including legislation to stop tobacco 
sales from vending machines from October 2011 
x continuing to follow a policy of using tax to maintain the high 
price of tobacco products  
x promoting effective local enforcement of tobacco legislation 
x encouraging more smokers to quit by using the most effective 
forms of support, through local stop smoking services 
x publishing a three-year marketing strategy for tobacco control 
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The implementation of this plan is in its infancy, but the measures 
that have already been taken are described later in this chapter. 
1.5.2 The EU and tobacco control in the UK 
Health policy and the organisation, financing and management of 
healthcare are a national responsibility of EU member states. As such, the 
EU has limited powers in the area of tobacco control as well as broader 
health policy. It nonetheless has substantial influence on tobacco control 
policy in the UK and other Member States.  
ArticOHRIWKH/LVERQ7UHDW\XQGHUOLQHVWKH(8¶VUROHLQIRVWHULQJ
cooperation and coordination in health policy between member states. Its 
most notable steps in this regard related to tobacco control have been two 
Council Recommendations, one on the prevention of smoking and on 
initiatives to improve tobacco control, and one on smokefree 
environments.68, 69 These are non-binding agreements, the latter of which 
calls for Member States to implement legislation on smokefree public 
places, develop methods to protect children from ETS and encourage 
smoking cessation. The former calls for Member States to introduce 
measures to reduce sales of cigarettes to minors, prohibit most types of 
tobacco advertising, prevent exposure to ETS in workplaces and public 
places, reduce prevalence and use cigarette price as a smoking deterrent. 
The EU has also funded an EU-wide stop smoking campaign targeted at 
young people, HELP. 
Due to the broad scope of tobacco control policy in the UK (which is 
described in detail in section 1.6), where smokefree legislation, mass 
media campaigns and other policies aimed at reducing smoking are in 
place, and the lack of power it has in health policy, it may appear that the 
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EU has a limited role in tobacco control in the UK. However, its most 
substantial contribution to tobacco control has come in other policy areas. 
The EU treaty states a requirement that all EU policies should protect 
health and, as a result, EU legislation has frequently incorporated aspects 
of tobacco control. Most notably, the EU single market rules have 
permitted (though not without resistance from the tobacco industry)70 the 
EU-wide implementation of legislation banning tobacco advertising 
(2003/33/EC) and on the manufacture, packaging and labelling of tobacco 
products (2001/37/EC, known as the Tobacco Products Directive (TPD), 
which is currently under review).71, 72 
1.5.3 The WHO Framework Convention on Tobacco Control and 
MPOWER 
Tobacco control policy in the UK and the EU is in line with the 
tobacco control policy framework set out by the World Health Organisation 
Framework Convention on Tobacco Control (FCTC). The FCTC is a global 
pXEOLF KHDOWK WUHDW\ WKH REMHFWLYH RI ZKLFK LV ³to protect present and 
future generations from the devastating health, social, environmental and 
economic consequences of tobacco consumption and exposure to tobacco 
smoke´73 It was signed by the UK in 2003 and came into force in 2005. 
The convention calls for parties, inter alia, to: 
x enact and undertake comprehensive bans on tobacco 
advertising, promotion and sponsorship 
x ban misleading and deceptive terms on cigarette packaging 
such as µlight¶, µlow-tar¶ and µmild¶  
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x implement rotating health warnings on tobacco packaging that 
cover at least 30 percent (ideally 50 percent or more) of the 
display areas  
x protect people from tobacco smoke exposure on public 
transport, and in indoor work and public places 
x adopt or maintain taxation policies aimed at reducing tobacco 
consumption  
x combat illicit trade in tobacco products 
Further to this, in 2008 the World Health Organisation (WHO) 
published a report on the worldwide tobacco epidemic which proposed six 
policies to be implemented in order to achieve comprehensive and effective 
tobacco control, collectively named MPOWER.1 These policies are in line 
with the framework set out by the WHO FCTC. 
x Monitor tobacco use and prevention policies 
x Protect people from tobacco smoke 
x Offer help to quit tobacco use 
x Warn about the dangers of tobacco, 
x Enforce bans on tobacco advertising, promotion and 
sponsorship 
x Raise taxes on tobacco 
These policies, and others, have been implemented in the UK in 
recent years. 
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1.6 Recent tobacco control policy in the UK 
The key priorities for tobacco control are consistent at the national, 
EU and international levels, and thus the UK has been able to develop a 
comprehensive framework for tobacco control, the main elements of which 
are described in this section. 
1.6.1 Smokefree legislation 
As outlined in section 1.1, the risks posed by SHS exposure are 
high. The arguments for smokefree environments are therefore strong. 
In March 2004, Ireland became the first country in the world to ban 
smoking in the majority of work and public places. A study by Mulcahy et 
al. showed that, following the implementation of the ban, ambient nicotine 
air concentrations in a sample of city centre bars decreased by 83%.  A 
survey of hotel workers carried out as part of the same study showed that 
their self-reported exposure to SHS at work fell from a median of 30 hours 
per week to zero.74 Smokefree workplaces can reduce the prevalence of 
smoking, and may encourage the adoption of smokefree homes.75, 76  
Since July 2007, smoking has been prohibited in all enclosed and 
substantially enclosed work and public places in England. Smokefree 
legislation came into force in Scotland in March 2006 and in Wales and 
Northern Ireland in April 2007. 
Smokefree legislation in the UK appears to have been successful, to 
the extent that it is popular, widely complied with, has improved air 
quality, reduced passive smoke exposure and has had a positive impact on 
health outcomes.37, 77, 78 There is also some evidence that smokefree 
legislation has had a positive effect on quitting behaviour, although no 
decrease in UK smoking prevalence has been observed since it was 
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implemented.50, 79, 80 Nonetheless, it has limitations. The majority of 
passive smoking occurs within the home, and other non-public places, such 
as cars. Tackling exposure to SHS in these settings, particularly that of 
children, is a pressing challenge for policy makers; policies to address SHS 
exposure in children may be developed within the next years.37 
1.6.2 Mass media campaigns 
International evidence has shown that mass media campaigns can 
cause positive changes or prevent negative changes in a range of health 
behaviours.81 Tobacco control campaigns, which are usually funded by 
governments or charities, have been shown to increase smoking cessation 
and reduce smoking prevalence.82-87 The existing studies are, however, 
heterogeneous, in terms of both the nature and intensity of the media 
campaigns and the populations studied, and the quality of the studies is 
variable.82, 83, 86 In 2008 the UK government spent over £15 million on anti-
smoking advertising. Campaigns have conveyed the dangers of smoking, 
the implementation of smokefree legislation and smoking cessation 
services, with the aim of changing smoking behaviour. Some are targeted 
directly at encouraging people to quit and try to help to enable quit 
attempts by aGYHUWLVLQJ WKH VHUYLFHV DYDLODEOH WR VXSSRUW SHRSOH¶V TXLW
attempts. However, this spending has recently come under threat from 
government spending cuts; a freeze on all Department of Health-funded 
public health mass media campaigns was imposed in April 2010. Although 
tobacco control campaigns have been re-introduced since the publication of 
the tobacco control plan in 2011, the rate of funding is lower than prior to 
the cut.88 
Government (and charity-funded) mass media campaigns are not 
the only source of anti-tobacco advertising in the UK. Pharmaceutical 
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company-funded advertisements for nicotine replacement therapy (NRT) 
provide information on different types of NRT with the primary aim of 
increasing sales of NRT. By also conveying the health benefits of quitting 
these adverts may also increase the number of people who want to quit 
smoking and influence quitting behaviour. There is some international 
evidence that pharmaceutical company advertising can have a positive 
effect on NRT sales.82, 89, 90 In addition, the aforementioned EU-funded 
HELP campaign, aimed at getting young people to stop smoking and 
discouraging them from taking up smoking, has had a high internet and 
television presence in recent years. 
There is scant evidence of the effectiveness of anti-smoking mass 
media campaigns in the UK. Chapter 7 of this PhD thesis is a study 
exploring the impact of mass media campaigns on quitting behaviour in 
England.  
1.6.3 Health warnings 
Evidence from the UK and elsewhere suggests that health warnings 
on tobacco products are another measure that raise awareness of the risks 
of smoking and influence quitting behaviour, although most of the 
evidence is based on survey data which may be prone to recall bias.91, 92 
Health warnings have been displayed on cigarette packs in the UK since 
1971. The EU Tobacco Products Directive, enforced in the UK since 2002, 
requires all tobacco products to display a general health warning covering 
at least 30% of the front of the pack, and an additional warning covering 
at least 40% of the back of the pack.93 The Tobacco Products Directive, 
inter alia, also lays down maximum tar, nicotine and carbon monoxide 
yields for cigarettes manufactured or sold in the UK, and sets out 
regulations for labelling cigarette packs and other tobacco products.  
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In May 2007 Belgium became the first EU country to introduce 
compulsory graphic pictorial health warnings on tobacco packaging. The UK 
introduced compulsory pictorial health warnings, which survey evidence 
suggests are more effective than text warnings, in October 2008.94, 95 
1.6.4 Bans on tobacco advertising, promotion and sponsorship 
Highly effective marketing, through advertising and sponsorship, is 
LQWHJUDO WR WREDFFR FRPSDQLHV¶ PDUNHWLQJ VWUDWHJLHV LW HQFRXUDJHV QRQ-
smokers, particularly young people, to take up smoking, and discourages 
current smokers from quitting. Advertising has been shown to have a 
positive effect on tobacco consumption, although the evidence is 
inconsistent.96, 97 Evidence also suggests that advertising bans can be 
effective in reducing tobacco consumption, but to do so, must be 
comprehensive. Saffer et al. suggest that banning advertising in just one 
or a small group of advertising media leads to tobacco companies diverting 
resources to different marketing channels, thus preventing a reduction in 
advertising expenditure and tobacco consumption.97 
Television advertising for tobacco products was banned in the UK in 
1965 under the Television Act 1964, pre-empting a now amended EU 
Directive which did the same in 1989 (Television without Frontiers 
Directive (89/552/EEC). This directive was replaced by the Audiovisual 
Media Services Directive (2007/65/EC) adopted in December 2007).72, 98-100 
The Tobacco Advertising and Promotion Act 2002 banned most remaining 
tobacco advertising in the UK from 2003.101 Tobacco advertising in the 
press and on billboards was banned from February 2003 and direct 
marketing from May 2003. Tobacco company sponsorship was phased out 
from July 2003, in OLQH ZLWK WKH (8¶V Tobacco Advertising Directive 
(2003/33/EC) which banned cross-border tobacco advertising in all media 
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other than television (which had already been banned) and at events 
involving several Member States, such as Formula One races.71 
Currently, however, tobacco companies continue to have other 
means of advertising their products in the UK: point of sale (POS) tobacco 
displays and branded tobacco packaging. Both of these have been 
identified as important marketing tools, particularly in attracting young 
smokers.102, 103 In England, POS displays are set to be banned in large 
shops from April 2012, and in all other shops from April 2015. In Scotland, 
legislation to ban POS displays has been passed, but its implementation is 
currently being hindered by legal challenges. In Wales, a consultation of 
POS has taken place but final regulations and a date for implementation 
have not been announced. The Northern Ireland Assembly has stated that 
it intends to introduce a ban from spring 2012. No countries in the UK 
currently have plans to introduced plain packaging, but the government 
stated that it will consult on this measure in the tobacco control plan, and 
has announced that it will launch a consultation in spring 2012.67 
1.6.5 Raising taxes on tobacco 
Raising the price of tobacco has been suggested as the single most 
effective means of reducing tobacco consumption.104 Evidence also 
suggests that it is the most effective way to reduce smoking-related 
inequalities in health.105 It is estimated that, globally, on average, a 10% 
increase in tobacco price will reduce consumption by 4%; that is, tobacco 
has a price elasticity of -0.4%. 106 Poor smokers and young smokers are 
more responsive to price, and therefore a price increase of 10% may 
reduce consumption in these groups by more than 4%.106 In the UK, 
tobacco has been estimated to have a price elasticity of -0.5%.107  
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In the UK, there have been rapid increases in tobacco price since 
the 1990s as a result of increases in the tax on tobacco. In 1993 a tobacco 
tax inflator was introduced, thus tobacco tax rose by 3% and then 5% 
above the rate of inflation. The inflator was stopped in 2001 following 
concerns about the contribution of increased cigarette prices to smuggling 
of tobacco products into the UK, but was re-introduced in April 2010. Tax 
currently constitutes approximately 78% of the price of cigarettes in the 
UK and, in 2008, the UK had the highest price of cigarettes in Europe.104, 
108 
1.6.6 Combating illicit tobacco 
In the late 1990s, an estimated 20-30% of the market for tobacco 
in the UK was made up of illegally imported cigarettes.109, 110 Illicit tobacco 
undermines tobacco control policy by reducing the price of cigarettes, thus 
increasing demand. Illicit tobacco also contributes to tobacco-related 
health inequalities; the most disadvantaged smokers are twice as likely to 
buy illicit tobacco as the most affluent.111 
Since 2000, HM Revenue and Customs has taken measures to 
reduce tobacco smuggling in the UK, including additional customs officers, 
additional specialist investigators and intelligence staff; additional x-ray 
scanners; tougher sanctions and penalties; and a public awareness 
campaign.  Recent estimates suggest that about 10% of the market is now 
smuggled.112 However, the illicit market share for hand rolled tobacco 
(HRT) remains large, at about 46%.112  
1.6.7 Rise in legal age of sale of cigarettes 
On 1st October 2007 the minimum age of sale for tobacco products 
in England and Wales and Scotland was raised from 16 to 18 years old. 
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Because most adults smokers begin smoking in adolescence, this was 
perceived as an important measure to reduce adult smoking prevalence in 
the future, as well as a way of reducing adolescent smoking prevalence. 
This may have been effective: one study found that, in England, 
prevalence decreased more in 16-17 year olds following the increase in age 
of sale than in older age groups, although this study was limited by the 
fact that it was not able to take into account long term trends in 
prevalence in this age group.113 This is consistent with much of the existing 
evidence, which suggests that restricted access to tobacco, when well 
enforced, reduces use in minors.114 
1.6.8 Ban on tobacco vending machines 
A more recent measure to reduce smoking in young people is a ban 
on cigarette vending machines, which was implemented in October 2011. 
Evidence has shown that adolescents in the UK were more likely to 
purchase tobacco from vending machines than the population as a whole, 
and that young people were more likely to be successful in buying 
cigarettes from vending machines than any other outlet.115, 116 The vending 
machine ban may therefore prove to be an important measure in reducing 
smoking in young people. 
1.6.9  The Quality and Outcomes Framework 
In 2004 a new contract for GPs was introduced. The contract is 
voluntary, but has been taken up by most GPs.117 Part of the contract is 
the Quality and Outcomes Framework (QOF), a group of pay-for-
performance targets which aims to improve the management of patients 
with chronic disease. A group of the QOF targets are related to the 
management of smoking. The requirements of the QOF have changed 
slightly over time, but currently include: 
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x Recording the smoking status of patients aged 15+ in the 
general population at least every 27 months (except never 
smokers, where smoking status is to be checked annually until 
age 25, and ex-smokers, who are to be asked about smoking 
status on an annual basis until they have been a non-smoker for 
3 years.) 
x Recording the smoking status of patients with any of a group of 
specified chronic diseases at least every 15 months 
x For patients with chronic diseases, offering and recording in the 
SDWLHQWV¶QRWHVVPRNLQJFHVVDWLRQDGYLFHRUUHIHUUDOWRVSHFLDOLVt 
smoking cessation services at least every 15 months 
x Providing general smoking cessation support through 
information provision 
The QOF has been shown to improve recording of patient smoking 
status.118, 119  
1.6.10  NHS Stop Smoking Services 
At an individual level, UK tobacco policy is targeted at offering 
people the best help to quit smoking. In the UK, 67% of smokers want to 
stop smoking, and 53% have made a significant attempt to quit smoking in 
the past five years.56 However, only 3-5% of unaided quit attempts are 
successful, therefore providing smokers with the support needed to 
increase the likelihood of a successful quit attempt is a fundamental aspect 
of tobacco control.120 The UK has a comprehensive framework of support 
to help smokers quit. A range of interventions has been shown to be 
effective in yielding higher success rates, and many of these are available 
in the UK, some free at point of delivery.  
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In the UK the NHS provides access to free Stop Smoking Services 
(SSS) which are provided locally. These services may be provided in 
primary care, in pharmacies, or in community settings. NHS SSS provide 
counselling and behavioural support to smokers who want to quit, and are 
also able to provide access to smoking cessation medication. The services 
are effective; 14% of users have been shown to be successful quitters at 
52 weeks.121 The services are also cost-effective and may reduce 
socioeconomic inequalities in smoking prevalence.122, 123  The NHS also 
runs a free stop smoking helpline, which offers advice and support to 
smokers who want to quit.  
The main limitation of the SSS is their limited reach. It has been 
estimated that although nearly half of smokers make a quit attempt each 
year, only 5% of quit attempts are made with the support of the SSS.124 
By contrast, measures such as mass media campaigns, health warnings 
and tax increases may be less effective in individuals, but reach a much 
greater proportion of smokers. 
The NHS National Institute of Health and Clinical Excellence (NICE) 
has issued guidance on how health professionals in primary care and other 
settings should deliver brief stop smoking interventions to patients. Health 
professionals are advised to offer to refer smokers who wish to quit to NHS 
Stop Smoking Services, or offer to prescribe one of three licensed 
pharmacological smoking cessation treatments.125  
1.6.11 Pharmacotherapy 
Pharmacotherapy for smoking cessation can increase the chances of 
quit attempt success. In the UK, three medications are licensed for 
smoking cessation: Nicotine replacement therapy (NRT), bupropion (brand 
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name Zyban) and varenicline (brand name Champix in the UK, Chantix in 
the USA). 
NRT 
NRT is the only nicotine-based pharmacotherapy licensed for 
smoking cessation in the UK. Six different forms of NRT are licensed in the 
UK: gum, tablet, patch, inhalator, nasal spray and lozenge. NRT works by 
providing an alternative source of nicotine during quit attempts, allowing 
quitters to cope without their typical smoking behaviour and rapid delivery 
of nicotine, while not experiencing the worst effects of nicotine withdrawal, 
by providing smaller quantities of nicotine. Later, NRT use is stopped. 
NRT increases the likelihood of quitting by 50 to 70%.126 The 
likelihood of successful quitting without pharmacological aid is low; 
therefore the chances of an unsuccessful quit attempt using NRT are still 
quite high. Nonetheless, due to the health benefits of stopping smoking, 
NRT is highly cost-effective as well as effective.126  NRT has been available 
on NHS prescription since April 2001 and is also available over-the-counter 
(OTC). It became available OTC, initially from pharmacies only, in the 
1980s. Since March 1999 an increasing number of NRT products have 
become available on general sale (i.e. over the counter outside 
pharmacies). In December 2005 the indications for NRT were broadened 
such that adolescents aged 12-17, pregnant smokers and CVD patients can 
also be prescribed NRT. The effect of this licensing change has yet to be 
evaluated; its impact is therefore investigated in Chapter 6. 
Bupropion 
Bupropion, which in some countries but not the UK, is licensed as 
an antidepressant, is licensed as a smoking cessation medication in the 
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UK. It has been available on NHS prescription since June 2000 and cannot 
be obtained without a prescription. 
Bupropion is similarly effective as NRT: it increases the chance of 
long-term cessation by approximately 70% compared with unaided 
quitting.127 
Varenicline 
Varenicline is the newest medication for smoking cessation available 
on the NHS. Like bupropion, it is a non-nicotine smoking cessation drug, 
and it has been approved in the USA, in the EU, and in other countries. It 
was introduced in the UK in December 2006 and, like bupropion, is only 
available on prescription. 
Varenicline is a partial agonist which eases symptoms of craving 
and withdrawal during smoking cessation. It also reduces the rewards and 
reinforcing effects of nicotine by preventing it from binding to Įǃ
nicotine receptors. It increases the likelihood of a successful quit attempt 
between two- and threefold and is cost-effective.128, 129 It may be more 
effective than NRT and bupropion in achieving continuous abstinence.128, 129 
The impact of the introduction of varenicline to the market for smoking 
cessation medication in England has also not been explored. Chapter 4 is a 
study of the impact of varenicline on prescribing of other smoking 
cessation medications.  
1.7  The evaluation of tobacco control policy  
1.7.1 Why evaluate? 
Having a comprehensive framework of tobacco control policy, such 
as that in the UK, is clearly vital. The final element of the MPOWER 
framework also underlines the importance of monitoring in order to ensure 
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the success of the tobacco policies that are put in place. In addition to 
general monitoring of smoking and quitting behaviour, however, it is 
important to evaluate the impact of individual tobacco control policies to 
establish which policies are effective (and, in some cases, cost-effective) 
and in which circumstances and why. Policy evaluation also helps to 
ascertain how policies may be improved so that they have the greatest 
impact on reducing smoking-related harm and inequalities. In this way, 
ineffective policies can be dropped or improved, while effective policies can 
be kept and, if possible, improved further in order to optimise their impact. 
For example, the 2010 Royal College of Physicians Report µPassive 
Smoking and Children¶ concluded that the primary aims of smokefree 
legislation - WR ³SURWHFWZRUNHUVDQG WKHJHQHUDO SXEOLF IURPH[SRVXUH WR
WKH KDUPIXO HIIHFWV RI SDVVLYH VPRNH H[SRVXUH´ - have largely been 
achieved in enclosed workplaces and public places.130 However, it 
highlights areas in which smokefree legislation could be extended and 
better enforced, particularly to increase its benefit for children.37 
Evaluation may not only guide policy in the country or region in which the 
policy is in place; it may also aid policy development elsewhere. Following 
evaluation, therefore, the international dissemination of findings is also 
crucial.1 
This section seeks to summarise, using examples from previous 
policy evaluations, the key elements of how best to carry out such an 
evaluation, including outcomes, study designs and data sources. It sets the 
background for the main body of this thesis, which explores, taking into 
consideration the features identified as important to policy evaluation in 
this section, the suitability of a range of existing data sources in England 
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for the evaluation of tobacco control policy, and uses existing data to 
evaluate a set of tobacco control policies recently implemented in England. 
1.7.2 What to evaluate 
Like the ,QWHUQDWLRQDO $JHQF\ IRU 5HVHDUFK RQ &DQFHU¶V ,$5&
Handbook on Methods for Evaluating Tobacco Control Policies (henceforth 
referred to as the IARC Handbook), on which this section draws, this thesis 
does not discuss the evaluation of individual-level interventions that can be 
tested in randomised trials, such as pharmacological smoking cessation 
aids or behavioural interventions.131 Instead, this research focuses on the 
evaluation of the impact of population-level policy interventions which are 
aimed at getting smokers to quit. 
1.7.3 Outcomes 
The IARC Handbook states that there are five broad types of 
outcomes which may be included in the evaluation of tobacco control 
policy: 
x Changes in knowledge (such as awareness of the health risks of 
smoking) 
x Changes in attitudes and related normative beliefs (such as 
attitudes towards smoking in the home) 
x Changes in behaviour patterns (such as smoking prevalence) 
x Changes in exposures (for example, secondhand smoke) 
x Changes in health outcomes (for example, the incidence of 
heart attacks)  
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Generally, it is ideal to conduct evaluations using a range of these 
different outcomes in order to obtain comprehensive evidence as to the 
impact of a policy.  
Changes in knowledge and attitudes are potentially important short-
term outcomes as they may act as mediators of a policy effect. In other 
words, they may be precursors to changes in behaviour.132 Identifying the 
mechanisms through which tobacco control policies work may help to 
increase the effectiveness of policies.132 However, demonstrating the 
impacts of policies on knowledge and attitudes alone, without showing that 
these changes lead to changes in behaviour, provides only weak evidence 
for the effectiveness of policy. Very few existing data sources provide 
sufficiently detailed data to enable the investigation of mediating effects, 
and therefore these outcomes are not used in this thesis. An exception is 
the International Tobacco Control Policy Evaluation (ITC) Project, which 
has been used to evaluate a range of tobacco control policies both in the 
UK and elsewhere.132 The ITC Project is described in section 1.7.7. 
The most important outcome for all types of tobacco control policy 
evaluations is health outcomes, as this is the best way of quantifying the 
public health (and potentially economic) impacts of policies. Changes in 
health outcomes may, however, not occur in the short-run, and evaluating 
these may therefore not be possible if the timescale is short. Furthermore, 
some individual policies may not have a detectable impact on health 
outcomes. Measuring changes in health outcomes as a result of tobacco 
control policy therefore poses a substantial challenge. 
Most tobacco control policies aim to reduce the harm caused by 
tobacco by influencing smoking behaviours (such as quitting or initiation), 
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and therefore changes in behaviour are important outcomes. Furthermore, 
changes in behaviour are likely to occur in the short and medium term, 
and are therefore likely to be more sensitive to change than health 
outcomes. This thesis deals specifically with the effect of tobacco control 
policy on quitting behaviour. The most direct outcome of quitting behaviour 
is successful quit attempts. Smoking prevalence is also an important 
outcome related to quitting behaviour, although smoking prevalence is also 
determined by new smokers, and deaths of smokers, as opposed to just 
quitting. Tobacco consumption is also potentially an outcome of interest, 
but is probably less important for public health. This is because a decrease 
in consumption may not necessarily be associated with a decrease in 
prevalence, as it may reflect people smoking less (but potentially more 
intensively) rather than quitting.133 Furthermore, some measures of 
consumption may not take into account illicit tobacco. However, 
consumption may be more sensitive to changes in policy, making it easier 
to detect policy effects. 
Other outcomes related to quitting behaviour include smoking 
cessation medication use, calls to stop smoking helplines, and attendance 
at smoking cessation services. They are less direct measures of quitting, 
but may nonetheless provide important evidence as to the impact of a 
policy. 
Regardless of the most appropriate outcome measure, data may 
not be readily available or collected in a way that is adequate for analysing 
policy and thus relevant alternative outcomes may need to be used. At any 
rate, as highlighted in the IARC Handbook, in order to obtain a broad 
evidence base for the impact of a policy, it is desirable to evaluate using a 
whole range of outcomes related to the policy; consistent demonstration of 
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its favourable effects improves the evidence profile for the effectiveness of 
the policy. For example, Fowkes and colleagues and Lewis and colleagues 
used different outcomes (quitting and use of stop smoking medication) 
which both suggested that Scottish smokefree had a positive impact on 
quitting behaviour.134, 135 Thus, when evaluating the impact of a policy on 
quitting behaviour, it is desirable to look at its effect on quit attempts, 
prevalence, use of cessation services, quitlines and use of smoking 
cessation medication. 
The selection of the outcomes can be depicted using a logic model, 
such as that used in the (pre-implementation) planning of the evaluation of 
Scottish smokefree legislation (Figure 1-3).136 A logic model helps to 
understand how policies have the impact they have by depicting the likely 
short-term, intermediate, and long-term outcomes and linking those 
outcomes to each other.  
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Figure 1-3. Logic model of expected outcomes associated with smokefree legislation 
 
Source: Haw et al. 2006136
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The logic model highlights that the choice of outcomes may be 
influenced by the time scale of the evaluation. The effects of policies may 
vary across the short, medium and long term, and the outcomes of interest 
will vary accordingly.  
As mentioned above, this section, like the rest of this PhD thesis, 
focuses on evaluating the effect of policies on quitting behaviour. However, 
the majority of the study design features that are identified as important in 
the rest of this chapter are also relevant to the evaluation of effects on 
other outcomes.  
1.7.4 Target populations 
A final consideration in the selection of outcome measures is in 
whom the outcome should be measured. Some policies are not targeted at 
the whole population; the outcome measures should reflect the relevant 
population group. For example, evaluations following an increase in the 
legal age for buying cigarettes should focus on smoking prevalence and 
uptake and smoking behaviour in young people. It is also often important 
to explore differential impacts in different sociodemographic groups, in 
order to establish the implications of the policy for health inequalities, to 
which smoking is a major contributor.137  
1.7.5 Study designs 
The limits of a gold standard: RCTs 
Randomised controlled trials are held as the gold standard in study 
design for the evaluation of health care interventions, because they are 
able to minimise both bias and confounding. They are ideally suited to 
establishing the efficacy of individual level or small group interventions in 
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controlled settings. For all that they are vital in testing interventions, 
however, RCTs have limitations: because they evaluate interventions in 
experimental conditions, they are inadequate for evaluating real-world 
effectiveness and dissemination.131, 138 Implemented policies (or laws) 
cannot be randomised; they are natural experiments and cannot be 
evaluated in controlled experiments. For this reason, DiFranza states that 
³WKHHYDOXDWLRQRIODZVFDQQRWEHUHDVRQDEO\KHOGWRDVtandard that holds 
the randomized controlled trial to be the only valid source of 
NQRZOHGJH´139  
For example, elements of some current UK tobacco control policies 
can be evaluated using RCTs (e.g. pharmacotherapy, elements of SSS, 
impact of mass media campaigns) ± and this is most frequently the main 
rationale for their implementation - but these do not tell us anything about 
effectiveness in real-world settings and the extent to which they will be 
taken up in the relevant population groups. For example, making smoking 
cessation medications available on prescription will not be effective in 
making people quit if it is not effective in practice, and/or few people 
choose to use it; one cannot be sure what their population-level impact, as 
well as their impact in specific sociodemographic groups, may be until they 
have been implemented in the real-world. Policy evaluations can explore 
these effects and therefore play a vital role that cannot be played by RCTs.  
The IARC Handbook underlines that because of the uncertainty 
surrounding real-world intervention effects, it is inappropriate to cite lack 
of evidence as a reason for obstructing necessary policy change.131 
 While policy cannot be evaluated using an RCT design, its 
evaluation can, like an RCT, seek to comprise features which address 
issues that are found in traditional epidemiological studies, namely bias, 
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confounding and chance and temporality. As far as possible, measures 
should be incorporated which help to rule out alternative explanations for 
observed effects.  
The following sections describe the study design features which can 
be included to maximise the validity of an evaluation. They demonstrate 
that, due to data constraints, this is easier said than done; it is probably 
indeed unfair to judge evaluation studies as harshly as observational 
studies and RCTs. Nonetheless, the fundamental criteria on which they are 
judged should be similar. 
Control groups  
Including a control group is a common feature of epidemiological 
study design that is used to reduce the risk of alternative explanations for 
a change in an outcome following an intervention. Control groups can also 
be used in policy evaluation. The control group in a policy evaluation is one 
that has not been exposed to the policy to be evaluated. When a control 
group is included, the change in the outcome in the control group is 
compared to that in the exposure group; if the policy is effective, the 
difference in the policy groups will exceed that in the non-policy group.131 
Because randomisation is not possible with implemented policies, 
using a control group will only improve the quality of the evaluation if the 
exposed and control groups are similar in features relevant to the policy 
(such as smoking prevalence, sociodemographics and tobacco control 
intensity), so that they are comparable.131  
It is also important to consider potential confounding events. For 
example, if evaluating the effect of a tax decrease on tobacco consumption 
in country A, results may be confounded if graphic health warnings on 
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cigarette packs were introduced in the control country, country B, at a 
similar time. 
It may be difficult to find a control group which adequately fulfils all 
these criteria; it may be particularly challenging when using existing data, 
which may not be available for different countries, or may not have been 
collected using the same methodology and may therefore not provide 
adequate control data. On the other hand, when collecting primary data, 
the inclusion of an appropriate control may be prohibitively expensive. As a 
result, until now, few evaluations have incorporated whole country control 
groups.  
The main example of the inclusion of control populations in tobacco 
control policy evaluation until now is the ITC Project, which now includes 
20 countries and therefore a range of potential control populations.132   
Pre- and post-policy measures 
The most important feature of evaluation design is that there 
should be a pre-policy estimate as well as a post-policy estimate. Without 
a pre-policy measurement, it is impossible to know what the measurement 
at a subsequent time point might have been, and thus it is not possible to 
estimate the effect of the policy.131 
For example, in their study on the impact of smokefree legislation in 
Scotland, Hyland et al. reported smoking cessation figures for the year in 
which the policy was implemented. However, as no pre-policy measures 
were collected, they were not able to estimate the effect of the policy.140 
This underlines the value of planning evaluations before a policy is 
implemented; if primary data collection is required, this will enable the 
collection of pre-policy data. 
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Multiple pre- and post-policy measures 
As is illustrated in the IARC Handbook using the example of pub 
sales following the introduction of smokefree legislation in Ireland, it is 
most useful to have several measurements before the policy change so 
that pre-existing trends and historical events (such as other tobacco 
control policies) may be taken into account in determining the effect of a 
policy.  
Figure 1-4 shows pub sales volumes in Ireland in the years before 
and after the implementation of the smoking ban in public places in 
Ireland. Sales in 2004 were lower than in 2003 and therefore, based on 
these two data points alone, it may seem that smokefree legislation caused 
a decrease in sales in the following year. Figure 1-5, however, shows pub 
volume sales for several years before the ban and one year after the ban. 
It clearly demonstrates that pub sales volumes were already decreasing in 
the years before the ban; therefore it seems likely that the ban did not in 
fact reduce pub sales. This shows the importance of having several 
measurements before the implementation of a policy. It is also valuable to 
have several measurements following the policy implementation in order to 
explore the long term effects of policy.   
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Figure 1-4. Pub sales volumes immediately before and after 
implementation of the Irish smoking ban in 2004 
 
Source: Central Statistics Office of Ireland 
Sales volumes are indexed so that sales volume in 1995 = 100 
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Figure 1-5. Pub sales volumes in Ireland, 1995-2004 
 
Source: Central Statistics Office of Ireland 
Sales volumes are indexed so that sales volume in 1995 = 100 
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A limitation of many existing evaluation studies is that they 
compare just one pre and post-policy measurement. For example, 
Hackshaw et al. found that in England, a greater percentage of smokers 
reported making a quit attempt in July and August 2007, when smokefree 
legislation was implemented, compared with July and August 2008.79 
However, this may simply reflect an existing decreasing trend in quit 
attempts. The results of such studies are useful, but are not conclusive. 
Where no data with multiple measurements are available, triangulation 
with other studies measuring similar or proxy outcomes is important, as 
this will increase the validity of the results. 
Where including several pre-policy measurements is not possible, 
including a control group may significantly improve the validity of an 
evaluation by demonstrating what the change in the outcome would have 
been in the absence of the policy. In this case, knowledge of secular trends 
in the target population is not necessarily needed.  
Limited pre-policy data may also underestimate the effect of a 
policy. Advertising and media coverage of an imminent policy may 
encourage behaviour change ahead of the implementation of a policy. As a 
result, including only data points shortly before the policy may 
underestimate policy effects, which may precede implementation. For 
example, Semple and colleagues studied changes in SHS exposure in bar 
workers in England following the implementation of smokefree 
legislation.141 They found a significant improvement in air quality in bars 
(73-91% PM2.5). However, because they took their pre-policy 
measurements in May and June 2007, just before the legislation was 
introduced in July, and because there was significant publicity surrounding 
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the legislation in the months leading up to July 2007, people may have 
begun to change their behaviour before the pre-policy measurements were 
taken. Their measurements may therefore have underestimated the true 
improvement in air quality. 
As highlighted in the IARC Handbook, the benefit of having several 
pre-policy measurements underlines the advantage of having surveillance 
systems in place which collect data on outcomes of interest. When a policy 
is introduced with little warning, or is brought forward, there may be scant 
opportunities for relevant primary collection, making existing datasets all 
the more valuable.  
Time series analysis 
Time series consist of data collected at multiple, ordered, points in 
time, usually at equally spaced intervals, as in Figure 1-5. The importance 
of placing policy effects in the context of time trends emphasises why time 
series analysis is a particularly useful tool in policy evaluation. Interrupted 
time series analysis is a powerful statistical method which uses statistical 
modelling of data collected at regular intervals over time, to estimate the 
impact of an intervention introduced at a specified point in time. Multiple 
time series analysis (MTSA) can be used to estimate the effect of a policy 
exposure that is measured on a continuous scale, such as cigarette prices. 
These methods allow for the non-independence between data points 
(independence being a vital assumption of linear regression), and control 
for underlying trends (thus ensuring that post-intervention changes are not 
merely continuations of longer-term trends) and seasonal effects. Given 
appropriate data (time series analysis usually requires at least 50 data 
points) and appropriate methods, time series analysis can provide strong 
evidence of policy effects.142 Time series approaches have until now rarely 
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been applied in a public health context, but have been successfully 
adopted in a small number of previous tobacco control policy 
evaluations.82, 143-145  For example, Sims et al. used Hospital Episode 
Statistics to explore the impact of smokefree legislation in England on 
hospital admissions for heart attacks. They used a long monthly time 
series (from July 2002 to September 2008) and were able to take account 
of pre-policy trends and found that the legislation led to a short-term fall in 
admissions for myocardial infarction of 2.4%.145  
When adequate data are available, time series analysis is able to 
provide high-quality evidence on policy effects. These methods are 
therefore used to analyse policy effects in this thesis. Chapter 4 provides a 
more detailed overview of the strengths and limitations and application of 
these methods. 
Data intervals 
Another important consideration in the design of a policy evaluation 
is the time interval between data points. Data intervals can substantially 
affect the flexibility of data and the strength of the conclusions that can be 
drawn from them. 
Short data intervals make it easier to detect small and transient 
effects of policy; annual data may miss these effects, therefore monthly or 
quarterly data are preferable.82 Shorter data intervals also increase the 
likelihood of reaching the required number of data points for a time series 
analysis, which, as described above, is an extremely valuable study design 
in policy evaluation. Further to this, short data intervals also make it easier 
to separate the (potentially confounding) effects of different policies which 
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may be implemented during any one year ± although even with such data, 
disentangling these effects is often not possible.  
The key limitation of monthly data is that they may be expensive, 
particularly if they are obtained through primary data collection. In 
particular, it may be costly to obtain the necessary sample sizes to ensure 
adequate power on a monthly basis. For example, the Opinions survey is a 
general survey carried out in households in Great Britain each month, and 
contains data on smoking prevalence.146 However, the confidence intervals 
of the monthly data have been shown to be too wide to identify significant 
trends.147 
1.7.6 Data and data sources 
Evaluation of tobacco control policy requires high quality and timely 
data on smoking and smoking cessation behaviour both in the general 
population and in relevant sociodemographic groups. The data used should 
be relevant, valid and representative of the population being studied. As 
highlighted in section 1.7.3, it is desirable to conduct evaluations using a 
range of outcome measures, and therefore it is worthwhile exploring a 
whole variety of data sources to obtain outcome measures. 
Data may be available from existing sources including national or 
regional surveys, or routinely collected data such as primary care data. The 
advantage of survey data is that they may be cheap or free for researchers 
to access, and are likely to be available for a long time period. However, 
there are significant disadvantages to this type of data, including potential 
reporting and recall bias (participants may not report smoking behaviour 
accurately or may misremember it), potentially inadequate sample sizes, 
and the fact that most surveys are carried out only annually. 
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The use of routinely collected data is likely to overcome many of the 
drawbacks of survey data: they may contain objective measures (thus 
minimising bias), and are likely to be available on a monthly or quarterly 
basis. Some routine data, such as electronic health care data, are also 
more likely to have large sample sizes, despite the short data intervals. 
The main disadvantages are that they may not measure exactly what 
needs to be measured.  
In the UK, there is a range of existing data sources containing 
information on smoking and smoking behaviour. Many have not been used 
in the evaluation of individual tobacco control policies. The suitability of a 
group of these existing data sources for the evaluation of tobacco control 
policy is discussed in detail in Chapter 2. 
If suitable existing data are not available, specifically-collected data 
may be more appropriate, as these can be tailored to the needs of the 
evaluation. The major disadvantages of these types of data are the 
substantial costs to researchers, as well as the need to begin collecting 
data before the implementation of the policy to enable adequate before 
and after comparisons. This requires the planning of data collection from 
the point at which discussions regarding the policy begin. This may not 
allow sufficient time for pre-policy data collection, and may be affected by 
unexpected changes in the content or timing of policies.  
It may be the case that insufficient data to draw definitive 
conclusions about the effects of a policy are available. This may particularly 
be the case in countries where the infrastructure and funding for data 
collection and research are limited; however, as is explained in Chapter 2, 
even many types of existing data in England and the rest of the UK have 
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substantial limitations for the evaluation of tobacco control policy. Where 
national data and, thus, national evidence are limited, it is useful to take 
international evidence into account. For example, although there are few 
studies on improvement in health outcomes following the implementation 
of smokefree legislation in England, taking into consideration the reported 
impact of smoking bans in international settings could lend support to 
arguments that such bans have a positive impact on health outcomes.  
1.7.7 Case study: The ITC Project  
Background 
The biggest tobacco control policy evaluation project undertaken to 
date is the ITC Project. It has many of the features described above as 
important to good policy evaluation; however, it also has a range of 
limitations. It provides a useful case study to demonstrate the importance 
of the various evaluation features described in this section. 
The ITC Project was designed to evaluate FCTC policies and provide 
evidence on the impact of national tobacco control policies on psychosocial 
indicators (such as beliefs and attitudes and perceived risks of smoking) 
and smoking behaviours (e.g. quit attempts). It began in 2002 in the UK, 
United States, Canada and Australia, and now comprises 20 countries. 
Design 
The ITC Project uses a longitudinal survey design with multiple 
country controls and theory-based mediational models. It collects data on 
cohorts of approximately 2000 smokers in each country. The cohorts are 
replenished for each wave of data collection to ensure that the sample size 
is retained regardless of attrition. The survey is comprehensive, comprising 
questions on mediators, including policy-specific variables (such as warning 
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label salience) and psycho-social mediators (such as beliefs, attitudes and 
quit intentions), as well as questions on smoking behaviour. The 
conceptual model of the project assumes that each policy has an influence 
on behaviour through a specific chain of psychological events. In other 
words, it is assumed that the impact of a policy on behaviour is mediated 
by psycho-social factors.  
Strengths 
The ITC Project has several strengths which make it able to provide 
strong evidence of the effects of tobacco control policies in a range of 
countries. The longitudinal design allows the identification of temporal 
relationships, which would not be possible with a cross-sectional survey 
design. Further to this, collecting data at several time points means that 
temporal trends can be taken into account. The country controls help to 
disentangle policy effects from secular trends and confounding events. In 
addition, using the same method of data collection across all countries 
enables comparisons between them. Finally, as the surveys comprise 
behavioural and mediational variables, both the impact of policies and the 
mediators for policy impacts can be investigated. 
Limitations 
A key limitation of the ITC Project is that it is based on survey data, 
which is prone to recall and reporting bias. The results of the project would 
therefore benefit from triangulation with evaluations based on objective 
data. There is also high attrition between survey waves.148 Further to this, 
the ITC data tend to have insufficiently large sample sizes to evaluate sub-
national policies, which are common in some of its countries, such as the 
US.132 
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Perhaps the most significant limitation of the ITC Project is the 
frequency and regularity of data collection. In some countries, only one 
wave of data has currently been collected, and thus evaluations cannot 
incorporate longitudinal data. In the ITC countries where there have been 
more waves (e.g. up to 8 in the UK, Canada and Australia), the surveys 
have been irregular, with data collection tending to span many months. 
Thus it is more difficult to take accurate account of temporal trends, or to 
detect the effect of specific policies, which may be gradual, occur with a 
lag, or be confounded by other events. Further to this, the surveys are 
often conducted at different times of year from one wave to the next, and 
responses may therefore be influenced by seasonal effects on quitting 
behaviour and intentions. These problems are likely to be only partially 
mitigated by the country controls given that they are common across 
countries. These issues are primarily due to the significant costs of running 
such large, detailed surveys, and highlight the potential value of data 
which are routinely collected. 
1.8 Summary 
The burden of smoking in the UK is, despite significant decreases in 
smoking prevalence over recent decades, enormous. In recent years, a 
comprehensive framework of tobacco control policies has been 
implemented in the UK to reduce the burden, and that framework 
continues to develop. The evaluation of population-level tobacco control 
policy is necessary to establish which policies are effective and how they 
may be improved in order to maximise their impact. 
 A range of study design features that will improve the quality of an 
evaluation have been highlighted in this chapter, including the use of 
control groups and long time series data with multiple pre- and post-policy 
53 
 
observations. Time series analysis has been highlighted as a valuable 
statistical method in the evaluation of policy.  
Various types of data may be used in the evaluation of tobacco 
control policy; however, all data sources have strengths and limitations. 
The combination of the information generated by different studies using a 
range of outcomes is likely to increase the validity of overall conclusions as 
to the effect of a policy.131  
The ITC Project is the best attempt to date to integrate all of the 
features of good policy evaluation into one design, and provides extensive 
data on smoking, quitting behaviour and attitudes in the UK and other 
countries. However, it has various limitations. The work in this thesis will 
complement the ITC Project, by identifying other high quality data and 
methods that can be used to evaluate tobacco control policy in England.  
1.9  Aims and objectives 
The aims of this PhD thesis are to investigate the suitability of a 
range of existing data sources for evaluating the impact of tobacco control 
policies in England on quitting behaviour; validate potentially suitable 
measures; and use validated measures to evaluate the impact of recent 
tobacco control initiatives in England using time series analysis. This thesis 
focuses on policies in England, because tobacco control policy is largely 
dealt with separately in each UK country, and it is therefore beyond the 
scope of this research to cover each country separately. It has three 
specific objectives:  
x To analyse and describe a range of data from existing sources 
which provide information on smoking cessation behaviour in 
terms of their adequacy for evaluating individual population-
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level tobacco control policies in England, based on the criteria 
for good study outcomes, design and data types outlined in 
Chapter 1 (Chapter 2). 
x To validate previously unvalidated measures identified in 
Chapter 2 as potentially valuable in the evaluation of 
population-level tobacco control policies in England (Chapter 3). 
x To describe a range of approaches to time series analysis that 
may be used in tobacco control policy evaluation based on 
existing literature (Chapter 4). 
x To utilise validated measures of smoking cessation activity to 
evaluate the impact of recent tobacco control initiatives on 
quitting behaviour using the time series methods described in 
Chapter 4. The evaluated policies are: the introduction of 
varenicline (Chapter 5), the broadening of NRT indications to 
include adolescents and CVD patients (Chapter 6), and anti-
tobacco mass media campaigns (Chapter 7).
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CHAPTER 2:  INDICATORS OF 
QUITTING BEHAVIOUR IN ENGLAND 
± ARE ANY OF THEM SUITABLE FOR 
POLICY EVALUATION? 
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2.1 Introduction 
As highlighted in section 1.7.3, it is preferable to use a selection of 
relevant outcome measures to evaluate any one policy, in order to obtain 
comprehensive evidence of its impact. When investigating the impact of a 
tobacco control policy on quitting behaviour, large-scale, regular data 
covering a long time period on quit attempts, smoking prevalence and use 
of smoking cessation support (such as pharmacological cessation aids and 
cessation advice) are all useful. 
In England there are several existing sources of data on quitting 
behaviour which could potentially fulfil the criteria for conducting accurate 
tobacco control policy evaluations. This chapter seeks to establish which of 
the data sources in England contain data which may be appropriate for the 
evaluation of the impact of tobacco control policy on quitting behaviour. It 
takes into account the issues described in section 1.7 in order to explore 
the suitability of measures from the different data sources for such 
evaluations. Thus this chapter helps to provide the rationale for the 
selection of the data used in the policy evaluations in subsequent chapters 
of this thesis. In addition, however, it provides important information as to 
the breadth and quality of the data available for the evaluation of the 
impact of tobacco control policy on quitting behaviour in England (and, in 
some cases, the rest of the UK, as some data sources do not cover 
England alone), and highlights ways in which the data could be improved 
to ensure that high quality evaluation using existing data is made possible.  
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2.2 The Nottingham Tobacco Control Database 
The data used in this thesis form part of the Nottingham Tobacco 
Control Database (NTCD). The NTCD was developed at the University of 
Nottingham by Jack Gibson, as part of a project funded by the National 
Prevention Research Initiative (NPRI), on which the majority of the work of 
this PhD project is based, and is maintained by me and Yue Huang. It 
contains data from a range of existing data sources (including survey data 
and other types of existing data) and a wide (but not exhaustive) range of 
measures which can be used to monitor smoking cessation behaviour, 
including prevalence, prescribing and sales of smoking cessation 
medication, and quit attempts. A full list of variables included in the NTCD 
is provided in Appendix 9.1. In the NTCD the data are, where possible, 
stratified by sex, age, region (based on strategic health authority) and 
socioeconomic status. 
This chapter describes the data contained in the NTCD and their 
various strengths and limitations. Section 2.3 describes the survey data in 
the NTCD: The General Lifestyle Survey, the Health Survey for England 
(HSE), the Opinions Survey and the Smoking Toolkit Study (STS). Section 
2.4 describes the non-survey data in the NTCD: Commercial OTC NRT 
data, national smoking cessation medication prescribing data, quitline calls 
data and general practice data on smoking from The Health Improvement 
Network (THIN). 
The majority of the analysis in this chapter is descriptive, and draws 
on previously published work about these data sources. Where this chapter 
includes original graphs based on survey data, NTCD data have been used 
to calculate the indicators by dividing the outcome variables (e.g. the 
number of current smokers) by the relevant denominators (e.g. the 
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number of survey respondents). All of the survey data are weighted to 
make them representative of the general population. 
2.3 Survey data 
2.3.1  General Lifestyle Survey (GLF) 
Overview 
The GLF, formerly known as the General Household Survey (GHS), 
is a continuous survey carried out by the Office for National Statistics 
(ONS).149 It collects information on a range of topics from people living in 
private households in Great Britain including around 12,500 in England 
each year.  
Indicators of smoking and quitting behaviour 
The GLF has included questions on smoking status, as well as 
quitting intentions and amount and type of smoking product smoked every 
year since 2000; before 2000 questions on smoking were included every 
other year.  
Strengths 
7KH*/)¶VODUJHVDPSOHVL]HXVHRIZHOO-established data collection 
methods and long time span make it a valuable resource in monitoring 
smoking behaviour over time. It is generally regarded as a gold standard 
measure of smoking prevalence in the UK.150, 151 Figure 2-1 shows how the 
GLF can be used to monitor general trends in smoking prevalence over 
time. 
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Figure 2-1. Adult smoking prevalence, Great Britain, based on GLF, 
2000-2008 
 
 
Limitations 
The GLF has many of the limitations that are generally inherent in 
cross-sectional surveys. Like most surveys, the GLF may be prone to 
reporting and recall bias. In particular, it is likely that it underestimates 
prevalence, particularly in young people. To reduce this bias, respondents 
aged 16 and 17 fill in the smoking section of the survey with no one else 
present.  
In addition to this, while the overall sample size of the GLF is large, 
when broken down into smaller demographic groups the confidence 
intervals around its estimates are extremely large, preventing accurate 
monitoring. This has been demonstrated at the regional level.152 Figure 2-2 
and Figure 2-3 show the GLF prevalence estimates and confidence 
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intervals for the regions with the smallest (North East ± 642 in 2008) and 
largest (South East ± 2082 in 2008) samples. For both regions, the 
confidence intervals around the prevalence estimates are wide.  
Figure 2-2. Adult smoking prevalence, North East England, based 
on GLF, 2000-2008 
 
Adapted from Langley et al. (2011)152 
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Figure 2-3. Adult smoking prevalence, South East England, based 
on GLF, 2000-2008 
 
Adapted from Langley et al. (2011)152 
Furthermore, while the GLF is an important monitoring tool, it is 
less suitable for the evaluation of tobacco control policy. Its major 
limitation in this regard is its frequency. GLF data are collected on an 
annual basis and therefore suffer from the limitations associated with 
infrequently collected data: using annual data, it is difficult to detect small 
and transient changes in behaviour, and the length of any lag between the 
implementation of a policy and the associated behaviour change. It is also 
particularly difficult to take account of the confounding effects of other 
tobacco control measures implemented during the year. A further 
limitation of the GLF data is the lag between the data collection and the 
availability of the data, which may prevent timely policy evaluation.151 
The GLF will be discontinued from January 2012, but data collection 
for a related, larger (though less detailed) survey, the Integrated 
Household Survey (IHS) has already begun.153 
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An extension of the GLF: The Integrated Household Survey (IHS) 
The IHS is a continuous survey which combines key questions from 
a number of ONS surveys, including the GLF.154 It began in 2008. The 
µ&RUH¶TXHVWLRQVDUHDVNHGDW WKHEHJLQQLQJRI WKH LQFOXGHGVXUYH\V7KH
GLF, the Living Cost and Food Survey, the English Housing Survey, the 
Labour Force Survey/Annual Population Survey and the Life Opportunities 
Survey. The survey aims to obtain data on key topics by using an 
extremely large sample size - over 420,000 - making it the largest UK 
survey after the Census. The broad topics included are economic activity, 
education, health and disability, identity and income. The IHS includes two 
questions about smoking: whether the respondent has ever smoked, and 
whether they currently smoke, which provides estimates of prevalence. 
The IHS covers the whole of the UK and, unlike previous surveys, 
can be broken down to local authority level. The IHS has been cited in the 
Tobacco Control Plan as an important source of prevalence data, 
particularly for planning tobacco control at a local level.67 As shown in 
Figure 2-4 below, results from the 2009-10 survey suggest that the survey 
provides prevalence estimates with very narrow confidence intervals down 
to the regional level. However, at the local authority level, accuracy 
appears likely to be poor, at least in smaller authorities, due to the much 
reduced sample sizes. As an example, Figure 2-5 shows the wide 
confidence intervals of the estimates from the April 2009-March 2010 
survey for estimates of smoking prevalence for Yorkshire and Humber local 
authorities.  
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Figure 2-4. Adult smoking prevalence by Government Office 
Region, Great Britain, based on the IHS, April 2009-March 2010 
 
Source: Smoking prevalence by local authorities in Yorkshire and Humber, 
Yorkshire and Humber Public Health Observatory (2010)  
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Figure 2-5. Adult smoking prevalence by Local Authority, Yorkshire 
and Humber, based on the IHS, April 2009-March 2010 
 
Source: Smoking prevalence by local authorities in Yorkshire and Humber, 
Yorkshire and Humber Public Health Observatory (2010) 
 
The data are currently classified as experimental (new official 
statistics undergoing evaluation), and ought therefore to be used with 
caution. Annual data are to be published on a quarterly basis (e.g. annual 
data April 2009 - March 2010 followed by July 2009 - June 2010), although 
the time lag to publication is currently not known.  
If monthly data are also made available, the continuous nature of 
the data collection may provide sufficiently large monthly samples to 
provide accurate monthly prevalence estimates. It is not clear, however, 
whether the sampling method creates representative samples on a 
monthly or quarterly basis. If so, when sufficient data points are available, 
the data may be appropriate for time series analysis and evaluating the 
impact of policies.  
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The IHS seems likely to provide accurate and regular estimates of 
prevalence for the UK as a whole and at the regional level. However, 
currently, only one year of data is available, and it can therefore not be 
used in the context of this PhD.  
2.3.2  Health Survey for England (HSE) 
Overview 
The HSE is an annual survey which seeks to measure health and 
health-related behaviours in adults and children living in private 
households in England.155 It has been carried out every year since 1991. It 
regularly collects information on knowledge, attitudes and behaviour 
related to smoking, alcohol, diet and physical activity, as well as having a 
varying key topic. The sample size varies across survey years, from around 
7000 to 16000 adults. Generally, a large survey in one year is followed by 
a smaller survey in the next year. 
Indicators of smoking and quitting behaviour 
The HSE contains questions on smoking prevalence, amount 
smoked and attitudes to quitting in a range of sociodemographic groups in 
England. 
Strengths 
The HSE is regularly carried out, and every second year has a large 
sample size. Its major strength is that it provides information on a range of 
health issues not covered by other surveys; however, the information it 
contains about smoking appears to be less reliable than that in other 
surveys, as discussed in the following section. 
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Limitations 
Generally, the limitations of the HSE are similar to those of the 
GHS. For example, it is also prone to underestimates of smoking 
prevalence and takes similar steps to the GLF to overcome them. Evidence 
suggests that self-reported cigarette smoking status using the HSE 
underestimates true smoking prevalence by approximately 2.8% compared 
with biochemically-validated estimates.156 This is not necessarily a 
limitation when exploring trends, assuming that the error is consistent over 
time, but may lead to underestimates of the public health burden of 
smoking. In addition to this, the HSE is also annual, which is a substantial 
limitation in the use of these data in the evaluation of individual tobacco 
control policies.  
A major limitation of the HSE smoking data is its sampling error. 
Comparing the standard errors for the GLF and the HSE underlines the 
higher sampling error of the HSE. In the 2007 and 2009 surveys, years 
with relatively small sample sizes, the standard error of the smoking 
prevalence estimates in the HSE was around 1; for the GLF it was around 
0.5.157-159 The standard error will be higher still in estimates based on 
questions asked to smokers only, due to the much reduced sample size. 
The impact of this error on HSE estimates, and thus the potential impact 
on observed trends, can be demonstrated using graphical analysis. In 
Figure 2-6 below, prevalence estimates from the HSE and the GLF are 
overlaid. It shows that HSE estimates are highly variable from one year to 
the next. This contrasts with the GLF estimates, which show a fairly 
smooth decreasing trend over time. The variability in the HSE estimates 
suggests that the often smaller sample size compared with the GLF results 
in substantial sampling error. Figure 2-6 also shows the HSE sample size in 
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each year. Unsurprisingly, it appears that the HSE estimates are generally 
further away from the GLF estimates in years with smaller sample sizes, 
although the estimate for 2001, when the sample size was over 15000, is 
nearly two percentage points lower than that from the GLF. 
Figure 2-6. Adult smoking prevalence, England, based on HSE and 
GLF, 2000-2006 
 
 
2.3.3  ONS Opinions Survey  
Overview 
Like the GLF, the Opinions Survey (previously known as the ONS 
Omnibus Survey) is carried out by the ONS and is a regular, multi-purpose 
survey which was carried out in eight months of the year until April 2005, 
after which it became a monthly survey.146 Approximately 1800 adults in 
private households are surveyed each month. 
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Indicators of smoking and quitting behaviour 
Opinions Survey data on smoking and quitting behaviour come from 
two different survey modules about smoking behaviour. Module 130 
(Smoking) is comprehensive and contains a variety of questions about quit 
attempts, support used, attitudes to smoking and restrictions on smoking, 
and occasional topical questions about proposed policy changes. However, 
this module is only included once or twice a year. Module 210 contains 
fewer questions, covering smoking status, use of cigarettes vs. roll-ups 
and differences between weekday and weekend consumption, but is 
included on an almost monthly basis.  
Strengths  
The Opinions Survey prevalence data up to 2000 have been 
compared with GHS prevalence estimates on an annual basis and found to 
be similar to these both overall and in different sociodemographic 
groups.147 This is likely due to the large annual sample size of over 20,000. 
Figure 2-7 shows that since 2000 too, the annual prevalence estimates 
based on Module 210 have been similar to those from the GHS. By 
contrast, those from Module 130 are much more variable. This is due to 
the smaller denominators for this part of the survey, which is included less 
frequently than Module 210.  
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Figure 2-7. Adult smoking prevalence, England, based on Opinions 
survey and GLF, 2000-2006 
 
 
Limitations 
A potential advantage of the Opinions Survey is that it provides 
monthly data, and hence a long time series which allows trends to be 
taken into account in policy evaluations. However, a previous study, which 
looked at data to 2000, found that confidence intervals for the monthly 
data were too wide to allow accurate monitoring of monthly prevalence.147 
Figure 2-8 demonstrates that this is also the case for more recent years of 
the survey: There is significant fluctuation in estimates of smoking 
prevalence from month to month, suggesting extremely high standard 
errors and confidence intervals. This would make it very difficult to 
accurately identify the effect of a policy. This is an even more significant 
problem for all questions asked to smokers only, such as those related to 
quit attempts, as the denominators are further reduced.  
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Figure 2-8. Adult monthly smoking prevalence, England, based on 
Opinions survey, October 2001-August 2006 
 
 
2.3.4 Smoking Toolkit Study (STS) 
Overview 
The STS involves repeated cross-sectional household surveys of 
national samples of smokers and recent ex-smokers in England.150, 160 The 
surveys have been carried out on a monthly basis (with a small number of 
months with no survey) since November 2006 and include around 500 
smokers.  
Indicators of smoking and quitting behaviour 
The STS covers a wide range of parameters related to smoking and 
quitting behaviour, including prevalence, quit attempts, ways of quitting 
and attitudes to smoking and quitting. 
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Strengths 
Aside from the ITC Study, the STS is the only ongoing survey that 
specifically focuses on smoking and quitting behaviour in England. As such 
it provides extremely detailed data over five years on a wide range of 
measures, including direct measures of quitting, and a variety of 
sociodemographic data. This means that it can be used to answer a wide 
range of questions related to tobacco control. The data are also made 
available soon after collection. 
The STS is nationally representative, and pooling results from 
several waves of the survey yields large sample sizes. The survey has been 
shown to generate annual estimates of smoking prevalence comparable to 
those from the GLF and HSE in 2008 and 2009, as shown in Figure 2-9. 
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Figure 2-9. Adults smoking prevalence and cigarettes per day, England, based on the Smoking Toolkit Study, GLF and HSE, 
2007-2010 
 
From: Fidler et al. (2011)150 
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Data from the STS have been used to investigate a range of issues 
related to smoking cessation, including the affective impact of quitting, 
sociodemographic differences in triggers to quitting smoking, and the 
social gradient in quit attempts, use of aids to cessation and the success of 
quit attempts.161-163 
Limitations 
Despite its many strengths and the wealth of useful data that it 
provides, the STS has some specific limitations (in addition to those 
inherent in surveys) which reduce its adequacy as a dataset for evaluating 
the effects of specific tobacco control policies on quitting behaviour. 
The availability of monthly data on a range of measures is 
potentially valuable in that it could permit the examination of possible 
intervention effects more easily than annual surveys; however, the 
monthly sample of smokers is small at around 500. 150 As a result, monthly 
estimates will have high standard errors, making accurate formal statistical 
analysis of the monthly data, particularly using time series analysis, 
difficult.  
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2.4 Non-survey data 
2.4.1 Commercial OTC NRT data 
Overview 
Increases in sales of OTC NRT may mirror increases in the number 
of people quitting smoking, and OTC NRT has therefore been used as an 
indicator of quitting activity.135, 164, 165 The OTC sales data used in the NTCD 
are monthly Electronic Point of Sales scanner data obtained from 
Information Resources Inc. (IRI, now Symphony IRI).166 They include data 
from all stores except Boots stores in Great Britain, and are available at 
the regional level, and broken down by brand and product.  
Strengths 
These data have a range of strengths which make them suitable for 
the evaluation of policies which may influence quitting behaviour. They are 
available at four-weekly intervals over several years, resulting in the sort 
of long time series that is ideal for such evaluations. OTC sales are also an 
objective measure, i.e. they are not prone to the same recall or reporting 
biases as survey data. Furthermore, because they are population level 
data, they ought to be completely representative of national and regional 
sales. Finally, OTC sales may be more sensitive to policy than, for 
example, prevalence, making it easier to detect small or short-term effects 
on quitting behaviour. 
Limitations 
These data also have certain limitations. Firstly, they can be 
expensive to obtain. Furthermore, although there are numerous sources of 
such data, because of the cost of these data, it can be difficult to compare 
them with other data sources for the purposes of validation. In addition, 
the IRI data do not contain data from Boots stores. It has not been 
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possible to obtain information as to the proportion of total OTC NRT sales 
Boots sales account for, or whether the trends in Boots sales are different 
from those in other stores; it is therefore not clear how great a limitation 
this is. 
Furthermore, OTC sales of NRT is an indirect indicator of quitting; 
NRT may be purchased for cutting down, or for use in situations where 
people may not smoke, as opposed to for use as part of a quit attempt, 
and changes in NRT sales may therefore not truly reflect changes in 
quitting behaviour. Nonetheless, it seems likely that increases in sales 
indicate efforts by smokers to reduce or cease smoking, thus, particularly 
in the absence of extensive high quality data on direct indicators of 
quitting, such as quit attempts, OTC NRT sales appears a useful outcome. 
To enhance the validity of results, studies using these data as a marker of 
quitting behaviour should be triangulated with those using other data. 
A final limitation of these data is that, although regional data are 
available, further sociodemographic data are not. As a result, these data 
cannot be used to explore variations according to, for example, age, sex 
and socioeconomic status. 
2.4.2 National smoking cessation medication prescribing data 
Overview 
Prescribing of smoking cessation medication may also be a good 
indicator of quitting behaviour. One source of data on prescribing is 
national dispensing data. Within the NHS, pharmacies dispense 
prescriptions and are then reimbursed for the products that they dispense. 
NHS Prescription Services (previously the Prescription Pricing Division) 
process NHS prescriptions dispensed in England for reimbursement and 
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remuneration, and collect information on what is prescribed and the cost of 
prescriptions via their ePACT system.167 Prescriptions written in hospitals, 
prescriptions dispensed in hospitals, dental prescribing and private 
prescriptions are not included. The NTCD contains ePACT data from August 
2003 to July 2008 for the three smoking cessation medications licensed 
during this period ± bupropion, NRT and varenicline. The ePACT data in the 
NTCD are not published, and can be obtained on request from the NHS 
Information Centre, listed by drug name and by region.  
Strengths 
ePACT processes all GP, nurse and other non-medical prescriber 
prescriptions dispensed in England, and is therefore likely to be a source of 
accurate primary care dispensing data, and a useful resource in the 
evaluation of tobacco control policy that may be expected to have an 
impact on prescribing of this group of medications in England. The ePACT 
data have many of the same advantages as the OTC NRT data described 
above: they are an objective measure of the provision of stop smoking 
medication, and they are available at monthly intervals and over a long 
time period. 
Data on prescribing of smoking cessation medication may be a 
more accurate indicator of quitting behaviour than OTC sales of NRT, as it 
seems more likely to be provided as part of a planned quit attempt, as 
opposed to for cutting down or for use in situations where one may not 
smoke. 
Limitations 
A limitation of the ePACT data is that they are not available in 
sociodemographic strata. Although trends can be examined by region, it is 
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not possible to look at trends according to sex, age or socioeconomic 
status, as is desirable in many evaluations. As such, ePACT is not an 
optimal source of data on prescribing of smoking cessation medication; a 
potential alternative measure, which includes sociodemographic data, 
primary care data on prescribing, is described in section 2.4.4. 
Furthermore, while the ePACT data seem likely to be a sensitive measure 
of quitting behaviour, they may not be an accurate measure of medication 
use, as dispensed medication may not necessarily be used. Previous 
studies have estimated that between 5.2% and 20% of patients do not 
redeem their prescriptions.168-172 
2.4.3 Quitline calls 
Overview 
The NHS runs a variety of free stop smoking helplines where people 
seeking advice on smoking cessation can speak to a trained smoking 
cessation advisor. There are UK-wide services, as well as nation-specific 
services, a pregnancy smoking helpline, and helplines in a range of 
languages. Quitlines have been shown to be effective in helping smokers 
quit, and quitline calls are therefore an important measure of smoking 
cessation activity.173-175 ,Q D UHFHQW WULDO FRPSDULQJ µSURDFWLYH¶ UHSHDWHG
FDOOVIURPDFHVVDWLRQDGYLVRUWRWKHFOLHQWZLWKµUHDFWLYH¶UHVSRQGLQJRQO\
to smokers calls) telephone counselling in England (PORTSSS) 
approximately eight per cent of study participants had quit at six months 
follow-up.176 However, there was no significant difference between those 
receiving standard reactive support and proactive support, and the study 
also found that offering free NRT via the quitline did not increase quit 
success. The NTCD contains monthly quitline calls data from the NHS stop 
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smoking helplines in England from November 2004 to December 2009. The 
data are available from the Department of Health. 
Strengths 
Quitline calls seem likely to be a good proxy measure for quit 
attempts, although we cannot extrapolate what proportion of callers go on 
to make a quit attempt. The major strengths of these data are that they 
are objective, and that they are available on a monthly basis over a long 
period of time. The quitline data are population level data, and therefore 
ought to be completely representative of national calls. Finally, quitline 
calls also seem likely to be more sensitive to policy than prevalence, 
making it easier to detect small and short-term effects on quitting 
behaviour. 
Limitations 
The quitline data have several limitations. Firstly, they do not 
contain information about the length of calls; therefore we do not know 
how many recorded calls were hoax calls or extremely brief calls that were 
unlikely to include adequate cessation advice. Further to this, the calls are 
provided as aggregated data; the data therefore contain no 
sociodemographic information. In addition, although there is international 
evidence for the effectiveness of quitline calls, there have been no recent 
studies of the effectiveness of the quitlines in increasing quit attempts and 
quit success in England. Thus although it is likely that increases in quitline 
calls indicate a behavioural action to seek support, we cannot be sure that 
increases in calls translate to increased quit attempts and success. 
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2.4.4  General practice data 
Overview 
A further, more comprehensive source of non-survey data on 
smoking and quitting behaviour is primary care data. The primary care 
data in the NTCD are from THIN. THIN is a database containing the 
primary care records of approximately 8 million patients from 446 UK 
general practices, including 329 practices in England. 3.2 million patients 
are currently registered with a practice and can be followed prospectively; 
retrospective data are available for the remaining patients who have since 
either died or transferred from THIN practices.177 Prospective medical 
records are recorded using the Vision general practice computer system 
software (In Practice Systems, London, UK), and serve as the primary 
medical record for the practice. GPs are able to record diagnoses, 
demographic information, lifestyle characteristics and other medical 
information. Prescriptions are automatically recorded when the relevant 
details are entered into a computer to generate prescription forms. 
The validity of THIN data has been demonstrated for major 
events.178-183 Studies have demonstrated the accuracy of recording of 
death178, hepatitis C179, gastrointestinal ulcer180, lymphoma181 and skin 
cancer182. A further study was able to replicate well-established 
associations between diseases (for example hypertension and stroke) and 
between diseases and drugs (for example aspirin and colon cancer) in case 
control studies.183 
Indicators of smoking and quitting behaviour 
THIN contains data on a range of measures of smoking and quitting 
behaviour. It contains data on recorded smoking status, prescribing for 
smoking cessation medication, brief stop smoking advice provided by GPs, 
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and referrals to stop smoking services. As explained in section 1.6.9, the 
QOF provides incentives for GPs to record smoking status in all patients 
and offer smoking cessation advice and referrals to smoking cessation 
services to smokers with certain chronic diseases. 
Strengths 
There are several general advantages to using THIN data compared 
with national survey data. THIN data are routinely collected, are released 
three to four times per year, and have a lag of only three to eight months 
before data becomes available.184 THIN also has an extremely large sample 
size, and data are available on a monthly basis. Data are available over a 
long time period (since January 2000), and, contrary to the data on sales 
and dispensing of smoking cessation medication described above, can be 
broken down into different sociodemographic groups. These data are 
therefore potentially an extremely valuable source of data for policy 
evaluation, fulfilling the majority of the criteria described in section 1.7.  
Limitations 
Not all the indicators of smoking and quitting behaviour have been 
validated. Those that have, however, have been shown to be of varying 
and variable quality; care must therefore be taken in using the data and 
drawing conclusions from such work. The validity of the prevalence, GP 
advice and referrals data has been explored in previous studies, which are 
summarised below.185 The smoking cessation medication prescribing data 
have, until now, not been validated; therefore a validation study of these 
data follows in the subsequent chapter of this thesis. 
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Prevalence data 
The data on smoking status can be used to generate estimates of 
smoking prevalence. Szatkowski et al. compared estimates of smoking 
prevalence from THIN with those from the GHS between 2000 and 2007.184 
They found that from 2006 there was good agreement between THIN and 
GHS estimates. However, as shown in Figure 2-10, there was disparity in 
estimates of up to five percentage points in the previous five years. This 
suggests that recording of smoking status has improved in recent years, 
probably as a result of the incentives provided by the QOF to record 
smoking status, which previous studies have shown to improve recording 
of patient smoking status.118, 119 The authors concluded that THIN can 
possibly be used to identify current smokers with sufficient accuracy to 
monitor national smoking prevalence (though recording of ex- and never-
smokers is less complete), although a limitation of these data is that, like 
survey data, they are self-reported.  
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Figure 2-10. Adult smoking prevalence, England, based on THIN, 
2000-2009 
 
Source: Lisa Szatkowski, PhD thesis 
 
A further study has replicated these results at the regional level.152 
This study formed part of a medical sciences student project designed and 
supervised by me and Sarah Lewis. It has subsequently been published in 
BMC Public Health and is also included as an appendix in this thesis 
(Appendix 9.2). Despite the diminished sample size of the THIN data at the 
regional level, the results of this study were broadly consistent with those 
of the study of these data carried out at the national level. As at the 
national level, prevalence estimates based on THIN from most regions 
were found to be similar to those based on the GLF from 2006 onwards.  
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Brief advice data 
Brief stop smoking advice in a general practice setting has been 
shown to be an effective and cost-effective way of getting people to quit 
smoking.186, 187 Brief advice recorded in primary care records is therefore a 
potentially valuable indicator of quitting behaviour. The introduction of the 
QOF provided a financial incentive for GPs to record that they had offered 
smokers smoking cessation advice.188 In the year following the introduction 
of the QOF, rates of advice giving tripled; however, this may have been 
due to GPs¶ increased propensity to record advice as opposed to reflecting 
a genuine increase in advice giving.189  
Szatkowski et al. compared advice recorded in THIN with that 
recalled in a survey of NHS patients in England, the Primary Care Trust 
(PCT) Patient Survey to explore agreement between these two data 
sources and to establish whether THIN may be a good source of data on 
advice giving.190 The researchers found that, as previously reported, the 
proportion of patients with a record of cessation advice increased during 
the study period, particularly in the year of and following the 
implementation of the QOF. As Figure 2-11 shows, there was good 
agreement between recording of cessation advice in THIN and recall rates 
in 2004. In 2005 and 2008, however, recall rates were much lower. This 
may reflect recall or reporting bias in the Patient Survey, recording of 
advice that was refused, or the recording in THIN of advice that was not 
actually given. Regardless of the reason for the discrepancy, if GP advice is 
not recalled by patients, it seems likely that smokers are not responding to 
advice. Therefore, recording of brief advice in THIN is probably not a good 
indicator of quitting behaviour. 
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Figure 2-11. The proportion of THIN patients aged 16+ with 
recorded cessation advice and predicted recall rates, 2000-2009 
 
Source: Szatkowski et al. 2011 
 
Referrals data 
As described in section 1.6.10, the NHS SSS are highly effective at 
helping people to quit smoking.191 As a result, GP referrals to smoking 
cessation services are a potentially useful measure of quitting behaviour. 
Szatkowski found that there was no source of data that was directly 
comparable to the THIN data for validation, but used Omnibus survey data 
on the number of self-reported smokers who also self-reported having 
been referred or self-referred to a stop smoking group, clinic or service in 
the past year. As shown in Figure 2-12, the proportion of patients with a 
referral to a smoking cessation service recorded in their records is 
extremely low. The number of people predicted to recall referral based on 
the Omnibus data increased until 2006 and then levelled out, and is much 
higher than recorded referral. This discrepancy may be due to the 
differences between the two data sources. Nonetheless, there remains 
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significant uncertainty about the quality of the smoking cessation service 
referral data in THIN, and it therefore seems inappropriate to use them in 
policy evaluation. 
Figure 2-12. The proportion of THIN patients aged 16+ with 
recorded referral and predicted referral rates, 2000-2009 
 
Source: Lisa Szatkowski, PhD thesis 
 
2.5 Conclusions  
Comprehensive evaluation of the impact of tobacco control policy on 
quitting behaviour benefits from having high quality, regular data over a 
long time period in a large, representative sample with extensive 
sociodemographic data. Key indicators are successful quit attempts and 
smoking prevalence, and combining these with other indicators of quitting 
behaviour such as the use of pharmacological smoking cessation aids and 
smoking cessation support services can provide a broad evidence base as 
to the impact of a policy on quitting behaviour. This chapter has 
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summarised a large group of data sources which can provide data on these 
indicators in England. 
The key characteristics of the data sources described in this chapter 
are summarised in Table 2-1 and Table 2-2. This chapter has 
demonstrated that surveys are a valuable source of data for the monitoring 
of smoking behaviour in the UK; they are generally less appropriate for 
evaluating the impact of specific tobacco control policies. These data are 
often collected on an annual basis, and those that are more frequently 
collected tend to have small sample sizes. The inability to take into account 
confounding by other policies and/or the presence of large standard errors, 
particularly in smaller demographic groups, limits the level of evidence that 
can be obtained from these data sources. The IHS may prove to be a 
valuable source of data in the future, but currently the non-survey sources 
described in this chapter seem to provide more appropriate data for the 
evaluation of tobacco control policy. 
Some of the non-survey data have the disadvantage (compared 
with surveys), of having little sociodemographic data, which makes them 
inadequate for exploring differential impacts of policy across demographic 
groups. However, they provide long time series with short data intervals 
based on large sample sizes. This makes them suitable for the evaluation 
of individual policies. 
Of all the data sources described in this chapter, THIN primary care 
data appear to be best suited to the evaluation of policy ± THIN provides 
time series data based on an extremely large sample size, even on a 
monthly basis. There is, however, uncertainty about the quality of THIN 
data on the delivery of cessation advice and referral of smokers to 
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cessation services. THIN also, however, has large-scale smoking 
prevalence data which, though seemingly only valid from 2006, may prove 
to be an extremely valuable source of prevalence data which can be used 
to accurately estimate policy impacts in the future. The availability of 
detailed demographic data in such a large sample over a long time period 
makes primary care data uniquely suited to the evaluation of the impact of 
tobacco control policy on quitting behaviour.  
Overall then, it seems that the data available for tobacco control 
policy evaluation in England have significant gaps and limitations, with no 
validated monthly measure of quit attempts or success, and no validated 
monthly measure of smoking prevalence which covers a long time series. 
There are, however, good data on a group of proxy measures for quit 
attempts, such as smoking cessation medication sales and dispensing, and 
quitline calls, although these lack sociodemographic data. Unfortunately, 
the incomplete nature of the data for much of the period for which data are 
available means that THIN prevalence data cannot be used in this PhD 
thesis. The next chapter of this thesis, however, turns to the validation of 
the final indicator of smoking and quitting behaviour, prescribing of 
smoking cessation medication, which has, to my knowledge, not previously 
been validated.  
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Table 2-1. Summary of characteristics of quitting behaviour data sources: Survey data 
 Key measures of 
quitting 
behaviour 
Geographical 
coverage  
Sociodemographic 
data 
Sample 
size  
Data intervals Date data 
first 
available 
GHS - Smoking 
prevalence 
- Attitudes to 
quitting 
Great Britain - Sex 
- Age  
- Region 
- SES 
16000 Annual 1971 
Omnibus - Smoking 
prevalence* 
Great Britain - Sex 
- Age  
- Region 
- SES 
18000 Monthly. 
Smoking data in 
most months* 
Oct 1990 
HSE - Smoking 
prevalence 
- Attitudes to 
quitting 
England - Sex 
- Age  
- Region 
- SES 
7000-
16000 
Annual 1991 
Smoking 
Toolkit 
- Prevalence  
- Quit attempts 
- Medication use 
- Attitudes to 
quitting 
England - Sex 
- Age  
- Region 
- SES 
2000 Monthly Nov 2006 
*Refers to Module 210. Module 130 is more detailed but is only carried out 1 to 2 times per year
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Table 2-2. Summary of characteristics of quitting behaviour data sources: Routine data 
 Type of data Key measures of 
quitting behaviour 
Geographical 
coverage  
Sociodemographic 
data 
Sample 
size  
Data 
intervals 
Date 
data 
first 
available 
OTC NRT 
data 
Scanner data - Unit sales of OTC 
NRT 
Great Britain - Region Population 
level 
Monthly Oct 2003 
ePACT Dispensed NHS 
prescription 
data 
- Dispensed 
prescriptions for stop 
smoking medication 
England - Region Population 
level 
Monthly Aug 2003 
NHS Stop 
Smoking 
Helpline 
Quitline calls 
data 
- Number of quitline 
calls 
England - None Population 
level 
Monthly Nov 2004 
THIN Primary care 
data 
- Smoking status 
- Prescriptions 
- Brief stop smoking 
advice 
- SSS referrals 
UK - Sex 
- Year of birth 
- SES 
- Region 
6 million Monthly Jan 2000 
90 
 
CHAPTER 3: VALIDATION STUDY 
OF THIN DATA ON PRESCRIBING OF 
SMOKING CESSATION MEDICATION
  
3.1 Introduction 
Whether prescriptions recorded in primary care can provide an 
accurate indicator for monitoring trends in prescribed smoking cessation 
medications and evaluating tobacco control policy depends on the 
completeness of the primary care data. Comparing prescribing records with 
dispensing records provides a means of assessing this. I carried out a 
validation study comparing secular trends in monthly rates of prescribing 
for smoking cessation medications based on THIN data with monthly rates 
of dispensing of these treatments based on national dispensing data for 
January 2004 to December 2005. Due to their likely completeness, I 
compared the THIN data with the ePACT data from NHS Prescription 
Services described in section 2.4. The aim was to assess whether THIN 
data are complete and can therefore be used to monitor trends in 
prescribed smoking cessation medications and identify changes in 
prescribing following the implementation of a tobacco control policy. This 
study has been published in Pharmacoepidemiology and Drug Safety.192 
3.2 Methods 
NHS Prescription Services collect data on prescriptions dispensed in 
England only; therefore, only data from the 329 English practices in THIN 
were used in the analyses this chapter.  
The outcome measures were rates of prescribing of all NRT and 
bupropion per 100,000 of the population per month based on THIN, and 
rates of dispensing of the same medications per 100,000 of the population 
per month based on the ePACT data. 
The total number of NRT and bupropion prescriptions in all patients 
for each month between January 2004 and December 2005 were extracted 
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from the THIN database. The combined total was used as a measure for 
total smoking cessation medication prescriptions. Varenicline did not 
become available in the UK until December 2006 and is therefore not 
included in this analysis. The denominator for each month was the total 
number of live individuals contributing data to the THIN database 
throughout the month. It was assumed that those contributing data within 
each month provided one person-month of follow-up, and the numbers of 
prescriptions were divided by the total person months to derive the rate of 
prescribing per 100,000 of the population per month.  
The total number of dispensed NRT and bupropion prescriptions for 
each month of the study period was also extracted from the ePACT data. 
The monthly population denominators for these data were calculated using 
the Office for National Statistics mid-year population estimates for England 
for each year, increasing by one twelfth of the annual increase per 
month.193 The monthly dispensing rates were calculated in the same way 
as the prescribing rates.  
The rates of prescribing of smoking cessation medications in THIN 
and of dispensed prescriptions for these treatments from ePACT were 
compared for each month for the period January 2004 to December 2005. 
This period was selected due to the lack of major tobacco policy changes 
which may have influenced behaviour or prescribing in these two years. 
The analysis had no age limits due to the lack of age-stratification in the 
ePACT data. 
Monthly prescribing and dispensing rates were compared graphically 
for the study period to assess whether THIN smoking cessation medication 
prescribing data are similar to NHS Prescription Services dispensing data. 
93 
 
All analysis was carried out in Stata Version 10.0 (Stata Corp, College 
Station, TX). 
The difference between the rates of prescribing and dispensing was 
estimated as the percentage difference between the mean rates of 
prescribing and dispensing over the study period.  
The analysis of THIN data for this study was approved by the 
Derbyshire ethics committee.  
3.3 Results 
Figure 3-1 shows the rate of total prescribing of smoking cessation 
medication in THIN between January 2004 and December 2005, as well as 
the rates of dispensing of smoking cessation medication from ePACT. 
Throughout this period the rates were very similar for these two sets of 
data, although numbers of dispensed prescriptions tended to be very 
slightly higher than prescriptions written in general practice. There were 
peaks in written and dispensed prescriptions in January and March of both 
years, coinciding with New Year and No Smoking Day. The agreement 
between rates of prescribing and dispensing remained consistent during 
the period studied.  
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Figure 3-1. Rates of prescribing of smoking cessation medication, 
England, based on THIN and ePACT, January 2004-December 2005 
 
 
NRT products made up the majority of prescriptions. A discrepancy 
between dispensing and prescribing of NRT products, which was largely 
consistent over time, was observed (Figure 3-2). Across the two years 
studied, NRT dispensing exceeded GP prescribing by 5.5% on average. For 
bupropion, which was much less frequently prescribed than NRT, the rate 
of prescribing tended to exceed the rate of dispensing (Figure 3-3). 
Bupropion prescriptions exceeded dispensing by 5% on average across the 
study period. Here too, the small amount by which prescribing and 
dispensing differed was largely consistent over time.  
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Figure 3-2. Rates of prescribing of NRT, England, based on THIN 
and ePACT, January 2004 to December 2005 
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Figure 3-3. Rates of prescribing of bupropion, England, based on 
THIN and ePACT, January 2004-December 2005 
 
 
3.4 Discussion 
These results show that the rates of prescribing of smoking 
cessation medication recorded in THIN are highly comparable to the rates 
of dispensing of prescriptions based on data from ePACT, and remain 
consistently so over the time period studied. To my knowledge, this is the 
first study to assess the validity of THIN prescribing data for specific drugs 
and, as these data are a valuable source of information on prescribing 
patterns, finding them to be consistent with dispensing patterns is 
important.  
Only data up to 2006 were analysed to avoid the period since 2006 
when major changes in tobacco policy, including the introduction of 
smokefree legislation, may have served to change the underlying patterns 
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of prescribing. Appendix 9.3 shows that the agreement between the two 
data sources is in fact also consistent after December 2005, including the 
period after varenicline was introduced. 
Previous studies have suggested that prescriptions are well 
recorded in electronic primary care records. In a systematic review of the 
quality of electronic patient records, Thiru et al. found that prescribing data 
tended to be more complete than diagnostic or lifestyle data.194 In 
particular, prescribing data from the General Practice Research Database 
(GPRD), of which approximately 50% of contributing practices also 
contribute to THIN, have also been demonstrated to be of high quality.168, 
195, 196 In computerised medical records systems, where prescription forms 
are generated from within electronic medical records, as is the case in 
THIN, prescription records would be expected to be complete. The high 
level of consistency between rates of smoking cessation medication 
prescriptions in THIN and ePACT data provides support for the convergent 
validity of these data. THIN prescriptions data cannot, however, provide 
direct estimates of actual medication use, as this is dependent on 
medication compliance. Assessing the latter is difficult without surveying 
recipients, and that was beyond the scope of this study.  
The rate of dispensing slightly exceeds that of prescribing, overall, 
and specifically for NRT prescriptions. These data might therefore be seen 
to indicate that the recording of written prescriptions in THIN is 
incomplete. However, THIN data include only prescriptions written within 
IDPLO\ SK\VLFLDQ¶V SUHPLVHV ZKLOVW WKH ePACT data also include 
prescriptions written by community-based nurses and pharmacists, which 
are also dispensed in community pharmacies. During the study period a 
minority of specially-trained nurses and pharmacists were permitted to 
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prescribe nicotine replacement therapy (but not bupropion). Between April 
and September 2005 three brands of NRT were in the top twenty 
dispensed products prescribed by nurses, accounting for 6.7% of all NRT 
prescribed in this period.12 These prescriptions may not always be recorded 
in THIN. A limitation of this study is that it is not known what proportion of 
dispensed prescriptions are written by community-based nurses (and 
therefore would not be recorded in THIN), but as non-GP prescribing for 
stop smoking medication may occur in unique settings, such as in stop 
smoking groups, it seems likely to be high.  Overall, the discrepancy 
between NRT prescribing and dispensing seems likely to be largely caused 
by the inclusion of prescribing outside of general practice in the dispensing 
data.  
For bupropion, contrary to the results for NRT, the rate of 
prescribing exceeded the rate of dispensing. The major factor which is 
likely to have led to the discrepancy between rates of prescribing and 
dispensing is the non-use of prescriptions. As stated in section 2.4.2, 
previous studies have estimated that between 5.2% and 20% of patients 
do not redeem their prescriptions.168-172 The lower rate of dispensed 
compared to written prescriptions for bupropion seems likely to be 
attributable to this cause. Over the two years included in this study, the 
rate of prescribing was 5% higher than the rate of dispensing for 
bupropion. This figure may provide some indication of the proportion of 
written bupropion prescriptions that are not dispensed. It is at the lower 
end of the range of unredeemed prescriptions found in other studies, and 
may be an underestimate, if recording of prescriptions in THIN is not 
entirely accurate. Failure to use bupropion prescriptions could be a 
consequence of reports of sudden deaths associated with bupropion.197 
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Subsequent research studies demonstrating a favourable safety profile for 
bupropion may not have fully allayed these fears in the public arena.198 
That dispensed prescriptions exceed written prescriptions for NRT 
suggests that the proportion of unused prescriptions is lower for NRT. A 
limitation of this study is that it is not possible to separate this effect from 
that of the other factors, previously described, that may contribute to the 
discrepancies.  
Because THIN prescription data and national dispensing data are 
highly comparable and small differences between these are relatively 
consistent over time, THIN prescription data could be used to monitor 
longitudinal trends in prescribing for smoking cessation medications. As 
sociodemographic information is also available in THIN, these data could 
also be used to investigate variation in prescribing across different 
demographic and socioeconomic groups and provides a means for 
monitoring the smoking cessation behaviour of the population in response 
to tobacco control policy. In doing so, it would be important to take into 
consideration the fact that these medications may not necessarily be 
prescribed for smoking cessation. In particular, NRT may be used for 
cutting down or temporary abstinence so that its use for smoking cessation 
may be overestimated. In non-UK settings, bupropion may be prescribed 
for depression, but in the UK it does not have a license for treating 
depression, therefore all bupropion prescriptions will be for smoking 
cessation. 
3.5 Conclusions 
THIN appears to be a source of highly valid data on prescribing of 
smoking cessation medication. It is arguably the best measure of quitting 
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behaviour in the NTCD, because it is valid on a monthly basis, includes 
extensive sociodemographic data, and covers a long time period. THIN 
prescription data could therefore be used to monitor longitudinal trends in 
prescribing for smoking cessation medications and can be a useful tool in 
studying the smoking cessation behaviour of the population in response to 
tobacco control policy.  
The smoking cessation medication data in THIN lend themselves to 
the evaluation of several policies that have recently been implemented in 
England which aimed to increase access to smoking cessation medication. 
The THIN prescribing data are therefore used as outcome measures 
throughout this thesis.
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CHAPTER 4: TIME SERIES 
METHODS FOR THE EVALUATION OF 
TOBACCO CONTROL POLICY
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4.1 Introduction 
The concept of time series analysis and its potential value in the 
evaluation of tobacco control policies has been discussed in the 
introduction. This chapter takes a more detailed look at why time series 
analysis is needed, and at the different types of time series analysis that 
may be employed when estimating the effect of health policies. Section 4.2 
describes why specific methods are needed to analyse time series. Section 
4.3 deals with interrupted time series analysis ± a method which looks at 
the impact of a policy introduced at one point in time. Section 4.4 explores 
multiple time series analysis ± a method for measuring the impact of a  
policy exposure which changes over time. For each method the following 
questions are considered: 
x What questions will the method help to answer? 
x What data are required? 
x How is the model specified? 
x How are the results interpreted? 
x What are the strengths and limitations of this approach? 
 
The Stata commands needed for all the time series models 
described in this chapter are presented in Appendix 9.4. 
The remainder of this thesis uses these different methods to 
evaluate a range of different tobacco control policies introduced in England 
in recent years.  
4.2 Why we need time series analysis: autocorrelation 
In time series data, instead of fluctuating randomly from one period 
to the next, successive observations tend to be close to each other; this is 
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known as autocorrelation. Autocorrelation may also be seasonal. In this 
case, in a monthly time series, a value of the series at one point in time is 
related to that 12 (and in some cases 24, 36 and so on) months 
previously. 
Autocorrelation in a time series violates a central assumption of 
linear regression, namely independence between data points. This causes 
standard errors to be underestimated (if the autocorrelation is positive), or 
overestimated (if the autocorrelation is negative).199 Therefore, modelling 
the impact of an intervention without taking account of the autocorrelation 
in a time series may lead to making either a type one (rejecting a true null 
hypothesis) or type two (accepting a false null) error. Thus, if time series 
data are autocorrelated and we do not take account of the autocorrelation, 
we may make inaccurate inferences about the effect of policies. For 
example, we may incorrectly conclude that a policy was effective, or 
incorrectly conclude that a policy was not effective. Such errors could lead 
to an inefficient use of resources, for example through trying to improve a 
policy that is in fact meeting its objectives, or through encouraging 
policymakers in other regions or countries to implement a policy that is 
unlikely to be effective. Time series techniques accommodate 
autocorrelated errors and avoid these problems. 
4.2.1 Identifying autocorrelation 
An autocorrelation function (ACF) can be used to demonstrate 
graphically whether autocorrelation is present in a time series. Figure 4-1 
below shows the average autocorrelation between data points in one of the 
time series that was validated in Chapter 3 ± prescribing of NRT in THIN. It 
shows that the correlation between data points and their one-month lags is 
104 
 
high and significant, at 0.6, and decreases as the lag increases. The ACF 
also suggests that there is seasonal autocorrelation, as there is also high 
correlation with the value at the 12 month lag.  
Figure 4-1. Example of an autocorrelation function 
 
 
4.2.2 The partial autocorrelation function and types of 
autocorrelation 
Partial autocorrelation is the correlation between a value at a point 
in time and lag of itself that is not explained by correlations at lower-order 
lags, and can be seen in a partial autocorrelation function (PACF). Thus if 
the PACF has a significant spike at lag 1 only, the higher-order correlations 
are almost entirely due to the lag 1 autocorrelation. Figure 4-2 shows an 
example of a PACF using the NRT prescribing data from THIN. The PACF 
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can be used in conjunction with the ACF to identify the type of 
autocorrelation that is present in a time series. 
Figure 4-2. Example of a partial autocorrelation function 
 
 
There are two types of autocorrelation: autoregressive (AR) and 
moving average (MA).  
If there is autoregressive autocorrelation in a time series, the value 
of the series at a point in time is a function of the value of the series at a 
previous point in time, plus an error component. In an autoregressive 
process of order one ± AR(1) ± the value at one point in time, t, is a 
function of the value of the series at the point in time immediately prior to 
it, t-1.200 The order of autoregressive autocorrelation is rarely greater than 
two.201 
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If there is moving average autocorrelation in a time series, the 
value of the series at a point in time is a function of the error component 
from the series at an earlier point in time and the error component at the 
current point in time. In a moving average process of order one ± MA(1) ± 
the value at one point in time, t, is a function of the error component other 
the series at the point in time immediately prior to it, t-1, and the error at 
the current point in time.200 As for AR processes, the order of MA 
autocorrelation is usually not greater than two. 
There are rules of thumb for identifying the order of autocorrelation 
present in a time series using ACFs and PACFs. As will be explained in this 
chapter, these autocorrelation terms are then fitted in the time series 
model. Table 4-1 contains a summary of practical recommendations for 
identification by Pankratz.202 
Table 4-1. Recommendations for identifying the autocorrelation 
process 
Process (order) ACF PACF 
AR(1) Exponential decay Spike at lag 1, no 
correlation for other 
lags 
AR(2) Sine-wave pattern or 
set of exponential 
decays 
Spikes at lags 1 and 2, 
no correlation for other 
lags 
MA(1) Spike at lag 1, no 
correlation for other 
lags 
Damps out 
exponentially 
MA(2) Spikes at lags 1 and 2, 
no correlation for other 
lags 
Sine-wave pattern or 
set of exponential 
decays 
AR(1) and MA(1) Exponential decay 
starting at lag 1 
Exponential decay 
starting at lag 1 
Adapted from ARIMA methodology: 
http://www.statsoft.com/textbook/time-series-analysis/#arima (Accessed 
29th October 2011) 
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These rules can also be applied to identify seasonal autocorrelation. 
For example, if there is seasonal autoregressive autocorrelation in monthly 
data, there will be significant autocorrelation at lag 12 with exponential 
decay in the ACF and a spike at lag 12 with no correlation for other lags in 
the PACF. 
4.3 Interrupted time series analysis 
Interrupted time series analyses are methods used to determine 
whether an intervention, such as a public health policy, affects a time 
series of outcome measurements. In interrupted time series analysis, the 
intervention must be introduced at a single, known point in time so that 
the data can be separated into pre± and post-interruption series. This 
chapter presents two approaches to interrupted time series analysis, each 
with strengths and limitations. One is a regression framework, and one is a 
class of mathematical models called Autoregressive Integrated Moving 
Average (ARIMA) models. Both of these methods and their application to 
the evaluation of public health policy have been described in detail 
elsewhere; therefore, this section provides a brief overview of the key 
points related to each method.185, 203 
4.3.1 Segmented regression analysis 
What questions will the segmented regression help to answer? 
Segmented regression analysis is one approach to comparing pre- 
and post±intervention series; this method has increasingly been used to 
estimate the effects of health services and policy interventions, but is still 
rarely used to evaluate the impact of national public health policy.203-207  
The segmented regression approach can be used to assess how 
much an intervention, such as the introduction of smokefree legislation, 
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changed an outcome of interest, such as the national prevalence of 
smoking, immediately and over time. Segmented regression analysis 
estimates the trend in a time series before an intervention, and step 
changes in the level and changes in the trend of the series at the time 
point immediately following an intervention, taking into account any 
seasonal patterns in the data.203  
Data requirements 
Segmented regression analysis requires data to be in regular, 
equally-spaced time intervals.203 Segmented regression can be undertaken 
with relatively short time series, although recommendations as to the 
PLQLPXPOHQJWKRIWKHWLPHVHULHVYDU\&RFKUDQH¶V(IIHFWLYH3UDFWLFHDQG
Organisation of Care Group recommend that interrupted time series 
models (but not ARIMA models, for which the recommendations are 
longer) have at least three observations prior to the intervention and at 
least three in the post-intervention period.208 However, a more appropriate 
recommendation when using monthly data is for at least 12 data points 
prior to and after the intervention.203 This allows seasonal variation to be 
taken into account. This recommendation is not based on power, however, 
and the power of the model is more likely to depend on the complexity of 
the autocorrelation.209 Power calculations for this type of analysis are in 
their infancy.209  
Fitting a linear segmented regression model 
Wagner et al. describe in detail how to fit a segmented regression 
model.203 Simple segmented regression models can be fitted as linear 
regression models that include terms to describe the trend in the outcome 
in the pre-intervention period, any immediate step change in the level of 
outcome following the intervention, and any change in the trend in the 
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outcome in the post-intervention compared to pre-intervention data, as 
shown in equation (1).210 
Yt = ǃ0 + ǃ1*timet + ǃ2*interventiont + ǃ3*time since intervention + İt (1) 
 In equation (1), ǃ1 is the trend prior to the intervention, ǃ2 is the 
change in level immediately after the intervention, and ǃ3 is the change in 
the trend following the intervention. Thus (ǃ1+ ǃ3) is the post-intervention 
slope. A parsimonious model is built by eliminating non-significant terms 
from the model. Table 4-2 shows an example of how one would structure a 
dataset to investigate a change in prescribing following an intervention 
introduced at time point 16.
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Table 4-2. Structure of data for segmented regression analysis 
Time 
(timet) 
Level 
(interventiont) 
Slope 
(time since 
interventiont) 
Prescriptions 
(Yt) 
1 0 0 31.91 
2 0 0 30.71 
3 0 0 36.70 
4 0 0 37.68 
5 0 0 50.95 
6 0 0 44.92 
7 0 0 50.79 
8 0 0 50.76 
9 0 0 46.62 
10 0 0 45.73 
11 0 0 40.69 
12 0 0 29.69 
13 0 0 38.64 
14 0 0 41.38 
15 0 0 71.75 
16 1 1 50.93 
17 1 2 99.27 
18 1 3 58.88 
19 1 4 86.35 
20 1 5 55.83 
21 1 6 61.62 
22 1 7 52.05 
23 1 8 32.36 
24 1 9 39.38 
25 1 10 51.23 
26 1 11 79.52 
27 1 12 39.11 
28 1 13 39.99 
29 1 14 108.36 
30 1 15 111.28 
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Interpreting the results 
Running a segmented regression model generates estimates of 
coefficients, confidence intervals and p-values for the pre-intervention 
trend, immediate change in level and change in trend of the time series. 
The values of the outcome variable predicted by the model can also be 
obtained and plotted against the original time series to demonstrate, 
graphically, any changes in the trend and/or level of the time series 
following the intervention. 
Dealing with autocorrelation in segmented regression models: General 
Additive Models 
Simple linear regression does not, however, account for 
autocorrelation. If the ACF of the residuals of the model reveals AR 
autocorrelation at one lag, Prais-Winsten estimation can be used to take 
this into account.211 However, the Prais-Winsten method is not able to 
correct for MA autocorrelation or AR autocorrelation of an order higher 
than one. Thus if these types of autocorrelation are present in a time 
series, we risk drawing incorrect conclusions about the impact of a policy. 
Alternative models can be used to take account of more complex 
autocorrelation structures.  
When autocorrelation structures in data are found to be more 
complex than AR(1), more flexible types of model can be used: 
Generalised Additive Models (GAMs) and Generalised Additive Mixed 
Models (GAMMs). GAMs enable the fitting of seasonal smoothing terms, 
and therefore allow seasonal autocorrelation to be taken into account.212 
GAMMs can also fit AR and MA autocorrelation terms, thus ensuring that all 
autocorrelation is taken into account.210  
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GAMs and GAMMs can both be fitted in the statistical package R by 
first running a linear regression model as described above, and then using 
stepwise elimination to obtain a parsimonious model. If there is evidence 
of seasonal autocorrelation in the residuals of the model, a smoothing term 
is included to model any regular seasonal pattern in the outcome. The 
ACFs and PACFs of this model are then used to establish which 
autocorrelation terms are required.  
These methods have recently been used to evaluate the impact of 
smokefree legislation in England on hospital admissions for myocardial 
infarction.145 The code required to conduct a segmented regression 
analysis using GAMs and GAMMs in R is presented in Appendix 9.5. 
Strengths and limitations of segmented regression analysis 
 
The key strength of segmented regression analysis is that it can 
control for underlying trends, which is important for ensuring that correct 
conclusions are drawn. By using GAMs and GAMMs, seasonal effects and 
autocorrelation can also be taken into account. Further to this, segmented 
regression can be used to estimate two key parameters ± immediate 
changes in the mean of a series and changes in the trend following an 
intervention, which gives a useful indication of the immediate and longer 
term impact of an intervention. 
The main strength of segmented regression is that it can be used 
with relatively short time series. This is particularly important in public 
health research where long series with regularly-spaced data are not 
always at hand for the variables of interest. 
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Segmented regression also has several limitations. A fundamental 
limitation of all analysis that investigates the effect of a policy introduced 
at one point in time is that it is not possible to reliably separate the effects 
of different policies that are introduced at the same time or in proximate 
time. For tobacco control policies this is often the case, and care must 
therefore be taken in interpreting the results. 
A further limitation of segmented regression analysis is that it may 
fail to capture effects that occur prior to the intervention (for example, 
people trying to quit smoking in the run up to smokefree legislation). It 
may also fail to detect any transient effects on the trend of a time series. 
This may be overcome by shortening the time series, so that a shorter 
time period following the introduction of a policy is analysed, but this will 
reduce the power of the model. Autoregressive Integrated Moving Average 
(ARIMA) models provide a more flexible method for investigating the 
effects of policy changes which does not have these limitations. 
Finally, because segmented regression involves fitting linear 
regression models, it can only be used when the trends before and after 
the policy change are linear. ARIMA models can be used when there are 
non-linear trends in the time series. 
4.3.2 Autoregressive Integrated Moving Average (ARIMA) 
modelling 
What questions will the ARIMA approach help to answer? 
ARIMA models are frequently used by econometricians to make 
economic forecasts, and have also be used for forecasting the incidence of 
diseases.213, 214 However, they are also an alternative approach to 
interrupted time series analysis, and allow changes in the outcome variable 
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before and after the intervention to be explored. As such, ARIMA models 
are increasingly being employed in public health evaluation. 
Like segmented regression analysis, the ARIMA model can be used 
to assess whether there were changes in an outcome of interest, such as 
the rate of prescribing of stop smoking medications, after the introduction 
of an intervention, such as smokefree legislation. Changes are expressed 
relative to the underlying level of the outcome variable, taking long-term 
and seasonal trends into account. Unlike segmented regression, however, 
ARIMA models can be used to investigate, in detail, the nature of the 
change: whether it pre-empted the policy, and whether the effects are 
transient or permanent.  
The ARIMA method models the behaviour of the time series and 
establishes whether an intervention has a statistically significant impact on 
the time series by assessing whether the data-generating process of the 
time series has changed between the pre-and post-policy period. In other 
words, ARIMA modelling tells us whether the intervention component helps 
to predict the behaviour of the time series over and above the seasonal 
and serial correlation components.  
Data requirements 
Recommendations as to the length of time series required for 
ARIMA modelling vary. The Cochrane Effective Practice and Organisation of 
Care Group recommend that at least 20 observations prior to the 
intervention are required, but this appears unlikely to enable accurate 
modelling if there are seasonal effects in the time series.208 Other authors 
recommend at least 50-100 observations, though some simulations 
suggest 250 or more observations are needed for accurate modelling.215 
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The number of observations needed increases if a series exhibits 
seasonality, which is often the case for monthly data. If it is likely that a 
policy will take time to have an effect, enough post-intervention data are 
required to ensure that the lag in effect is captured. Methods to calculate 
the power of interrupted time series analysis using ARIMA models have 
recently been developed.216 
Preparing the data 
The first step in an ARIMA analysis is to check the time series for 
outlying values. Outliers can bias the results of time series analysis, and 
can be replaced by imputed values.200 If they appear at the beginning of a 
time series, and the time series is long enough, they can be omitted from 
the analysis. 
ARIMA modelling needs to be carried out on stationary data; the 
mean and variance of a series must be stable over time.215 If the variance 
of the time series is not stable, it is typically log-transformed to stabilise 
the variance.215 When a log-transformation is not possible, for example, 
when the series contains zero values, an alternative transformation, such 
as an inverse hyperbolic sine, can be used, as shown in equation (2) 
below.217 
arcsinh z = log (z+sqrt(1+z2)                          (2) 
Next, any trend in the data must be removed to ensure that the 
mean of the time series is constant over time. This can be achieved by 
differencing the time series: the value of the series at each point in time is 
replaced by the value of the difference between that point and the value of 
the time series in the previous month, as shown in Table 4-3.   
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Table 4-3. Example of differenced data 
Date Original series Value of logged series Differenced series 
Jan-03 247.254952 5.51042 - 
Feb-03 225.789918 5.419605 -0.09082 
Mar-03 242.645857 5.491603 0.071998 
Apr-03 231.211066 5.443331 -0.04827 
May-03 204.722008 5.321653 -0.12168 
Jun-03 188.828085 5.240837 -0.08082 
Jul-03 201.394969 5.305268 0.064432 
Aug-03 159.277028 5.070645 -0.23462 
Sep-03 193.894074 5.267312 0.196667 
Oct-03 220.104845 5.394104 0.126793 
Nov-03 198.322005 5.289892 -0.10421 
Dec-03 182.240091 5.205325 -0.08457 
 
The ACF and plots of the time series (and differenced time series) 
can be used to establish whether the series needs to be (further) 
differenced. A correctly differenced series will fluctuate around a well-
defined mean and the ACF will decay fairly rapidly to zero.218 A time series 
which needs to be differenced once to become trend stationary is said to 
be integrated of order one (I(1)). 
If there is significant autocorrelation at seasonal lags, the time 
series must also be seasonally differenced: in a monthly time series each 
value is replaced by the difference between that value and the value of the 
data point in the same month the previous year. 
Model identification and diagnosis 
The next step is to identify an appropriate ARIMA model. This is 
done using the pre-intervention data only.215  
An ARIMA model is conventionally described using the general 
syntax: 
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ARIMA (p, d, q)(P, D, Q)s 
 
where: 
 
p = order of non-seasonal autoregressive autocorrelation 
d = order of non-seasonal differencing needed to obtain non-
seasonal stationarity 
q = order of non-seasonal moving average autocorrelation 
P = order of seasonal autoregressive autocorrelation 
D = order of seasonal differencing needed to obtain seasonal 
stationarity 
Q = order of seasonal moving average autocorrelation 
s = seasonal order of series (number of seasons in a year)  
The autocorrelation and partial autocorrelation functions of the (if 
necessary, logged, differenced) series are examined to help determine the 
order of moving average (MA) and autoregressive (AR) terms and seasonal 
MA and AR terms needed to model the autocorrelation in the stationary 
series. The rules of thumb described in section 4.2.2 are used to identify a 
tentative model. 
This tentative model is then estimated, and several diagnostic 
checks carried out to ensure that the model is parsimonious and valid. 
Firstly, the autocorrelation terms included in the model must be 
statistically significant. This is checked based on the output from the 
model. Secondly, the model residuals must be normally distributed and 
random and independent (i.e. should display no autocorrelation). This can 
be checked by estimating the residuals of the model, and then examining 
the distribution of the data and the ACF and PACF. 
As shown in Figure 4-3, if the tentative model is inadequate, the 
process is repeated until a valid model is found. 
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Figure 4-3. Stages involved in using ARIMA to assess the impact of 
an intervention on a time series 
 
 
Intervention analysis  
When a valid, parsimonious model has been selected, it can be 
applied to the whole time series to estimate the effect of the intervention 
on the time series. The intervention is included as a dummy variable, 
which can be used to model an immediate, permanent step change in the 
outcome ± in which case the dummy takes the value 0 before the 
intervention and 1 from the time the intervention was introduced. 
Alternatively, the dummy variable can be used to model a pulse effect, 
which lasts for either only one time period (e.g. one month) or a small 
number of time periods, in which case the dummy takes the value 0 before 
the intervention, takes the value 1 for the pulse effect period and 0 
thereafter. If it is anticipated that an intervention may have an effect prior 
to its implementation, or have a lagged effect, the dummy can also take 
the value 1 prior to implementation or take the value 0 for a time after 
implementation. Thus a study found that smokefree legislation increased 
prescribing of smoking cessation medication for six months prior to the 
119 
 
implementation of the policy and up to ten months after implementation, 
but that there was no permanent increase in prescribing.184 
Confounding events can also be fitted as dummy variables, but it 
may not be possible to disentangle the effects of different interventions. 
For example, graphic health warnings may be introduced six months after 
smokefree legislation. It is possible to include a dummy variable for the 
effect of the health warnings in an evaluation of the impact of smokefree 
on quitting behaviour, but there may be a delayed impact of smokefree 
legislation; thus it will not be possible to differentiate between the effect of 
the smoking ban and that of the health warnings. 
Interpreting the results 
Running the ARIMA model for the whole time series with a dummy 
variable for the intervention generates a coefficient and corresponding 
confidence intervals and p-value for the effect of the intervention. If the 
time series has not been log-transformed the coefficient is interpreted as 
the absolute level change in the outcome as a result of the intervention. If 
the time series has been log transformed, the ARIMA model coefficients 
provide estimates of the percentage change in the outcome following the 
intervention. 
Strengths and limitations of ARIMA modelling 
ARIMA modelling has many of the same advantages as segmented 
regression, and these have been discussed in section 4.3.1: underlying 
trends can be taken into account and seasonal effects and autocorrelation 
can be modelled. 
The main advantage of ARIMA modelling over segmented 
regression is its flexibility. The dummy variable can be changed to model 
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different effects of a policy: changes prior to the implementation of the 
policy, permanent effects and transient effects. Thus much more detailed 
and potentially more accurate information can be obtained from an ARIMA 
model. In addition, as previously mentioned, ARIMA models can be used 
when there are non-linear trends in the time series. 
As mentioned in section 4.3.1, an inherent limitation with methods 
that explore the impact of a policy introduced at one point in time, is that it 
is difficult to take account of the confounding effects of simultaneous 
policies. In addition, as also previously mentioned, a potential limitation of 
ARIMA is the need for a long time series, which may not be available for 
the outcome of interest.  
4.3.3 Conclusions  
Segmented regression analysis is a powerful quasi-experimental 
approach for the evaluation of policy that can be used with relatively short 
time series. Where longer-term series of data are available, however, 
ARIMA modelling provides a more flexible approach to interrupted time 
series analysis. The relative power of the two methods is unclear; methods 
have been developed for computing the power of interrupted time series 
analysis using ARIMA models, but power calculations for segmented 
regression analysis are underdeveloped. ARIMA models allow both 
immediate and delayed, and transient and sustained, effects of 
interventions to be investigated.  
In this thesis, both types of analysis are used in order to illustrate 
how they are applied.  
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4.4 Multiple time series analysis 
Multiple time series analysis (MTSA) is a method frequently used in 
econometrics to investigate the relationships between economic time series 
measured on a continuous scale, for example income and consumption, or 
price and sales. Until now, this method has rarely been used in a public 
health context, but may be needed to deal with continuous exposure data 
such as cigarette price or health policy expenditure over time. There are a 
range of different multiple time series models, and the choice of analysis 
depends on the statistical properties of each time series and the nature of 
the temporal relationship between the time series. These properties and 
relationships are identified prior to fitting the models. This section 
describes two approaches to MTSA: dynamic regression analysis, and 
vector autoregression (VAR). 
4.4.1 Dynamic regression analysis 
What questions will dynamic regression help to answer? 
A standard MTSA approach is dynamic regression modelling (also 
known as ARMAX/ARIMAX or transfer function modelling).215 Dynamic 
regression is an extension of ARIMA modelling ± whereas in an ARIMA 
model the impact of an intervention is explained by a dummy variable, in 
dynamic regression models the time series of the outcome (output) series 
is explained in terms of current values and lags of one or more predictor 
(input) time series.215 This approach has previously been used in a study 
exploring the impact of tobacco price and mass media campaigns on 
smoking prevalence.82 
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Data requirements 
Dynamic regression requires two time series which cover the same 
period at the same temporal frequency of data collection. This author has 
not been able to identify explicit recommendations as to the number of 
data points required, but as these models are specified in a similar way to 
ARIMA models, it seems reasonable to assume that the same 
recommendations as outlined in section 4.3.2 apply. 
Preparing the data 
Like ARIMA modelling, dynamic regression analysis must be carried 
out on stationary data.215 If necessary, therefore, both time series should 
be transformed and differenced as described in section 4.3.2. If one time 
series needs to be transformed or differenced to achieve stationarity, the 
same should be done to the other time series to preserve the relationship 
between them.215 
Dynamic regression analysis assumes weak exogeneity between the 
input (Xt) and output (Yt) series i.e. Yt must depend on the lagged values 
of Xt, but the reverse must not be the case.
215 In other words, there must 
be a unidirectional relationship between the time series. If the relationship 
is bi-directional, it is said that there is feedback between the series, and an 
alternative method of analysis must be used.215 To confirm that there is 
weak exogeneity between the time series, each must be regressed on 
lagged values of itself and the other; statistical significance should only be 
found in one direction.219 This can be done using the Granger Causality 
test.215 If weak exogeneity is confirmed, dynamic regression can be used. 
If this assumption is violated, vector autoregression can be used. This 
method is described in the subsequent section. 
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Model specification 
 If weak exogeneity is confirmed, the model is specified as follows. 
A basic ARIMA model is specified in which the output series is regressed on 
sequential lags of the input series. Initially enough lags are included so 
that the proper lag can be determined by dropping lagged terms if they are 
non-significant to leave a parsimonious model. If the residuals of the 
model exhibit autocorrelation, autocorrelation terms are added to the 
model. The residuals of a correctly specified model should exhibit no 
autocorrelation and be normally distributed. Thus the general procedure 
for specifying a dynamic regression model is similar to that for ARIMA 
models. 
Interpreting the results 
Running the dynamic regression model estimates coefficients and 
corresponding confidence intervals and p-values for the effect of the input 
series on the output series in the contemporaneous time period and at 
lagged time periods, depending on the lags included in the model. If the 
time series has not been log-transformed, the coefficient is interpreted as 
the absolute change in the outcome as a result of a one-unit increase in 
the input series. If the time series has been log transformed, the model 
coefficients provide estimates of the percentage change in the outcome 
following a one percent increase in the input series. For example, in a 
study of the impact of price on sales, the coefficients provide estimates of 
the percentage change in sales following a one percent increase in price. 
Strengths and limitations of dynamic regression 
 The key strength of dynamic regression analysis is that it is able to 
take account of the complexities of time series data, including 
autocorrelation and seasonality, as well as any lags in effect. In a public 
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health context, the main limitation of dynamic regression can be the 
availability of data ± like ARIMA models, dynamic regression requires 
regular time series data over a long time period. 
A further limitation of this method is the weak exogeneity 
assumption, which can mean that other multiple time series modelling 
approaches, such as VAR, must be used.  
4.4.2 (Structural) Vector Autoregression  
What question will vector autoregression help to answer? 
When the weak exogeneity assumption of dynamic regression is 
violated, an alternative approach to estimate the impact of one time series 
on another is vector autoregressive (VAR) modelling.215 VAR is a 
framework developed to model a set of two or more dependent variables 
within a single model.220 These models were developed in order to capture 
the complex and often multi-directional relationships between 
macroeconomic variables and are often used in economic forecasting and 
policy analysis. To my knowledge, these methods have until now not been 
used in a public health context.  
However, VAR uses only lags of the input series, and can therefore 
miss valuable information when there is instantaneous causality 
(simultaneity) between two time series. There is instantaneous causality 
when the current value of Yt RXWSXWLVEHWWHUµSUHGLFWHG¶ZKHQWKHFXUUHQW
value of Xt LQSXW LV LQFOXGHG LQ WKH µSUHGLFWLRQ¶ RI Yt.221 This can occur 
when data are temporally aggregated or are recorded at insufficiently 
frequent time intervals to detect the temporal relationship between them. 
An extension of VAR, structural VAR allows assumptions to be made about 
the direction of causality in order to unpick the temporal relationships 
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between variables ± the relationships between time series within the 
current time period as well as any lagged effects in subsequent time 
periods. It is also possible to put appropriate restrictions on the model so 
that the relationship which is modelled is unidirectional. 
In evaluations of tobacco control policy, it is likely that any causal 
relationship runs from the policy to the outcome, rather than vice versa, at 
least in the short run; therefore it is appropriate to build a unidirectional 
model. Furthermore, there may be very little lag in the impact of tobacco 
control policies on certain outcomes; therefore, when using monthly or less 
frequent data that impact may appear to be, at least in part, 
instantaneous. SVAR models are likely to better capture this effect than 
VAR models, and this section therefore focuses on this type of model.  
Due to the likely rapid impact of tobacco control policies on quitting 
behaviour, this chapter describes short-run SVAR models. There are VAR 
and SVAR methods which model the long-run relationships between time 
series, but these are not dealt with here.  
Data requirements 
Like dynamic regression, SVAR modelling requires at least two 
series of data measured on continuous scales that cover the same period 
at the same frequency of data collection. 
Preparing the data 
SVAR (and VAR) modelling requires stationary data so the time 
series may need to be transformed and differenced to ensure 
stationarity.217, 222  
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Model specification 
SVAR models are estimated as follows, and the Stata commands 
required are included in Appendix 9.4.5.223 
First, matrices containing the constraints are specified; these 
determine the directions of causality in the model by restricting some 
parameters. (Normal VAR models are estimated in the same way but 
without this first step.) To explain this, an example of SVAR model looking 
at the effect of tobacco price (x) on smoking prevalence (y) is used. 
In this example, there are just two variables, and therefore the 
matrix to be estimated is a simple 2x2 matrix which represents the 
parameters in the SVAR model: 
[a    b] 
[c    d] 
Where: 
a = The effect of a change in x on x 
b = The effect of a change in y on x 
c = The effect of a change in x on y 
d = The effect of a change in y on y 
Hence: 
[xÆx    yÆx] 
[xÆy    yÆy] 
 Intuitively, the effect of a variable on itself is one. Therefore, in the 
SVAR model, we assume that the effect of price (x) on price is one, and 
that the effect of y on y is one, and that prevalence has no effect on price, 
thus yÆx = 0. The only parameter that needs to be estimated in the model 
is the effect of x on y. Thus the matrix is specified as follows: 
[1    0] 
[.     1] 
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The ¶.µwill be estimated in the model. By specifying the model in 
this way, we are setting up a model which models the effects of price on 
prevalence without allowing for an effect of prevalence on price. 
Information criteria - measures of the relative goodness of fit of a 
statistical model - are used to identify the optimal number of lags to 
include in the model; the lags account for any autocorrelation in the model. 
This is done by fitting models with different numbers of lags, and choosing 
the model which minimises the information criteria. Factors such as 
seasonal effects can be fitted as exogenous variables (variables which are 
independent from the other variables in the model). For example, if they 
improve the fit of the model (again, this is tested using information 
criteria), seasonal dummy variables can be added to the model. Once 
optimised, the model is run and diagnostic testing undertaken to establish 
that the model has been properly specified.223 These include tests for 
autocorrelation, stability (stationarity) and normality of the model 
residuals. If there is autocorrelation in the model, it should be respecified 
with a different number of lags to remove the autocorrelation. The tests for 
normality of the residuals can behave poorly in small samples and should 
therefore only be used as rough check of normality.224  
The final step in a policy analysis using a SVAR is obtaining the 
impulse response function (IRF) ± this tells us how a shock (change) to 
one variable (the impulse variable) affects future values of the second 
variable (the response variable). 
Interpreting the results 
A graphical example of an IRF is shown in Figure 4-4. IRFs show the 
change in the output variable (for example, smoking prevalence) in 
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response to a change in the input variable (such as price) in the same 
month and in the subsequent months. The solid line represents the IRF 
estimate at different time lags, and the shaded area the 95% confidence 
interval. Modelling transformed-differenced data provides the percentage 
change of each series; therefore the results can be interpreted directly as 
elasticities i.e. the percentage change in the outcome variable following a 
one percent change in the explanatory variable. Modelling non-transformed 
data provides level changes ± the absolute change in the outcome 
following a one unit rise in the exposure.   
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Figure 4-4. Example of an Impulse Response Function (IRF) 
 
 
Cumulative IRFs (CIRFS) which show the overall effect of a shock 
can also be obtained, as shown in Figure 4-5. Thus the solid line in the 
CIRF represents the total change in the response variable following a 
change in the input variable at different time lags. 
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Figure 4-5. Example of a Cumulative Impulse Response Function 
(CIRF) 
 
 
Strengths and limitations of vector autoregression 
VAR and SVAR models have broadly the same strengths and 
limitations as dynamic regression ± they are able to take account of 
autocorrelation, seasonality and lags in effect, but also require long time 
series. They offer an alternative to dynamic regression when the weak 
exogeneity assumption is violated.  
4.4.3 Conclusions 
Given the availability of appropriate data, multiple time series 
analysis is a robust way of investigating the relationship between a 
continuous exposure and a continuous outcome over time, and may 
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therefore be extremely valuable in the evaluation of tobacco control 
policies such as price increases and mass media campaigns.  
In Chapter 7 of this thesis, SVAR modelling is used to investigate 
the impact of anti-smoking mass media campaigns on quitting behaviour. 
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CHAPTER 5: PRESCRIBING OF 
SMOKING CESSATION MEDICATION 
SINCE THE INTRODUCTION OF 
VARENICLINE 
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5.1 Introduction 
The role of pharmacotherapy in increasing the success of quit 
attempts has been described in section 1.6.11. Smokers who make 
unsupported quit attempts have only a small chance of success, and 
smoking cessation medications are one way of increasing the rate of quit 
success.  
Until 2006, only two pharmacological smoking cessation aids were 
licensed in the UK: bupropion and NRT. Bupropion has been available on 
prescription as a smoking cessation aid from the NHS since June 2000. 
NRT has been available on NHS prescription since April 2001, and is also 
available over-the-counter. Varenicline became available on NHS 
prescription in December 2006, and NICE published guidance related to its 
use in July 2007.129 The introduction of this new cessation medication gave 
motivated smokers trying to quit a new treatment option.  This could have 
stimulated a general interest amongst smokers in attempting cessation and 
PLJKW KDYH LQFUHDVHG VPRNHUV¶ RYHUDOO TXLtting activity, which one would 
expect to be reflected in greater use of cessation medications.  
$OWHUQDWLYHO\YDUHQLFOLQH¶V LQWURGXFWLRQPD\KDYHRQO\VWLPXODWHG LQWHUHVW
in using this medication, such that overall numbers of quit attempts and 
total use of cessation medications remained unchanged. 
The THIN prescribing data that were validated in Chapter 3 provide 
a mechanism for investigating whether or not the introduction of 
varenicline has added to total prescribing of cessation medications in 
England, or replaced prescriptions for NRT or bupropion. Consequently, 
this chapter describes a time series analysis using monthly data from 
THIN, which was carried out WR LQYHVWLJDWH ZKHWKHU YDUHQLFOLQH¶V
introduction in December 2006, or the publication of NICE guidance related 
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to its use in July 2007, had an impact on recent trends in prescribing of 
smoking cessation medications in England. This study has been published 
in Addiction.225 
5.2 Methods 
Data 
The outcome measures were monthly rates of general practice 
prescribing for each of NRT, bupropion and varenicline and all smoking 
cessation medications combined. From the THIN database, the total 
number of NRT, bupropion and varenicline prescriptions in all patients 
written in England for each month between June 2000 and June 2009 was 
extracted, and rates of prescribing for each medication and all medications 
combined calculated using the procedure described in section 3.2.  
Analysis 
An interrupted time series analysis using ARIMA modelling was 
carried out to estimate the effect of the introduction of varenicline and the 
publication of the NICE guidance on rates of prescribing of NRT and 
bupropion and total prescribing for smoking cessation medications.226 
ARIMA modelling, as opposed to segmented regression, was used, because 
the trend in prescribing following the introduction of varenicline did not 
appear to be linear. A standard interrupted time series ARIMA modelling 
approach as described in section 4.3.2 was used.226 The three time series 
included in the analysis (NRT, bupropion and total prescribing) had 
outlying values at the beginning of the study period, reflecting the period 
soon after the medications became available on NHS prescription. 
Therefore, all the data points before July 2001 were omitted from the 
analysis. The series were log transformed to stabilise the variance, and 
differenced and seasonally differenced to remove trends. The 
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autocorrelation and partial autocorrelation functions were examined to 
determine the order of moving average (MA) and autoregressive (AR) 
terms and seasonal MA and AR terms needed to model the autocorrelation 
in the stationary series.   
To look at the effect of each intervention on the series, the 
appropriate model for the period before each intervention was identified, 
and then fitted to the complete dataset, augmenting the model with a 
dummy variable, coded 0 for the period before the intervention and 1 
thereafter. Since the introduction of smokefree legislation in England in 
July 2007 may have influenced prescribing during the study period, a 
variable was fitted to adjust for its effect. Based on initial descriptive 
analyses, the smokefree law appeared to increase prescribing in July 2007; 
therefore, this variable was coded 0 in every month except July 2007, 
which was coded 1, to model an immediate and abrupt (pulse) effect.  
As the time series had been log transformed, the ARIMA model 
coefficients provided estimates of the percentage change in the monthly 
rate of prescribing after the introduction of varenicline and publication of 
the NICE guidance. 
The analysis of THIN data for this study was approved by the 
Derbyshire Ethics Committee.  
5.3 Results 
Figure 5-1 shows the prescribing of smoking cessation medication 
per 100,000 patients in England each month between June 2000 and June 
2009 by type of medication, and indicates the introduction of varenicline in 
December 2006 and the publication of the NICE guidance in July 2007. 
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Figure 5-1. Rates of prescribing of smoking cessation medication, 
England, based on THIN, June 2000-June 2009 
 
 
Typically, as in the two years of NRT and bupropion prescribing data 
used in Chapter 3, there was a peak in prescribing in the first three months 
of each year, coinciding with New Year and national No Smoking Day in 
March. Legislation banning smoking in public places in England, which was 
introduced in July 2007, appears to have temporarily increased prescribing 
rates - there were peaks in prescribing of NRT and bupropion that month. 
For most of the study period, NRT was clearly the most commonly 
prescribed stop smoking medication. Bupropion was never very frequently 
prescribed and lagged well behind NRT for most of the study period. 
Prescribing of varenicline increased rapidly after it became available 
on the NHS, and became the second most commonly prescribed stop 
smoking drug in England after NRT. Prescribing of varenicline increased 
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most markedly in July 2007, growing to around 100 prescriptions per 
100,000 population, and remained around this higher rate for the rest of 
the study period. 
NRT prescribing increased steadily in the period before the 
introduction of varenicline (Figure 5-1). On inspection of Figure 5-1, aside 
from a brief peak when smokefree legislation was introduced, NRT 
prescribing rates appear to have been lower since varenicline was 
introduced, although, as shown in Table 5-1, the time series analysis found 
no statistically significant change in NRT prescribing either immediately 
after the introduction of varenicline (p=0.828), or after the publication of 
the NICE guidance (p=0.159).  
Bupropion prescribing has declined since reaching a peak in 2001. 
However, there was no statistically significant effect of the introduction of 
varenicline (p=0.401), or of the NICE guidance (p=0.108), on prescribing 
for bupropion. 
Despite the rapid growth in prescribing for varenicline, and the lack 
of significant fall in prescribing of existing medications, there was no step 
change in overall prescribing of smoking cessation medication after the 
introduction of varenicline (p=0.760) or after the publication of the 
guidance (p=0.134).  
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Table 5-1. Results of ARIMA time series analysis of the impact of varenicline on prescribing of smoking cessation 
medication 
 Introduction of varenicline NICE guidance on varenicline 
 
Outcome Change in 
prescribing (%) 
95% CI p-value Change in 
prescribing (%) 
95% CI p-value 
All -0.42 -3.10 ± 2.27 0.760 
 
-1.72 -3.96 ± 0.53 0.134 
NRT -0.31 -3.11 ± 2.49 0.828 
 
-1.78 -4.26 ± 0.69 0.159 
Bupropion -1.17 -3.90 ± 1.56 0.401 -2.80 -6.22 - 0.61  0.108 
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5.4 Discussion 
The results of this study suggest that the prescribing of varenicline 
has developed rapidly but, during the study period, did not lead to a 
statistically significant increase in overall prescribing for smoking cessation 
medications. The major strength of this study is that it uses validated 
large-scale data.192 Approximately 6% of the population of England are 
currently registered with a practice that contributes data to THIN.227 
Furthermore, because the vast majority of prescriptions for smoking 
cessation medication in England are written in primary care, these general 
practice data ought to be a strong indicator of the medication that NHS 
patients receive to support a quit attempt, although cessation medication 
is provided via other sources.228  
For example, within the NHS there is a mechanism, called Patient 
Group Directions (PGDs), whereby health professionals may supply certain 
medications to patients without prescriptions.  Some NHS Stop Smoking 
Services use PGDs to issue NRT, and occasionally, bupropion or 
varenicline. Medication that is provided via PGD may not always be 
recorded in THIN and, therefore, the THIN data may underestimate the 
supply of stop smoking medication provided by health professionals. 
However, as there have been PGDs for smoking cessation medication 
throughout the study period, it is unlikely that PGDs have influenced trends 
in prescribing in a way that could have had an impact on the results of this 
study. 
The study also does not include NRT purchased over-the-counter 
(OTC). This is not a major limitation, as the study deals with the impact of 
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a prescription-only medication, and it seems likely that this would have 
little influence on sales of an OTC cessation aid. However, it is possible that 
sales of OTC NRT increased as a result of varenicline becoming available, 
with more smokers motivated to quit as a result of the promotion of 
varenicline, but choosing not to obtain medication from a health care 
professional. On the other hand, the availability of varenicline may have 
reduced OTC NRT use due to smokers perceiving it as less effective than 
the new medication. 
During the study period there was a decrease in smoking 
prevalence of approximately 1% per year, which may in turn have resulted 
in a smaller pool of smokers trying to make quit attempts; this may be 
reflected in the trends in prescribing.51 However, these small annual 
decreases in prevalence translate to even smaller monthly changes in 
prevalence. Consequently, decreases in smoking prevalence are likely to 
have had a negligible effect on the monthly rates of prescribing estimated 
in this study, and are thus unlikely to have biased the results.  
Another limitation of this study is that it was not possible to obtain 
estimates of the amount of medication supplied on prescription and hence 
how long these might last patients; instead the total numbers of 
prescriptions were used. If prescriptions for varenicline lasted patients 
longer on average than for those for NRT and bupropion, the effect of its 
introduction on overall prescribing for smoking cessation medication may 
have been underestimated. Previous evidence suggests that the average 
length of a prescription for bupropion or NRT is two weeks.164 Varenicline is 
available in two week starter packs and in two and four week continuation 
packs. As GPs are likely to prescribe smoking cessation treatments 
similarly, it seems reasonable to assume that the average varenicline 
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prescription is similar in length to that for bupropion and NRT, but it 
remains possible that these could be longer. In a sensitivity analysis to 
establish whether this may have affected the study conclusions, the 
analyses were re-run with doubled rates of varenicline prescribing (hence 
assuming that varenicline prescriptions lasted for twice as long as those for 
bupropion and NRT). In these analyses, as in the original analyses, the 
introduction of varenicline did not have a significant effect on overall 
prescribing. Therefore, any variation in average length of prescriptions is 
unlikely to have affected the conclusions of this study. The results of this 
sensitivity analysis are presented in Appendix 9.6. 
A major strength of this study is that it used ARIMA modelling, 
which, as described in section 4.3.2, adjusts for the confounding effect of 
secular trends in the outcome before the intervention of interest. However, 
as also previously described, a limitation of time series analysis is that it 
cannot easily control for events that may confound the effects of the 
intervention. This study included a period when the underlying pattern of 
prescribing may have been affected by the introduction of smokefree 
legislation, which may have been expected to increase prescribing. The 
effect of this legislation was controlled for by modelling it as an abrupt and 
immediate effect in July 2007. In spite of this, there may be residual 
confounding as a result of changes in prescribing associated with the 
legislation which preceded or followed its implementation, which could not 
be incorporated in the model. However, the lack of significant increase in 
prescribing despite the introduction of smokefree gives weight to the main 
finding of the analysis that the introduction of varenicline did not increase 
prescribing of smoking cessation medication. 
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The lack of increase in overall prescribing at the same time as a 
rapid rise in prescribing for varenicline, suggests that varenicline replaced 
some prescribing for NRT and/or bupropion during the same period.  
However, the time series model did not detect significant decreases in 
prescribing for either medication. A further sensitivity analysis was carried 
out WR EHWWHU H[SODLQ WKLV DSSDUHQW µGLVFRQQHFW¶ LQ the results. ARIMA 
models for the prescribing of NRT and bupropion were run, omitting, one at 
a time, the final months of the time series, where there appeared, based 
on Figure 5.1, to be an increase in prescribing of both medications. The 
sensitivity analysis showed that following the publication of the NICE 
guidance (but not the introduction of varenicline), there was a statistically 
significant decrease in prescribing of both NRT and bupropion, from August 
2007 to November 2008 and October 2007 to November 2008 
respectively. However, when subsequent months were included, the 
decrease was generally no longer statistically significant. This indicates 
that there is sufficient power to detect a decrease in prescribing, but that 
the ARIMA model is sensitive to the slight increase in prescribing of NRT 
and bupropion later in the study period, resulting in a statistically 
insignificant finding for the overall study period. The results of this 
sensitivity analysis are also presented in Appendix 9.6 
These results suggest that varenicline has been readily accepted as 
a standard therapy by English GPs. It has rapidly become the second most 
commonly prescribed drug for smoking cessation. However, during the 
study period neither the availability of varenicline, nor the publication of 
guidance for its use had an additive effect on overall prescribing for 
smoking cessation medications. As a result, the introduction of varenicline 
may not have led to a greater proportion of smokers being prescribed 
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smoking cessation medication. This contrasts with previous research which 
suggested that introducing a new stop smoking medication increased 
overall rates of use.164 The earlier study, based on data from 1999 to 
2002, differed from the current study in that it examined dispensed 
medications as opposed to prescriptions issued, and looked at the 
introduction of a new form of NRT as opposed to a completely new 
medication and both these factors could explain the contrasting results.  
Since this study was accepted for publication, other studies have 
investigated the impact of varenicline on quitting behaviour, both in 
England and in other countries. One study, by Kotz et al., used data from 
the Smoking Toolkit Study (STS) to assess whether varenicline substituted 
for, or added to, the use of NRT and bupropion, and whether it had an 
impact on quit attempts.229 Contrary to the current study, they found that 
NRT use increased after the introduction of varenicline, and that 
varenicline did not substitute for the use of other medication, although this 
was in people making quit attempts rather than the general population. 
They also found that the rate of quit attempts decreased after the 
introduction of varenicline. However, the STS data covered a short time-
period and may be prone to recall bias and significant sampling error due 
to small sample sizes. In contrast, the study in this chapter used objective, 
validated data with a monthly sample size of approximately 2.5 million 
over a much longer time-period. Furthermore, the study by Kotz et al. 
used monthly survey data but combined data to create only three time 
points which were used in the analysis and began only six months prior to 
the introduction of varenicline and was therefore not able to take account 
of underlying trends; the decrease in quit attempts observed may reflect a 
return to previous rates following an increase in quit attempts around the 
144 
 
introduction of smokefree legislation. Furthermore, the study used monthly 
survey data on self-reported quit attempts in the past three months, which 
may have introduced some misclassification. The differences between the 
two studies have been discussed in Letters to the Editor of Addiction.230, 231 
A further study, based on the ITC Four Country Survey, found that 
in quit attempters in the US, UK, Canada, and Australia, the introduction of 
varenicline led to an increase in the number of smokers who reported the 
use of evidence-based treatment during their quit attempts, rather than 
simply gaining market share at the expense of other medications.232 A key 
limitation of this study is that it uses only three years of survey data, and 
the underlying trends in medication use could therefore not be taken into 
account. In addition, the ITC study used self-report of stop smoking 
medications usage among quit attempters as an outcome, whereas in the 
current study, a more objective measure, medical records of prescriptions 
issued to all patients are considered. Furthermore, the ITC data include 
OTC NRT in addition to prescriptions. The inclusion of OTC medications 
may have accounted for the increase in stop smoking medications overall 
in the UK. This increase may partly be due to the introduction of smokefree 
legislation, as such legislation has been shown to increase OTC smoking 
cessation medication sales in other countries, and may therefore act as a 
confounder in the ITC study.233, 234 For example, in all countries, self-
reported NRT use remained the same across the study period, but this may 
reflect increased use of OTC NRT following smokefree combined with a 
decrease in prescribed NRT following the introduction of varenicline. 
The lack of increase in the rates of prescribing identified in this 
study suggests that introducing a new, possibly more effective 
pharmacotherapy for smoking cessation medication has not encouraged a 
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higher proportion of smokers to use pharmacotherapy to support quit 
attempts. The results of this study have implications, not only for the UK 
and in relation to varenicline, but in any setting where new and innovative 
smoking cessation aids have been, or may in future be approved. 
Introducing a new smoking cessation aid may not add to the use of 
smoking cessation aids overall, and may even partially replace prescribing 
of existing, highly effective, aids. The lack of increase in smoking cessation 
medications raises questions as to why prescribing has failed to increase, 
and, consequently, what measures need to be taken in order ensure that 
the availability of a new medication increases smoking cessation 
medication use. This depends largely on who drives the decision to 
prescribe smoking cessation medication ± physicians or patients - and 
there is little available data in this regard.  A study conducted prior to the 
introduction of varenicline showed that a significant minority of GPs do not 
prescribe NRT and bupropion even when it is requested by patients, 
demonstrating that physician decisions are an important part of the 
process.235 If it is physicians who drive the decision to prescribe, then 
measures may need to be taken to increase confidence in the effectiveness 
and safety of the medication, and to encourage them to prescribe 
varenicline to smokers who have previously tried to quit using NRT or 
bupropion and failed. If it is patients, raising awareness of varenicline, 
particularly in previously unsuccessful quit attempters, may be more 
important.236 Research into these processes is needed to ensure that the 
introduction of new cessation aids is used to offer smokers a wider choice 
of treatment and endeavour to draw more smokers into the quitting 
process.  
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5.5 Conclusions 
Prescribing for varenicline has developed rapidly in English general 
practice. However, it does not appear to have increased overall rates of 
prescribing for smoking cessation medication. The introduction of 
varenicline may not have led to a greater proportion of smokers being 
prescribed medication to help them stop smoking.
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CHAPTER 6: THE IMPACT OF THE 
BROADENING OF INDICATIONS FOR 
NRT ON PRESCRIBING TO 
ADOLESCENTS AND PATIENTS WITH 
CARDIOVASCULAR DISEASE
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6.1 Introduction 
The importance of smoking cessation for adolescents, CVD patients 
and pregnant women has been described in Chapter 1. The benefits of 
using NRT in quit attempts have also been described. When NRT became 
available on prescription from the NHS in April 2001, however, there were 
initially safety concerns regarding the use of NRT by adolescents, CVD 
patients and pregnant smokers. For example, there were fears that it could 
cause cardiovascular events in at-risk individuals as a result of blood vessel 
constriction by nicotine ± one of the mechanisms by which smoking itself 
causes acute cardiac events.237 These fears were reported internationally: 
an article in the Wall Street Journal linked NRT with cardiovascular risk, 
and a range of case reports also suggested that NRT can cause 
cardiovascular events.238, 239 As a result, until the end of 2005 there were 
inconsistencies and warnings in the product information for NRT regarding 
its use by these patient groups.240  
All NRT patient information leaflets initially contained cautionary 
statements about their use by patients with CVD. Most Summaries of 
Product Characteristics (SPCs) recommended that NRT not be used by 
under 18 year olds or had contraindications for children, but others 
indicated that use by adolescents was allowed with advice from a doctor. 
Furthermore, the advice given in SPCs and Patient Information Leaflets 
sometimes differed for the same products. Similarly, there were 
inconsistencies in the advice regarding NRT use by pregnant women.240 
These inconsistencies and warnings may have created a barrier to the use 
of NRT for people in these groups, and may therefore have reduced their 
chances of making a successful quit attempt. 
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In November 2005, the Medicines and Healthcare Regulatory 
Authority (MHRA) published a report of the safety and efficacy of NRT. 237 
The report offered reassurance that NRT is safe, or at least, safer than 
smoking in these patient groups. As a result, the licensing rules for NRT 
were changed such that it could be used by patients with CVD and 
adolescent smokers, as well as pregnant smokers.  
Based on a small number of studies providing evidence of the 
efficacy and safety of NRT in adolescents, and given rates of smoking in 
teenagers and the absence of evidence of abuse of NRT by this group, the 
licensing arrangements were changed such that all forms of NRT can now 
be used by smokers aged 12 to 17 years, with the exception of Nicotinell 
lozenges which are licensed for children under 18 years only when 
recommended by a doctor.241-244 
The report also concluded that, although there was limited evidence 
as to the safety of NRT in people with unstable CVD, there was 
considerable evidence that in smokers with stable CVD, the benefits of 
using NRT to quit smoking outweigh the risk.245-251 The licensing 
regulations were therefore changed such that all forms of NRT could be 
used by patients with CVD, with the caveat that people with unstable CVD 
should try to quit with non-pharmacological aids first and only initiate NRT 
use under medical supervision.  
The report also stated that while there were limited trial data on the 
efficacy of NRT in pregnant women, the risks of NRT use in pregnancy (and 
by breastfeeding women) to both mother and child are substantially lower 
than those posed by continued smoking.252, 253 Thus the licensing 
regulations were changed such that, although pregnant smokers should try 
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to stop smoking without NRT, they can use NRT if a pharmacologically 
aided quit attempt is more likely to be successful. 
Licensing rules for the prescribing of NRT to CVD patients remain 
inconsistent internationally. For example, the US Food and Drug Agency 
advises adolescent smokers, pregnant smokers and those with heart 
disease to talk to a health professional before using NRT.254 In the 
Netherlands, the regulations are similar to those in the UK. The use of NRT 
is contraindicated for patients with acute CVD, and adolescents and 
patients with stable CVD are advised to seek the advice of a health 
professional before using NRT.255 With regard to pregnant women, the 
Dutch guidance states that NRT should only be considered if 
pharmacologically unaided quitting is not possible and that they should 
seek the advice of a health profession before using it. The French guidance 
on smoking cessation treatment states that NRT does not cause 
cardiovascular events and poses no risks to adolescents. It does, however, 
say that NRT should only be used by adolescents with proven nicotine 
dependence and high motivation to quit and NRT is only licensed for over-
15 year olds.256 Like the Dutch guidance, the French guidance states that 
NRT use by pregnant women should only be considered if 
pharmacologically unaided quitting is not possible. 
The broadening of indications may have stimulated interest in the 
use of NRT in adolescents, CVD patients and pregnant smokers, or may 
have caused general practitioners to be more willing to offer NRT to 
smokers in patient groups previously perceived as high risk. This may have 
resulted in an increase in prescribing of NRT to people in these groups. In 
particular, because varenicline is not licensed for adolescents, its 
introduction will not have substituted for the use of NRT in recent years, 
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and therefore a greater increase in prescribing of NRT to young people 
may have occurred. In this chapter, the impact of the change in indications 
on prescribing of NRT to both adolescents (Section 6.2) and CVD patients 
(Section 6.3) is investigated. 
All analyses in this chapter were carried out in R version 2.12.0 and 
all graphs were drawn in Stata Version 11.0.257 These studies were 
approved by the Derbyshire Research Ethics Committee.  
6.2 The impact of the licensing changes on prescribing of NRT to 
adolescents 
Data from THIN were used to explore patterns in prescribing of NRT 
to 12 to 17 year olds in England between January 2002 and June 2009 and 
to establish whether the broadening of the indications led to an increase in 
prescribing of NRT to adolescents. This study has been published in 
Addiction.258 
6.2.1 Methods 
Data 
THIN contains the primary care records of approximately 400,000 
patients aged 12-17. Up to 200,000 of these adolescent patients are 
currently registered with a practice and can be followed prospectively. 
The outcome measures were rates of prescribing of all NRT products 
per 100,000 adolescents registered with a THIN practice per month. From 
the THIN database all patients who were aged 12 to 17 and contributing 
data each month between January 2002 and June 2009 were identified. 
The total number of NRT prescriptions each month recorded in the medical 
records of these patients was also identified. All the extracted data were 
stratified by age and sex.  
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The procedure described in section 3.2 was used to derive the rate 
of prescribing per 100,000 adolescents per month. The rates of prescribing 
of NRT for each month for all adolescents combined, for three smaller age 
groups (12-13, 14-15 and 16-17 year olds), and for males and females 
aged 12-17 were calculated.  
Analysis 
The trend in prescribing following the licensing change appeared to 
be linear, and a segmented regression analysis using GAMMs was therefore 
carried out to estimate the effect of the broadening of the indications on 
rates of prescribing of NRT to adolescents. The models estimated the 
changes in the level and changes in the trend of the series following the 
broadening of the indications on rates of prescribing of NRT in each age 
group and in adolescent males and females, using the procedure outlined 
in section 4.3.1. A GAMM was built for each time series, including, as 
appropriate, terms to describe the trend in NRT prescribing in the pre-
intervention period, any immediate step change in the level of prescribing 
when the indications were broadened, and any change in the trend of 
prescribing in the post-intervention compared to pre-intervention data.210 
Stepwise elimination of non-statistically significant terms was used to build 
a parsimonious model. The models were checked for autocorrelation and 
seasonal autocorrelation using ACFs and PACFs. Where necessary, the 
model also contained a smooth term to model any regular seasonal pattern 
in prescribing repeated from year to year, and an autocorrelated error 
term to account for non-independence of model residuals.  
6.2.2 Results 
Figure 6-1 shows the rate of prescribing of NRT for patients aged 
12-13, 14-15 and 16-17 between January 2002 and June 2009. 
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Throughout the study period, prescribing of NRT was highest in 16-17 year 
olds and extremely low in 12-13 year olds, generally under 10 
prescriptions per 100,000 adolescents per month.  
Figure 6-1. Rates of prescribing of NRT, 12-13, 14-15 and 16-17 
year olds, England, based on THIN, January 2002-June 2009 
 
 
154 
 
 Figure 6-2 shows the rates of prescribing for each age group and 
all adolescents combined during the study period, and fitted trends from 
the segmented regression model showing trends in prescribing before and 
after the broadening of indications and any step change in the level of 
prescribing. Table 6-1 contains the results of the segmented regression 
analysis for each age group and by sex. It shows the baseline trend in 
prescribing (the monthly change in number of prescription per 100,000 
adolescents before the licensing change), the step change in the monthly 
level of prescribing immediately after the broadening of indications and the 
change in the trend in the monthly numbers of prescriptions per 100,000 
adolescents following the broadening of indications, compared with the 
baseline trend.  
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Figure 6-2. Rates of prescribing of NRT and fitted trends for 12-17, 12-13, 14-15 and 16-17 year olds before and after the 
NRT licensing change, England, based on THIN, January 2002-December 2008 
 
Note: graphs have different y-axis scales. 
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Table 6-1. Results of segmented regression analysis of the impact of the broadening of the indications for NRT on 
prescribing of NRT to adolescents 
 ǃ1 - Baseline 
trend  
95% CI p-value ǃ2 - Step level 
change 
95% CI p-value ǃ3 - Change in 
trend  
95% CI p-value 
All 1.36 1.16-
1.55 
<0.001 - - - -1.16 -1.52 - -
0.79 
<0.001 
12-13 0.09 0.07-
0.12 
<0.001 - - - - - - 
14-15 1.08 0.82-
1.34 
<0.001 19.29 9.02-
29.59 
<0.001 -1.13 
 
-1.51- -
0.74 
<0.001 
16-17 2.62 2.16-
3.08 
<0.001 - - - -2.73 -3.59- -
1.88 
<0.001 
Females 1.66 
 
1.42-
1.91 
<0.001 
 
 
 
- - - -1.65 -2.10 - -
1.20 
<0.001 
Males 0.87 
 
0.59-
1.16 
 
<0.001 13.37 
 
2.21-
24.52 
 
0.02 -0.76 
 
-1.19 - -
0.33 
<0.001 
 
 Note: only parameters significant in parsimonious model included 
 ǃ1: monthly change in number of prescription per 100,000 adolescents before licensing change 
 ǃ2: step change in the monthly level of prescribing immediately after licensing change 
 ǃ3: absolute change in trend in monthly numbers of prescriptions per 100,000 adolescents after licensing change, compared with 
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In 12-17 year olds, prescribing increased by 1.36 prescriptions per 
100,000 adolescents per month before the broadening of indications (95% 
CI 1.16-1.55, p<0.001). There was no immediate step change in the level 
of prescribing following the licensing change, but there was a significant 
change in trend (p<0.001) such that there was still an increase but at a 
lower rate.  
In 12-13 year olds, prescribing increased by 0.09 prescriptions per 
100,000 adolescents per month throughout the study period (95% CI 
0.07-0.12, p<0.001); there was no step level or trend change following 
the broadening of indications. Prescribing of NRT to 14-15 year olds 
increased by 1.08 prescriptions per month per 100,000 adolescents prior 
to the licensing change (95% CI 0.82-1.34, p<0.001). In the same age 
group, prescribing increased by 19 prescriptions per 100,000 in the first 
month following the broadening of indications, before levelling off, as 
shown in Figure 6-2. In the oldest age group, prescribing followed an 
increasing trend until December 2005. There was no step change in the 
level of prescribing following the change in indications, and prescribing 
subsequently levelled off. 
Figure 6.3 shows the rates of prescribing for males and females 
during the study period, and fitted values showing the trends in prescribing 
before and after the broadening of indications. During the study period 
girls tended to be prescribed NRT more frequently than boys, though rates 
of prescribing were fairly similar from early 2007.  
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Figure 6-3. Rates of prescribing of NRT and fitted values for 12-17 year olds by sex before and after the NRT licensing 
change, England, based on THIN, January 2002-June 2009 
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As shown in Table 6-1, in both males and females, prescribing 
followed an increasing trend before the licensing change (p<0.001), before 
levelling off, as also shown in Figure 6-3. 
In females, there was no step change in the level of prescribing, 
whereas in males the rate of prescribing increased by 13 prescriptions per 
100,000 adolescents in the month immediately following the change in 
indications (95% CI 2.21-24.52, p=0.02). 
6.2.3 Discussion 
To my knowledge this is the first study into the effect of the NRT 
licensing change on prescribing of this medication to adolescents. This 
study found no evidence of an increase. The major strengths of this study 
are the use of validated, large-scale data and the use of segmented 
regression analysis to estimate changes in the level and trend of NRT 
prescribing following the change.  
A limitation of this study is that it used rates of prescribing of NRT 
to all adolescents as opposed to those recorded as smokers. However, as 
explained in section 2.4.4, research has suggested that the recording of 
smoking in THIN was incomplete until at least 2006, therefore including 
only recorded smokers is likely to have introduced bias.259 It was also not 
possible to control for adolescent smoking prevalence, as no validated 
monthly measure is available. However, national smoking prevalence 
survey data suggest that during the study period there were year-on-year 
changes in prevalence of no more than 3 percentage points in 11-15 year 
olds and 4 percentage points in 16-19 year olds, with much smaller 
changes in most years.52, 149 Any monthly changes in prevalence are 
therefore likely to have been very small. Consequently, changes in 
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smoking prevalence are likely to have had a negligible effect on the 
monthly rates of prescribing estimated in this study, and are thus unlikely 
to have biased the results. 
A further limitation of this study is that, as highlighted in the other 
studies in this thesis, the THIN data include only prescriptions written in 
general practice and will therefore, to some extent, underestimate the rate 
of NRT prescribing. The majority of prescriptions for NRT are, however, 
written in primary care, therefore these data ought to be a good indicator 
of the medication that adolescents receive from medical professionals to 
support a quit attempt.228  
Throughout the study period, prescribing increased with age, which 
reflects the fact that, in adolescents, the prevalence of smoking increases 
with age. In 2010 3% of 13 year olds were regular smokers (smoked at 
least once a week), whereas in 15 year olds the prevalence of regular 
smoking was 12%.52 The rate of prescribing was higher in adolescent 
females than males. This contrasts with research from the USA which 
suggests that NRT use is more frequent in teenage boys than girls.260 The 
higher rate of prescribing to girls in this study reflects a higher smoking 
prevalence in teenage girls than boys, but may also be due to the fact 
that, in England, teenage girls are more likely to visit their GP than 
teenage boys.261 In 2008, girls aged 15-19 had an average of 4.5 GP 
consultations per year, whereas boys had an average of two.261  
The primary aim of this study was to investigate whether the 
licensing change influenced GP prescribing. Changing the indications for 
NRT use to include adolescents might have been expected to lead to an 
increase in prescribing to this age group. However, this study found little 
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evidence that this occurred. This is particularly surprising given that the 
models were not able to take account of the introduction of the smoking 
ban, which may also have been expected to increase prescribing. In 12-17 
year olds (all adolescents), there was no step change in the level of 
prescribing, and the monthly increase in prescribing of NRT was 1.16 
prescriptions per 100,000 adolescents lower after the indications were 
broadened. In young adolescents, the gradual increasing trend in rates of 
NRT prescribing observed before the licensing change remained 
unchanged, and in older adolescents the increase in prescribing of NRT 
disappeared. There was also no step change in the level of prescribing to 
females. Small immediate increases in the prescribing of NRT were 
observed in 14-15 year olds and in adolescent males in the month 
following the broadening of indications, but here too prescribing rates 
subsequently levelled off. 
These increases are likely to have had a minimal public health 
impact; in the context of national estimates of smoking prevalence in this 
age group it is evident that, despite the change in indications for NRT use 
to include this age group, the rate of prescribing to adolescent smokers 
remains low. In 2008 there was an average of 92 NRT prescriptions per 
100,000 15 year olds per month. At most (bearing in mind that multiple 
prescriptions could have been given to the same individual), this equates 
to 0.09% of 15 year olds obtaining a prescription for NRT per month, 
despite a smoking prevalence within this age group of 12%.52 This low rate 
of prescribing suggests that measures to increase adolescent access to 
cessation support in primary care are needed. One study has suggested 
that when adolescents receive smoking cessation counselling in primary 
care, a significant proportion of them agree to make a quit attempt.262 This 
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suggests that general practice may indeed be an appropriate setting for 
adolescent smoking cessation, thus it is desirable to establish and 
overcome the factors which limit the prescribing of NRT to adolescents.  
Despite the lack of increase in prescribing, it seems likely that there 
were benefits of the licensing change that could not be observed in this 
study. One benefit of the licensing change is that GPs can prescribe NRT to 
adolescent smokers without concern that their prescribing is considered to 
be unusual, dangerous or against the consensus of good clinical practice 
because it contradicts the labelling. Similarly, non-prescribers can now 
educate adolescents about the safety of medications without their advice 
being inconsistent with the labelling. Furthermore, the licensing change 
may have led to people prescribing via PGD to prescribe more NRT to 
adolescents, as they are only permitted to prescribe according to the 
product license. 
There are both demand and supply side factors that provide 
possible explanations for the limited effect of the broadening of indications 
on prescribing in this age group. Teenagers make fewer visits to their GP 
than adults and may be less likely than adults to ask for NRT, therefore, 
despite the licensing change, general practice may not be an effective 
setting for the distribution of NRT to people within this age group.261 In 
particular, it may be that young people who are most likely to be nicotine 
dependent and may therefore benefit from NRT are less likely to visit their 
GP. Previous international research suggests that the majority of 
adolescent smokers would consider using NRT, but also indicates that 
some young people would find using NRT embarrassing, unpleasant or 
expensive, which may also discourage its use in this age group.263, 264 
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There may also have been a lack of awareness of the licensing 
change among GPs or ongoing concerns among health care professionals 
as to the safety of NRT for teenagers. Furthermore, adolescent smokers 
smoke less heavily than adults; regular 11-15 year old smokers smoke 5.4 
cigarettes per day on average, whereas adult smokers smoke an average 
of 13 cigarettes per day.51, 265 It may therefore be perceived as 
unnecessary to treat teenage smokers with NRT. A further possible factor 
is the limited evidence as to the effectiveness of NRT for smoking cessation 
in this age group. Three studies indicate that the nicotine patch may be 
effective in adolescents, but a further study found no effect, as did a study 
looking at the effectiveness of nicotine nasal spray in adolescents.241-
243,266,267 2QWKHRWKHUKDQGWKHODFNRIFKDQJHPD\VLPSO\EHGXHWR*3V¶
limited contact with addicted adolescents, particularly as they may be less 
likely to visit their GP than non-smokers.262 Alternatively, it is possible that 
the licensing change did not result in GPs who had never previously 
prescribed NRT to teenagers starting to do so and that those GPs who were 
already prescribing NRT to young people did not start offering prescriptions 
more frequently.  
Using NRT is likely to be less harmful than continued smoking as 
adolescent smokers who use NRT are not exposed to the toxic products of 
tobacco combustion.240 Research is therefore required to understand why 
there is a low rate of prescribing of NRT to adolescents in the UK despite 
the licensing change, and how access to NRT might be improved for young 
dependent smokers in the future.  
6.2.4 Conclusions 
Reducing the prevalence of adolescent smoking is important as a 
means of alleviating the burden of smoking-related morbidity and mortality 
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in the future. The lack of increase in prescribing following the change in 
indications for NRT, however, suggests that there are barriers to increasing 
adolescent smoking cessation through general practice settings.  Limited 
access to smoking cessation support may hinder a reduction in adolescent 
smoking prevalence now, which may have significant public health 
implications in the future.  
6.3 The impact of the licensing changes on prescribing of NRT to 
CVD patients  
Data from THIN were used to explore patterns in prescribing of NRT 
to patients with CVD in England between January 2002 and June 2009 and 
to establish whether the broadening of the indications led to an increase in 
prescribing of NRT to patients with coronary heart disease (CHD) and 
stroke, which are the main types of CVD in the UK, accounting for 46% 
and 23% of CVD deaths respectively.268 This study has been accepted for 
publication in Addiction. 
6.3.1 Methods 
Data 
This study used THIN data on prescribing of smoking cessation 
medication to patients in England who were aged 16 and over with CHD or 
stroke. The main outcome measures were the number of patients per 
100,000 with CHD and stroke that received a prescription for NRT each 
month. From the THIN database all adult (16+) CHD and stroke patients 
contributing data each month between January 2002 and June 2009 were 
identified using Read Codes based on the definitions of these diseases from 
the QOF.188 As described in section 1.6.9, the QOF sets out requirements 
for the management of smoking in patients with certain chronic diseases, 
and these include CVD. The CHD and stroke patients with a prescription for 
165 
 
NRT in each month during the study period were also identified. The rates 
of prescribing per 100,000 CHD and stroke patients were calculated using 
the procedure described in section 3.2.  
It is possible that varenicline may have substituted for some of the 
use of NRT in CVD patients after it was introduced in December 2006. 
Therefore, in order to examine trends in total prescribing of all licensed 
smoking cessation medications to this patient group (i.e. NRT, varenicline 
and bupropion), data on prescribing of these to CHD and stroke patients 
were also extracted. Rates of prescribing were calculated as described 
above.  
Data on prescribing to adults with recorded hypertension (a major 
risk factor for CVD), asthma and chronic obstructive pulmonary disease 
(COPD), as well as prescribing to the rest of the adult population were also 
extracted, in order to compare prescribing to CVD patients with that to 
groups for which the licensing for NRT did not change in November 
2005.269 Due to incompleteness in the recording of smoking status in THIN 
until 2006, we were unable to look at prescribing in smokers only for the 
whole time course of the study.184 However, we used data from 2007 and 
2008 (when the majority of patients in THIN had their smoking status 
recorded) to calculate average rates of prescribing per month in smokers 
with CHD and stroke and compare this with rates of prescribing in other 
disease groups, and in the rest of the population, in 2007 and 2008.184 The 
data on patients with hypertension, asthma and COPD were also identified 
using Read Codes based on the definitions of these diseases from the QOF. 
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Analysis 
The trend in prescribing following the licensing change appeared to 
be linear, and a segmented regression analysis was therefore carried out 
using GAMMs to estimate the effect of the broadening of the indications on 
rates of prescribing of NRT to patients with CHD and stroke, using the 
procedure described in section 4.3.1 and applied in section 6.2. GAMMs 
were also built for total prescribing (NRT, varenicline and bupropion) to 
explore overall trends in prescribing for smoking cessation medication 
during the study period.  
6.3.2 Results 
Data were available on up to 88,000 CHD patients and 39,000 
stroke patients each month. Figure 6-4 shows the rates of prescribing of 
NRT to CHD and stroke patients during the study period. As in the general 
population (shown in Chapters 3 and 5), in most years there was a peak in 
prescribing in January and March, coinciding with the New Year and No 
Smoking Day, and the time series plot suggests an increase in prescribing 
of NRT up to 2006 with a reduction in subsequent years. Figure 6-4 also 
shows the fitted trends from the segmented regression modelling for 
prescribing of NRT, the results of which are also presented in Table 6-2. 
There was no statistically significant immediate step change in the level of 
prescribing following the licensing change; therefore, this term was 
omitted from the model. Table 6-2 shows the baseline trend in prescribing 
(the monthly change in the number of people receiving prescriptions per 
100,000 before the licensing change) and the change in the trend in the 
monthly number of CHD and stroke patients receiving prescriptions per 
100,000 following the broadening of indications, compared with the 
baseline trend.  
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Figure 6-4. Rates of prescribing of NRT and fitted trends in CHD and stroke patients before and after the NRT licensing 
change, England, based on THIN, January 2002-June 2009 
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Table 6-2. Results of segmented regression analysis of the impact of the broadening of the indications for NRT on 
prescribing of NRT to CVD patients 
 ǃ1 - Baseline 
trend  
95% 
CI 
p-value ǃ2 - Step level 
change 
95% 
CI 
p-
value 
ǃ3 - Change 
in trend  
95% CI p-value 
NRT 
prescribing 
CHD 3.18 2.15-
4.21 
<0.0001 - - - -6.45 -8.36- -
4.53 
<0.0001 
Stroke 3.37 2.31-
4.43 
<0.0001 - - - -5.99 -7.96 - -
4.01 
<0.0001 
All 
prescribing 
CHD 2.73 1.23-
4.25 
<0.001 - - - -3.0670 -5.87 - -
0.26 
0.035 
Stroke 3.29 1.81-
4.76 
<0.0001 - - - -3.76 -6.49 - -
1.0175 
0.009 
Note: only parameters significant in parsimonious model included 
ǃ1: monthly change in number of prescription per 100,000 patients before licensing change 
ǃ2: step change in the monthly level of prescribing immediately after licensing change 
ǃ3: absolute change in trend in monthly numbers of prescriptions per 100,000 patients after licensing change, compared with baseline 
WUHQGǃ1 ǃ3 = post-intervention trend) 
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In CHD patients, the number of people receiving prescriptions for 
NRT was increasing at the rate of 3.18 per 100,000 patients per month 
between January 2002 and the  broadening of indications in 2005 (95% CI 
2.15-4.21, p<0.0001) (Table 6-2). There was no immediate step change in 
the level of prescribing following the licensing change, but after 2005 there 
was a significant change in trend (p<0.0001) representing a decrease in 
the rate of prescribing.  
A similar trend was observed in stroke patients. In this group, the 
number of people receiving NRT prescriptions was increasing by 3.37 per 
100,000 patients per month before the broadening of the indications (95% 
CI 2.31-4.43, p<0.0001) (Table 6-2 and Figure 6-4). There was no 
immediate step change in the level of prescribing following the licensing 
change, but there was a significant change in trend (p<0.0001) such that 
there was a decreasing trend in prescribing. 
Figure 6-5 shows the rates of prescribing of all smoking cessation 
medications combined (NRT, varenicline and bupropion) in CHD and stroke 
patients during the study period, and the results of the segmented 
regression modelling are also presented in Table 6-2. Figure 6-5 shows 
that overall prescribing of this group of medications to both CHD and 
stroke patients increased until 2005 and remained fairly stable in the latter 
part of the study period. The rate of prescribing for bupropion decreased 
during the study period and was extremely low in the final years of the 
study; generally, only between five and ten patients per 100,000 received 
a prescription for bupropion each month in the period following the 
170 
 
introduction of varenicline (not shown). The majority of prescriptions were 
therefore for NRT and, after December 2006, NRT and varenicline.  
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Figure 6-5. Rates of prescribing of all smoking cessation medications (NRT, varenicline and bupropion) and fitted trends in 
CHD and stroke patients before and after the licensing change, England, based on THIN, January 2002-June 2009 
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Figure 6.6 shows the average rate of prescribing of NRT to smokers 
with CHD, stroke, hypertension, asthma, COPD and without one of these 
diseases per month in 2007 and 2008. Prescribing was highest to smokers 
with COPD, at around 2500 per 100,000 smokers per month, and very 
similar in those with CHD, stroke and asthma, at around 1500 per 100,000 
smokers per month. Prescribing of NRT to the rest of the population was 
about a third of that to smokers with CHD and stroke. 
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Figure 6-6. Number of smokers with NRT prescriptions per month by disease group, England, based on THIN, 2007 and 
2008 
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6.3.3 Discussion 
To my knowledge this is the first study into rates of prescribing of 
NRT to individuals with cardiovascular disease. Like the previous study in 
this chapter, the major strengths of this study are the use of validated, 
large-scale data, and the use of segmented regression analysis to estimate 
changes in the level and trend of NRT prescribing following the licensing 
change.  
This study found that prescribing of NRT to CHD and stroke patients 
increased until the end of 2005 and subsequently decreased, with no 
immediate change following the MHRA licensing change. In 2007 and 2008 
rates of prescribing of NRT to smokers with CVD were similar to that to 
smokers with asthma, and about three times as high as in the general 
population.  
This study has several limitations which may explain part of the 
observed trends, but are unlikely to have affected the results. As in the 
other studies in this thesis, it was not possible to restrict the analysis of 
trends over time to smokers only, due to the incompleteness of smoking 
status data in THIN prior to 2006.184 However, as explained in section 5.4, 
the small annual decreases in adult smoking prevalence during the study 
period are likely to have made a negligible contribution to the monthly 
changes in rates of prescribing observed in this study.  
Similarly, as explained in earlier parts of this thesis, THIN smoking 
cessation medication prescribing data may underestimate the supply of 
stop smoking medication provided by health professionals, though it is 
unlikely that this has influenced trends in prescribing in a way that could 
have had an impact on the results of this study. 
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Like the other policy evaluation studies presented so far in this 
thesis, this study also does not include NRT purchased over-the-counter 
(OTC). However, it is unlikely that a sudden switch to OTC NRT has 
contributed to changes in prescribing of NRT during the study period, as 
NRT has been available OTC since 1999. In addition to this, smokers with 
CVD may be less likely to use OTC NRT, and more likely to seek medical 
advice before using NRT and therefore receive NRT on prescription. To my 
knowledge, there was no media publicity about the licensing change which 
is likely to have reassured patients with CVD that they could start buying 
NRT OTC rather than seeking the advice of a health professional. 
The results of this study suggest that only a small proportion of 
smokers with CVD are receiving smoking cessation support in primary 
care, despite overwhelming reasons for them to stop smoking. The study 
found that 1500 per 100,000 smokers (1.5%) with CVD receive a 
prescription for NRT per month. This suggests that a maximum of 18% of 
smokers with CVD are obtaining a prescription for NRT each year; as 
quitting episodes may last longer than a month, it is likely that the actual 
percentage is even lower. The rate of prescribing of NRT in CVD patients 
therefore seems low. It is not known what proportion of smokers with CVD 
attempt to quit each year, but in the general population in England 36% of 
adults reported having made a quit attempt in the past year in 2010.270 
Given the immediate health risks, it seems likely that the rate is much 
higher in CVD patients, and the rate of prescribing to these patients 
therefore seems low as a proportion of CVD patients who try to quit as well 
as overall. This study therefore suggests that opportunities to help these 
smokers quit are being missed. 
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Removing the barriers to health professionals prescribing NRT to 
patients with CVD may have been expected to increase prescribing of this 
medication to this group, either as a result of GPs being more willing to 
prescribe to a group perceived as high risk, or as a result of these patients 
being more willing to use it. We found no immediate increase in prescribing 
following the change in indications, and that in the period following the 
licensing change, prescribing in this disease group declined. As in the 
previous study in this thesis, this seems particularly surprising given the 
introduction of the smoking ban in this period, which may also have been 
expected to increase prescribing. This apparent decline seems unlikely to 
be due to the broadening of indications for NRT on the basis of evidence 
that it is safe in this group. Furthermore, the decreasing trend in 
prescribing for NRT is similar to that observed in the general population in 
the study in Chapter 5. It therefore seems likely that factors other than the 
licensing change, which are common to the majority of patients to whom 
NRT is prescribed, have led to a widespread decrease in prescribing for 
NRT from 2006 onwards.  
One possible explanation for the decrease in prescribing of NRT may 
be substitution by varenicline, which became available on NHS prescription 
a year following the licensing change and which, as shown in Chapter 5, 
rapidly became the second most popular smoking cessation medication. It 
is possible that varenicline, which had not yet been tested in CVD patients 
when it became available but seemed likely to have no cardiovascular 
effects, may have substituted for some of the use of NRT in CVD 
patients.271 Our results showed that, despite the decrease in prescribing for 
NRT in the period following the licensing change, overall prescribing for 
smoking cessation medication remained fairly stable, indicating that the 
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decrease in NRT prescribing was at least partly offset by prescribing for 
varenicline. It is not known whether varenicline halted an overall decline in 
prescribing of smoking cessation medication in this patient group, or 
whether it substituted for some prescribing of NRT. Either way, however, it 
appears that, overall, prescribing for smoking cessation medication to CVD 
patients has not reduced in recent years.  
Despite the lack of increase in prescribing of NRT to CVD patients, it 
is likely, as was highlighted in the previous study, that there were benefits 
of the licensing change that could not be observed in this study in terms of 
reassuring GPs who prescribe NRT to CVD patients, and non-prescribers 
who provide advice about its use.  
6.3.4 Conclusions 
Smoking cessation has been shown to slow CVD progression and 
reduce the risk of premature death by 50%, and it is therefore important 
that CVD patients are supported in making quit attempts. Prescribing of 
NRT to CVD patients who smoke is comparable to that in other patient 
groups, but remains low. MHRA recommendations approving the use of 
NRT by CVD patients have not increased prescribing ± NRT prescribing to 
this group of patients has declined since 2005, although the reduction may 
have been offset by a rapid increase in prescribing for varenicline. As such, 
it appears that opportunities for smoking cessation intervention in primary 
care patients with CVD are being missed. 
6.4 Chapter conclusions 
The results of the studies presented in this chapter are largely 
consistent with each other. Prescribing of NRT decreased in CVD patients 
following the licensing change, whereas in adolescents it levelled off; this 
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most likely reflects that varenicline replaced some NRT prescribing to CVD 
patients, whereas this was not the case for adolescents, for whom 
varenicline is not licensed in England. However, both studies found that, 
contrary to what may have been anticipated, the licensing change seems 
likely to have had an extremely limited impact on public health, in that it 
did not result in marked increases in prescribing of NRT. Both the study on 
prescribing of NRT to adolescents and the CVD patient study found that 
some GPs were already prescribing NRT to these groups before the 
licensing change, but that those that were resistant prior to the change 
remained so following it.  
In both groups, prescribing of smoking cessation medication 
appears to be low relative to the prevalence of smoking despite the change 
in licensing. Thus the overarching conclusion in both studies is that 
opportunities for smoking cessation intervention in primary care are being 
missed. To our knowledge, similar studies have not be conducted in other 
countries. If these results are replicated outside of the UK, it is possible 
that adolescent smokers and those with CVD around the world are not 
receiving adequate support to quit smoking. Further research is needed to 
identify the barriers to prescribing smoking cessation in these groups so 
that they can be adequately supported in future quit attempts.  
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CHAPTER 7: THE IMPACT OF MASS 
MEDIA CAMPAIGNS ON SMOKING 
CESSATION ACTIVITY
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7.1  Introduction  
The role of mass media campaigns in tobacco control has been 
introduced in Chapter 1. As explained in section 1.6.2, international 
evidence suggests that tobacco control mass media campaigns can 
increase the chances of quitting and reduce smoking prevalence; however 
the evidence is not conclusive. Furthermore, very few academic studies 
have looked at the effectiveness of mass media campaigns in the UK, none 
of which have been published in the past decade.173, 272-274 Many 
government or charity-funded campaigns undergo some evaluation of their 
immediate impact, but this is usually on the basis of small scale 
quantitative or qualitative surveys conducted over very short periods of 
time just before and after the campaign, without formal inferential 
statistical analysis; as such there is a dearth of UK-specific evidence.  
In addition, evidence from the US suggests that advertising for NRT 
may also influence quitting, but no peer-reviewed studies have been 
undertaken of its effect on quitting behaviour in the UK or elsewhere.89, 90 
As a result of the recent cuts in funding for tobacco control mass 
media campaigns, there is an urgent need to evaluate the effectiveness of 
both types of campaign in the UK. Investigating the effect of tobacco 
control campaigns is important to establish whether the cuts to 
government funding are justified, and what their implications may be for 
public health. These cuts also seem likely to place greater reliance on 
corporate-funded campaigns for NRT to encourage quitting, and it is 
therefore important to consider the effect of these campaigns as well as 
tobacco control campaigns. 
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During the course of my PhD research, I therefore obtained funding 
to conduct analyses of the impact of both types of mass media campaigns. 
ASH UK provided two months funding to carry out a preliminary descriptive 
analysis of the potential impact of both types of campaigns on a wide 
range on indicators of quitting behaviour. The report of this work is 
attached in Appendix 9.10. The report hinted at effects of both types of 
campaigns, but underlined the need for formal statistical analysis using 
high quality data to confirm and quantify the magnitude of those effects. I 
subsequently led on a project grant obtained from the Cancer Research UK 
Tobacco Advisory Group to conduct such an analysis. The results of this 
study are presented in this chapter. 
The aims of the study were to assess the association between 
tobacco control advertising and advertising for NRT purchased by the 
pharmaceutical industry, and a range of sensitive indicators of quitting 
behaviour which seemed likely to respond to changes in advertising: calls 
to the free NHS smoking helpline, and rates of prescribing and over-the-
counter (OTC) sales of NRT.  
7.2 Methods 
7.2.1 Exposure Data 
This study used time series data on television ratings points (TVRs), 
a standard broadcasting industry measure of the audience which views a 
television programme or advert, as its measure of exposure to anti-
tobacco mass media advertising and smoking cessation medication 
advertising. A TVR is defined as the percentage of a particular audience 
that has seen a commercial break. The measures of exposure to 
advertising in this study were:  
182 
 
x TVRs purchased for tobacco control campaigns by the Central 
Office of Information (COI, on behalf of the government), 
Cancer Research UK and the British Heart Foundation (the three 
main purchasers of such advertising during the time period) 
each month from January 2002 to May 2010, and  
x TVRs purchased by pharmaceutical companies to advertise NRT 
each month from January 2005 to December 2009.  
The tobacco control TVR data used in this study include all mass 
media campaigns related to smoking, including those targeting young 
people and related to smokefree legislation, as all of these campaigns may 
have influenced quitting behaviour. The TVR data nominally cover the 
whole of the UK, but due to devolved responsibilities for health promotion 
media campaigns in the UK, the COI TVR data primarily cover England 
only, with some overlap into other home nations through advertising in the 
press. The TVRs overlapping into Scotland and Wales have therefore been 
removed. Some of the outcome data cover England only, but due to the 
PDNHXS RI WKH 8.¶V 79 UHJLRQV 795V IRU :DOHV FRXOG QRW EH VHSDUDWHG
from those for England. 
The pharmaceutical company TVR data are available for the whole 
of the UK but, to allow better comparison with the government-funded 
campaign data, only data on England and Wales have been used in this 
study.  
The TVRs for England and Wales were calculated by summing 
population-weighted values of TVRs for each television region in England 
and Wales.  
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Advertising spend data are also available. For this study, however, 
TVR data were selected over spend data, as these ought to provide a more 
accurate representation of exposure to campaigns (as the cost of 
advertising is likely to vary over time) and were available for a longer time 
period. However, spend data were compared with TVR data to ensure that 
there would be no significant differences in the results depending on the 
exposure used. Appendix 9.9 shows that the trends in these two 
advertising exposures are extremely similar. 
7.2.2 Outcome data 
This study used time series data on three outcome measures which 
were available on a monthly basis for a long time period and seemed likely 
to be most responsive to changes in advertising exposure: calls to the NHS 
stop smoking helpline, prescribing of NRT, and OTC sales of NRT. The 
preliminary report for ASH also included quit attempts based on the STS 
and brief stop smoking advice data from THIN, but as explained in Chapter 
2, these seem likely to be of limited quality on a monthly basis and were 
therefore not included in this study. The helpline calls data are available 
only for England. The NRT prescribing and OTC sales data cover England 
and Wales.  
As explained in section 2.4.3, there is evidence that quitlines can 
help smokers to give up smoking, and numbers of quitline calls are 
therefore a useful measure of quitting behaviour. Many of the tobacco 
control mass media campaigns have included the NHS helpline number, 
and are therefore likely to have influenced calls to the helpline. This study 
uses the number of calls to the NHS helpline per month from November 
2004 to June 2010. 
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Sales of OTC NRT have been used as an indicator of quitting activity 
in previous studies and are anticipated to respond to NRT advertising, 
although tobacco control campaigns might also influence OTC NRT 
sales.135, 164, 165 NRT has been shown to be effective in aiding smoking 
cessation, and increases in sales may therefore lead to an increase in the 
number of people quitting.126 The OTC sales data used in this study are the 
Electronic Point of Sales scanner data obtained from IRI described in 
section 2.4.1.166 These data are supplied as 4-weekly summaries. To 
convert these to monthly equivalents, it was assumed that 1/28th of sales 
occur on each day in each 4-week period. The monthly population 
denominators for these data were calculated using the ONS mid-year 
population estimates for England and Wales for each year; year-on-year 
increases were apportioned uniformly by month.19 The unit sales each 
month were divided by the monthly population denominators to obtain the 
rate of sales per 100,000 population per month from November 2003 to 
September 2008. 
Prescribing of NRT may also be influenced by NRT advertising and 
tobacco control campaigns if these encourage smokers to seek smoking 
cessation medication or more general support with stopping smoking 
respectively, from their GP. Data on prescribing of NRT from THIN were 
used. The denominator for each month was the total number of live 
individuals contributing data to the THIN database throughout each month. 
It was assumed that those contributing data within each month provided 
one person-month of follow-up, and the numbers of prescriptions divided 
by the total person months to derive the rate of prescribing per month 
from January 2002 to June 2009.  
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7.2.3 Analysis 
Multiple time series analysis was used to investigate the impact of 
advertising on the quitting behaviour outcomes. To determine which type 
of MTSA should be used, Granger Causality tests were carried out on pairs 
of stationarised time series as described in section 4.4. It was found that 
the weak exogeneity assumption was violated. In the case of mass media 
campaigns, the effect of campaigns may occur the day or week following 
exposure to a campaign; therefore, the use of monthly data seems likely 
to create contemporaneous correlation, suggesting instantaneous 
causality. This is likely to explain the lack of weak exogeneity. Therefore, 
in this study, SVAR analysis was used. As explained in section 4.4, this 
method allows assumptions to be made about the direction of causality in 
order to unpick the temporal relationships between variables ± the impact 
of an intervention within the current time period as well as any lagged 
effects in subsequent time periods.  
SVAR modelling requires stationary data, so the time series were 
transformed and differenced to ensure stationarity. Due to zero 
observations in the data, an inverse hyperbolic sine transformation, rather 
than a logarithmic transformation, was used to stabilise variance in both 
the input and the output series.217, 222 Differencing the transformed time 
series rendered them stationary. 
Short-run SVAR models of the effect of tobacco control advertising 
and NRT advertising on quitline calls, OTC NRT sales and prescribing for 
NRT were run. The SVAR was estimated using the procedure outlined in 
section 4.4.223 First, matrices containing the constraints were specified 
such that the direction of causality was assumed to be from campaigns to 
quitting behaviour and not vice versa. Information criteria were used to 
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identify the optimal number of lags to use. Once optimised, the model was 
run and diagnostic testing undertaken to establish that the model was 
properly specified.223 Modelling the transformed-differenced data provides 
the percentage change of each series; therefore the results can be 
interpreted directly as elasticities i.e. the percentage change in the 
outcome variable following a one percent change in the explanatory 
variable. IRFs which show the percentage change in the output variable 
(the quitting behaviour outcomes) in response to a 1% change in the input 
variable in the same month and in the subsequent 12 months, were 
obtained.275 Cumulative IRFs which show the overall effect of campaigns 
up to a twelve month lag were also obtained. 
Since many of the time series displayed seasonal effects, the effect 
of adjusting for different seasonal indicator variables (quarterly, monthly 
etc.) as exogenous factors was examined and information criteria used to 
select the best fitting model as described in section 4.4.2. For each pair of 
variables, information criteria showed that the model which allowed a 
separate effect for each month provided the best fit. Nevertheless, 
adjusting for seasonality assumes that any seasonal effect in outcomes is 
independent of increased advertising at certain times of the year (it is well-
documented that quit attempts increase at the beginning of the year due 
to the New Year and No Smoking Day 79, 276, 277), whereas some of the 
seasonal increase in quitting may be due to increased advertising; it is not 
possible to separate the two effects. It is therefore possible that adjusting 
for seasonality causes the true effect of campaigns to be underestimated, 
and therefore the results of the seasonally unadjusted and adjusted 
models are presented for comparison. 
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The results are presented as a table of the contemporaneous (i.e. 
within-month) effects of all the models, and graphs of the IRFs for each 
month up to 12 months lag. Also presented are a table of the cumulative 
effects of campaigns at the 12 month lag, and CIRFs which show the 
overall effect of mass media campaigns each month up to 12 months 
following the campaigns. All analyses were conducted in Stata Version 
11.0. 
7.3 Results 
Figure 7-1 shows tobacco control TVRs from January 2002 to 
December 2009 and pharmaceutical company TVRs from February 2005 to 
December 2009. There was no discernible long-term trend in tobacco 
control TVRs during the study period, with much fluctuation from one 
month to the next. TVRs tended to peak in January, and were highest in 
January 2005 and 2010. There were few months with no advertising. 
Pharmaceutical company TVRs were characterised by peaks and troughs 
throughout the period studied. Most peaks in NRT TVRs were in January. 
The largest peaks were in January 2005 and July 2007, when smokefree 
legislation was implemented in England. 
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Figure 7-1. Tobacco control TVRs, England and Wales, January 2002 to December 2009, and pharmaceutical company TVRs, 
England and Wales, February 2005 to December 2009 
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Figure 7-2 shows plots of each outcome measure for the study 
period. There was a very large peak in quitline calls in January and 
February 2005, with around 70,000 calls. The number of calls then levelled 
off at between 10 and 30,000 for the rest of the period. Seasonal peaks 
generally occurred in January to March each year. As shown in previous 
chapters, NRT prescribing increased until 2005, and appears to have 
decreased since 2007. In most years there was a clear peak in prescribing 
in the first three months of the year and a much smaller peak in October. 
The level of OTC NRT sales increased gradually during the study period, 
with seasonal peaks of a similar magnitude in January to March each year. 
Sales in January tended to be approximately 50% higher than in the 
summer months. In July 2007, however, when smokefree legislation was 
introduced in England, sales were higher than in any other month during 
the study period.  
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Figure 7-2. Quitline calls, England, November 2004-December 2009; Rates of NRT prescribing, England and Wales, January 
2002-June 2009 and OTC NRT unit sales, England and Wales, November 2003-September 2009 
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Table 7-1 shows the contemporaneous (that is, within-month) 
results of the SVAR models. All of the elasticities were positive. In the 
seasonally unadjusted model, tobacco control campaigns had a statistically 
significant effect on quitline calls in the same month, with a 1% increase in 
tobacco control TVRs leading to a 0.129% increase in quitline calls. This 
effect was still statistically significant, but reduced, in the seasonally 
adjusted model. Tobacco control TVRs did not have a statistically 
significant within-month effect on OTC NRT sales or NRT prescribing. 
Pharmaceutical company TVRs had a small statistically significant 
effect on OTC NRT sales in the seasonally unadjusted model ± a 0.05% 
increase in sales per 1% increase in advertising. However, the increase 
was not statistically significant in the seasonally adjusted model. 
Pharmaceutical company TVRs did not have a statistically significant effect 
within-month effect on quitline calls (although the effect in the unadjusted 
model was borderline non-significant) or NRT prescribing.
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Table 7-1. Results of SVAR models of the impact of anti-tobacco mass media campaigns on quitting behaviour ± 
Contemporaneous effects 
Exposure Outcome  Unadjusted SVAR Seasonally adjusted SVAR 
  IRF 95% CI p-value IRF 95% CI p-
value 
Tobacco control 
TVRs 
Quitline calls 0.129* 0.053 -  0.205  0.002 0.085* 0.040 - 0.129 
0.007 
OTC NRT 0.0198  -0.018 - 0.058 0.313 0.007 -0.009 - 0.023 
0.430 
NRT prescribing 0.034 -0.008 - 0.077  0.121 0.012 -0.007 - 0.031    
0.220 
Pharmaceutical 
company TVRs 
Quitline calls 0.084 0.003 -  0.165 0.049 0.040 -0.012 - 0.091 
0.141 
OTC NRT 0.051* 0.014 -  0.088  0.011 0.012 -0.007 - 0.032 
0.213 
NRT prescribing 0.028 -0.023 - 0.080  0.285 0.020 -0.004 - 0.044    
0.121 
*Significant at 5% significance level 
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The IRFs for the seasonally adjusted models are presented in Figure 
7-3 and Figure 7-4. They suggest that there are no significant lagged 
effects of tobacco control or NRT advertising, except a very small and 
marginally significant effect of tobacco control TVRs on OTC NRT sales one 
month after the campaigns, and a small non-significant effect of tobacco 
control TVRs on NRT prescribing in the same period.  
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Figure 7-3. Impulse Response Functions: Impact of tobacco control TVRs on quitline calls, OTC NRT and NRT prescribing 
(seasonally adjusted model) 
Note: IRFs have different y-axis scales. 
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Figure 7-4. Impulse Response Functions: Impact of pharmaceutical company TVRs on quitline calls, OTC NRT and NRT 
prescribing (seasonally adjusted model) 
Note: IRFs have different y-axis scales. 
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Table 7.2 shows the cumulative effects of advertising at 12 months. 
In all models the point estimate was positive (and statistically significant 
for the effect of tobacco control advertising on quitline calls) at 12 months. 
Due to the lack of lagged effects, the estimates at one year were similar to 
the contemporaneous (within-month) estimates. The CIRFs are shown in 
Figure 7.5 and Figure 7.6.
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Table 7-2. Results of SVAR models of the impact of anti-tobacco mass media campaigns on quitting behaviour ± Cumulative 
effects at 12 months 
Exposure Outcome  Unadjusted SVAR Seasonally adjusted SVAR 
   COIRF 95% CI p-value COIRF 95% CI p-
value 
Tobacco control 
TVRs 
Quitline calls 0.110* 0.038-  0.181 0.005 0.083* 0.044- 0.122 <0.001 
OTC NRT 0.021 -0.014- 0.055 0.246 0.018 -0.003- 0.039 0.104 
NRT prescribing 0.037 -0.005- 0.079 0.093 0.015 -0.001- 0.031 0.076 
Pharmaceutical 
company TVRs 
Quitline calls 0.095* 0.017 -  0.172 0.022 0.031 -0.012- 0.091 0.165 
OTC NRT 0.0367* 0.004-  0.069 0.033 0.013 -0.007 - 0.073 0.220 
NRT prescribing 0.046 0.017- 0.172 0.071 0.020 -0.002- 0.042 0.081 
*Significant at 5% significance level 
 198 
 
Figure 7-5. Cumulative Impulse Response Functions: Impact of tobacco control campaigns on quitline calls, OTC NRT and 
NRT prescribing 
 
Note: CIRFs have different y-axis scales. 
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Figure 7-6.  Cumulative Impulse Response Functions: Impact of pharmaceutical company campaigns for NRT on quitline 
calls, OTC NRT and NRT prescribing  
 
Note: CIRFs have different y-axis scales. 
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7.4 Discussion 
This is the first study in over 10 years to provide evidence on the 
effect of tobacco control advertising on quitting behaviour in England and 
Wales. To my knowledge, it is also the first study to explore the impact of 
pharmaceutical company-funded advertising on quitting behaviour in the 
UK, and to examine the impact of both types of campaign on NRT 
prescribing. Tobacco control advertising was significantly associated with 
an increase in calls to the NHS helpline in the same month. A significant 
increase in calls was not observed beyond one month of the advertising. 
Pharmaceutical company advertising had a positive within-month effect on 
NRT sales, but this effect was markedly smaller than that seen for tobacco 
control TVRs on quitline calls, and not significant after controlling for 
seasonal effects of quitting behaviour. During the freeze on public health 
mass media campaigns between April 2010 and October 2011, no tobacco 
control campaigns were run, and the new tobacco control campaign has 
lower funding than that prior to the freeze. Based on these results, this is 
likely to have a detrimental effect on quitting behaviour.  
The major strengths of this study are the long time period studied 
and the use of monthly data, which enabled close matching of the timing 
and magnitude of campaigns to relevant outcomes. Whilst the outcome 
measures are indirect measures of quitting, the strength of these 
measures is that they are objective. This contrasts to campaign 
evaluations which use survey data, which is prone to recall bias, especially 
if not carried out immediately following the campaigns. Also, the measures 
used in this study are outcomes which are likely to have a significant 
influence on quitting; quitlines can help people to quit smoking, while NRT 
is an effective pharmacological cessation aid. Furthermore, this study uses 
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statistical methods which are able to take account of the many 
complexities of time series data, including simultaneity, seasonality, lags in 
effect and autocorrelation. To my knowledge, SVAR modelling had not 
been employed in a public health context prior to its application in this 
study. Since this study was conducted, however, my colleagues and I have 
also used SVAR modelling in a study investigating the impact of tobacco 
price and affordability on smoking prevalence in the UK. This study has 
been submitted for publication, and a conference abstract based on it is 
included in Appendix 9.9. 
A limitation of this study is that it may be underpowered to detect 
very small effects. The pharmaceutical company advertising models have 
fewer data points than the tobacco control advertising model, and lack of 
power may explain the lack of statistical significance in this model. The 
tobacco control TVRs and calls model was re-run over the same timeframe 
as the data available on sales to explore how this affected the results. This 
model yielded an effect of similar size and statistical significance as that 
modelled over the whole time series, and still over twice as big as the 
effect of NRT advertising on any outcome. This suggests that the 
differential effects reported here are not due to the different timeframes of 
available data. It was also not possible to separate the effect of seasonal 
advertising from independent seasonal quitting behaviours and therefore 
both the seasonally adjusted and unadjusted data are presented. If 
seasonal effects are a combination of advertising and factors independent 
of advertising, then the true effect of advertising most likely lies 
somewhere between the seasonally-adjusted and unadjusted estimates.  
Additionally, it was not possible to adjust for potential confounding by 
other interventions such as smokefree legislation, which was implemented 
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in England and Wales in 2007. Doing so would present the same problem 
as the adjustments for seasonality - a lot of the smokefree effect will have 
been due to the increased advertising, so it would not be possible to 
separate out the effects. 
Finally, it is important to note that, because this study looked at 
campaigns overall, as opposed to individual campaigns, these results may 
obscure the larger or more long-term impact of particularly good 
campaigns ± both tobacco control and pharmaceutical company-funded 
campaigns. The small magnitude of effect probably reflects the importance 
of content - in that less effective campaigns reduce the overall effect ± and 
perhaps reflects different effects in different population groups.  
The associations explored in this study have, until now, only been 
explored in a small group of countries. Further research should investigate 
whether the results of the study can be replicated elsewhere. In particular, 
the impact of pharmaceutical company campaigns for NRT and the impact 
of campaigns on prescribing of smoking cessation medication are under-
researched. The results of the current study are consistent with existing 
studies conducted in the US, New Zealand and Australia. Several studies 
have demonstrated an association between tobacco control advertising and 
calls to quitlines.173, 278-281 A limited number of studies in the US and 
Australia has shown that pharmaceutical company advertising can have a 
positive effect on NRT sales, although advertising has been shown not to 
increase demand for all products studied.82, 89, 90 The results of this study, 
which are based on aggregated data for all NRT products and find a small, 
non-significant positive effect of NRT advertising, may, as described above, 
also reflect that some pharmaceutical company-funded campaigns are 
more effective than others. To my knowledge, this is the first study to look 
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at the impact of tobacco control mass media campaigns on prescribing of 
smoking cessation medication. The limited effect identified in this study 
points to missed opportunities: tobacco control advertising may benefit 
from a greater focus on encouraging supported quit attempts (such as 
using a medication shown to increase quit success), while pharmaceutical 
companies should perhaps consider the advantages of using their 
advertising space to encourage smokers to seek advice and medication 
from their GP.  
This study found that the effect of campaigns was generally 
restricted to the month during which they were run. This short-term effect 
is consistent with existing studies and suggests that prolonged campaigns 
are needed to maximise their impact.82, 282, 283 The short-term effect may, 
however, be perceived to indicate that mass media campaigns bring 
forward quitting behaviour as opposed to increasing quitting overall, as 
previous studies suggest occurred when smokefree legislation was 
implemented in England in 2007.79, 80, 284 If this were the case with mass 
media campaigns, one would expect to see an increase in quitting 
behaviour followed by a decrease in subsequent months and no change 
overall. However, the CIRFs showed that in all models the point estimate 
was positive (and statistically significant for the effect of tobacco control 
advertising on quitline calls) at 12 months. This suggests that mass media 
campaigns do not simply redistribute quitting behaviour but have an 
additional impact. 
This study is important in that it provides evidence that tobacco 
control campaigns in England and Wales are effective in encouraging 
quitting behaviour. Further extensive UK-specific research is required to 
build on this study and should explore the impact of campaign type and 
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content; it is highly likely that some campaigns will have had a much 
greater effect than that estimated from the generic measure of campaign 
exposure used in this study. For example, campaigns that contain a 
quitline number may have a greater impact on calls, and campaign 
effectiveness may also vary with funding sources (for example government 
versus charity-funded campaigns). Further research is needed to explore 
effects of campaigns on a more comprehensive set of indicators of smoking 
behaviour and the cost-effectiveness of campaigns, as well as to explore 
the effect of campaigns in different sociodemographic groups to establish 
whether they influence behaviour in the groups with the highest rates of 
smoking. 
7.5 Conclusions 
This study has used robust methods previously not used in public 
health research to investigate the impact of mass media campaigns on 
quitting behaviour. The results suggest that tobacco control campaigns 
may be more effective at triggering quitting behaviour than pharmaceutical 
company NRT campaigns. The implication is that relying on corporate-
funded advertising to influence smoking cessation would be misguided, and 
there are likely to be implications for other areas of health behaviour such 
as alcohol control. In addition, the results of this study suggest that the 
recent freeze on publicly-funded spend on tobacco control mass media 
campaigns may have significantly reduced quitting behaviour. 
Furthermore, the short-term nature of the advertising effects that are 
observed suggests that any advertising needs to be sustained, which would 
have implications for reducing funding of such campaigns in the future.  
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CHAPTER 8: SUMMARY 
CONCLUSIONS AND FUTURE 
DIRECTIONS FOR RESEARCH 
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8.1  Introduction 
The overall aims of this thesis were to investigate the suitability of a 
range of data sources for evaluating the impact of tobacco control policies 
on quitting behaviour in England, and to use validated measures to 
evaluate the impact of recent tobacco control initiatives in England using 
time series analysis.  
This concluding chapter summarises the key lessons learned from 
the research in this thesis, and highlights avenues for future research for 
the four broad areas studied: the use of existing data for evaluating 
tobacco control policy, the use of time series methods for evaluating 
tobacco control policy, and the impact of two types of tobacco control 
policy ± increasing access to smoking cessation medication, and anti-
tobacco mass media campaigns. 
8.2 Existing data for evaluating the impact of tobacco control 
policy on quitting behaviour in England 
8.2.1 Summary of findings 
Chapter 1 of this thesis identified important indicators of quitting 
behaviour and highlighted that robust evaluation of individual tobacco 
control policies generally requires long time series data with short time 
intervals to enable long-term trends to be taken into account. 
Chapter 2 provided a comprehensive overview of the data sources 
containing information on quitting behaviour in England, and explored 
which sources provide data that lend themselves to tobacco control policy 
evaluation. It found that some of the survey data on quitting behaviour in 
England are good for monitoring behaviour, because they are conducted in 
large, representative samples, but are generally not suitable for the 
evaluation of individual policies using time series. This is because they are 
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usually annual, or have small sample sizes on a monthly basis, resulting in 
short time series which are insufficiently sensitive for identifying the 
impact of individual policies. 
In contrast, routinely collected data are often available in large 
samples over long time periods and on a monthly basis, making them 
appropriate for evaluating tobacco control policies, although they often do 
not measure key outcomes of interest. 
Existing evidence and the new validation study in Chapter 3 showed 
that, in particular, primary care data from THIN are a valuable source of 
time series data on smoking prevalence and prescribing of smoking 
cessation medication, although the smoking prevalence data are only valid 
from 2006. In addition, data on smoking cessation advice giving and 
referrals to smoking cessation services in primary care have previously 
been shown to be of limited quality. 
8.2.2 How can data on quitting behaviour in England be improved? 
None of the data sources described in Chapter 2 are without 
limitations. The THIN data have the potential to be more useful if GPs can 
be encouraged to consistently deliver and record cessation advice and 
referrals, and future research should explore how this could be achieved. 
Further to this, the prevalence data ought to be re-validated in the future 
to confirm the validity that has been shown at a national and regional level 
in recent years. 
A significant gap in the existing data is the lack of a valid, frequent 
measure of quit attempts. This would be an extremely important sensitive 
outcome for measuring the impact of tobacco control policies on quitting 
behaviour. The IHS provides a frequent, large and representative sample 
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of the population, and therefore including a question on quit attempts (for 
example, in the last month) in the survey seems likely to be a good way of 
obtaining good data on quit attempts. This, coupled with a monthly 
measure of smoking prevalence (for example, from the IHS or from THIN), 
would provide valuable data on the short-term and longer-term effects of 
policy on quitting. Both the IHS and THIN contain extensive 
sociodemographic data and would therefore allow investigation of 
differential policy effects in different population groups and, in particular, 
the effect of policies on health inequalities. 
It is important to combine subjective measures (such as self-
reported quit attempts and smoking status) with objective measures such 
as prescribing of cessation medication, use of cessation services and 
quitline calls. Indeed, objectivity is a major strength of the measures of 
quitting behaviour used in the evaluation studies in this thesis. When 
combined with such data, high quality data on quit attempts and 
prevalence would help to provide comprehensive evidence on the impact of 
policy on quitting behaviour.  
The more comprehensive a set of indicators is available for policy 
evaluation, the stronger the evidence on the effectiveness of policies will 
be. It would therefore be particularly useful if these indicators could be 
supported by evidence from other sources, such as the Smoking Toolkit 
Study (STS) and the ITC Project. The STS contains data on a range of 
indicators of quitting behaviour, such as quit attempts and cessation 
support used, but its use in policy evaluation studies is currently limited by 
the small monthly sample size and brevity of the time series. It could, 
however, become invaluable in policy evaluations if sustained over time. 
For example, survey waves could be combined to ensure adequate sample 
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sizes for time series analysis, and pre-policy trends could be taken into 
account. The key strength of the ITC Project data is that they include 
comparative data from a wide range of countries. To maximise the value of 
the ITC data, however, the surveys need to be conducted on a regular 
basis, and questions related to newly proposed policies added as rapidly as 
possible, to ensure that the necessary data are available. Evidence as to 
how policy affects behaviours, in addition to evidence as to whether it does 
so, would help us to understand how policy could be improved, which 
would guide policy development both in England and internationally. The 
ITC dataset contains proximal and distal indicators which can be used to 
obtain this type of evidence. The cost of running both the STS and the ITC 
Project are clearly, however, a potential barrier in their continuation and 
expansion. 
8.2.3 Avenues for future research 
In addition to the research related to primary care data proposed 
above, there are two key avenues of future research related to data for 
policy evaluations. 
The first is to conduct similar analyses of data sources in 
international settings. England probably has, despite the limitations of the 
data, more comprehensive and regular data on quitting behaviour than 
most other countries. For example, previous research has shown that the 
measurement and monitoring of trends in smoking prevalence in many EU 
countries is inconsistent and infrequent.285 It would therefore be useful to 
identify the gaps and limitations of data on quitting behaviour in other 
countries. In particular, the lessons learned in this thesis may facilitate 
setting up high quality data collection for future evaluations; the number of 
indicators need not be large, but ought to be relevant and collected in 
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large, representative samples and at frequent time intervals, to maximise 
the quality of evaluations. 
The second important line of research is to investigate data sources 
in other health policy areas, particularly in those that are less well 
developed than tobacco control. One example is alcohol policy. Alcohol 
consumption has been rising in the UK since the 1950s, with detrimental 
consequences for public health and public order.286 Policies and initiatives 
to address issues of alcohol misuse to date have been significantly less 
comprehensive than those to reduce tobacco-related harm, but policies on 
pricing, marketing and health messages are emerging or under 
consideration in UK countries. Monitoring changes in drinking habits over 
time, and in different population groups, and applying appropriate 
inferential statistical methods to these data, is key to evaluating the 
impact of these policies and to guiding future policy. In my future research 
I therefore propose to carry out work towards establishing a database of 
UK data relating to drinking behaviour, which will facilitate future research 
evaluating the impact of national alcohol policy. I will follow a similar 
approach to that which was used to develop the NTCD and in Chapter 2 of 
this thesis to identify key indicators of alcohol behaviour and misuse from 
existing datasets, describe any evidence for their validity (or how this 
might obtained), identify any gaps in the available data, and identify the 
policies, initiatives or public health interventions which might be evaluated 
using the existing data.  
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8.3 Using time series analysis for the evaluation of public health 
policies 
8.3.1 Summary of methods 
Chapter 1 identified time series analysis as a robust statistical 
method for evaluating the impact of tobacco control policy. Chapter 4 built 
on previous work on the application of time series methods to public health 
policy evaluations by describing a broader range of time series methods: 
ARIMA modelling and segmented regression analysis using GAMs/GAMMs 
(for interrupted time series analysis, used when a policy has been 
introduced at a specific point in time) and dynamic regression analysis and 
vector autoregression analysis (for multiple time series designs, needed to 
investigate the impact of a continuous policy exposure on a continuous 
outcome). All of these methods are currently infrequently used in public 
health policy evaluation, and in particular, to my knowledge, VAR and 
SVAR modelling have not been used in this context before. 
8.3.2 Interrupted time series analysis: Lessons learned and 
avenues for future research 
Segmented regression analysis is an interrupted time series method 
which can, depending on the complexity of the autocorrelation, be used 
with a relatively short time series. However, due to its added flexibility in 
modelling policy effects (such as being able to model temporary as well as 
permanent effects, as well as being able to model non-linear trends), if 
sufficient data are available, ARIMA modelling is often preferable to 
segmented regression analysis.  
Interrupted time series analysis is an extremely useful study 
design, because it takes account of existing trends and autocorrelation. 
Given that multiple tobacco control policies are often implemented at or 
around the same time, and the fact that it is difficult to disentangle the 
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effects of different policies, however, it is important to consider any 
potentially confounding policies and their likely effect when carrying out 
policy evaluation studies. Even when care has been taken to take account 
of confounding events, it may not be possible to conclude that there is a 
causal relationship between a policy intervention and a change in an 
outcome measure. High statistical significant and strength of effect may be 
key indicators of causality, but other, unobservable factors may still 
explain the results. For example, in Chapter 6 of this thesis a levelling off 
in prescribing of NRT to adolescents was observed immediately following 
the licensing change. However, it seems likely that other factors caused 
this levelling off; a lack of data on these factors means their impact cannot 
be estimated. Thus researchers conducting TSA should always try to be 
aware of possible alternative explanations for their results and it is also 
important to triangulate the results of interrupted time series studies with 
other types of policy evaluation if possible, so as to maximise the likelihood 
of identifying true policy effects. 
Chapters 5 and 6 of this thesis demonstrated how each of these 
methods can be applied to evaluate policy effects. In Chapter 5 ARIMA 
modelling was used to evaluate the impact of the introduction of 
varenicline on prescribing for smoking cessation medication.  
In Chapter 6 segmented regression was used to analyse the impact 
of the broadening of the indications for NRT on prescribing of the drug to 
adolescents and CVD patients. 
To increase their value, further research is needed into the relative 
power of the two methods, which, as described in Chapter 4, remains 
unclear. When correctly used, however, these methods can provide strong 
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evidence of policy effects, and are therefore potentially useful tools not just 
in tobacco control, but in all areas of public health policy. Ensuring that 
these methods become more routinely applied in public health policy 
research should therefore be a priority for researchers.  
8.3.3 Multiple time series analysis: Lessons learned and avenues 
for future research 
Dynamic regression analysis and VAR modelling are both methods 
for estimating the impact of one time series on another. Chapter 4 of this 
thesis described these models and the methods involved in choosing 
between them. Chapter 7 demonstrated how these methods can be used 
to evaluate the impact of a continuous tobacco control policy exposure, 
using a variation of VAR analysis, SVAR modelling. 
Multiple time series analysis also has some of the issues 
surrounding causality; if confounders (such as policy events which have an 
effect on the outcomes) have not been taken into account, statistical 
association may not reflect true causality. However, as the exposure is 
measured over time (unlike in an interrupted time series model), this may 
not be as problematic if confounder is not present throughout the time 
series. For example, smokefree legislation may have influenced quitting 
behaviour (over and above the effect of advertising related to smokefree) 
during some of the study period, but because the model is based on many 
months of data, its overall confounding effect is likely to be reduced. Most 
potential confounders can, if data are available, be fitted to these models, 
and thus the likelihood of a causal effect can be maximised.  
These methods have rarely been used in a public health context, 
and future research should explore other areas in which they could be 
applied. Our research team has already gone on to use a SVAR model to 
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estimate the effect of tobacco price on smoking prevalence in the UK. An 
abstract based on this study is presented in Appendix 9.9. I also hope to 
apply these methods in a future study to investigate the impact of price on 
OTC NRT sales in the UK. 
In addition to dynamic regression and VAR/SVAR, there are a range 
of other multiple time series models which it has been beyond the scope of 
this thesis to explore. The multiple time series literature is, unfortunately, 
extremely complex; because they have rarely been used in public health 
research, little attempt has until now been made to make these 
econometric methods accessible to public health researchers. This thesis 
has made a start, but future research should review other time series 
models to determine how these methods and their results differ from those 
described in this thesis, and whether and how they could be applied to 
maximise the strength of the evidence that can be obtained from them. In 
particular, research should look at the use of long-run time series models 
in public health. The methods described in this thesis have focussed on the 
short-run because it was anticipated that the continuous policy exposure 
investigated, mass media campaigns, would have a short-term impact on 
the outcomes of interest. 
To that end, I am collaborating with ASH UK and Landman 
Economics to conduct a detailed study of the impact of tobacco price on 
consumption. This will use data from an existing study by HM Revenue and 
Customs as a starting point, and compare the results of different multiple 
time series methods, including short and long-run models.287 
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8.4 The impact of increasing access to smoking cessation 
medications in England 
8.4.1 Summary of findings 
Chapters 5 and 6 of this thesis explored the impact of recent 
changes in the availability of pharmacological smoking cessation aids in 
England using prescribing data from THIN. These studies, which used an 
objective measure of prescribing, suggest that neither the introduction of 
varenicline nor the broadening of the indications for NRT are likely to have 
had a significant impact on public health. Although prescribing for 
varenicline increased rapidly in English general practice following its 
introduction, overall rates of prescribing for smoking cessation medication 
do not appear to have increased. Similarly, prescribing of NRT did not 
increase in adolescents or CVD patients following the licensing changes 
which permitted these groups to receive the drug. 
8.4.2 Implications of findings and avenues for future research 
Increasing access to smoking cessation medication then, does not 
appear to have had the desired effect on quitting behaviour: the general 
practice data suggest that it has not increased supported quit attempts. 
Future research should explore whether and how rates of smoking 
cessation support in primary care could be increased. 
There may, however, have been favourable effects of the changes 
that cannot be observed from the data used in this thesis. For example, 
varenicline may be more effective than NRT and bupropion, and therefore 
its use may have increased the success of quit attempts.128 Furthermore, 
the NRT licensing change may have reassured medical professionals who 
were already prescribing the drug, or increased the provision of NRT in the 
relevant groups in other settings, such as smoking cessation services. 
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This underlines the aforementioned need for the triangulation of 
evaluation studies ± comparing the results of studies which use different 
methods and different settings ± in order to obtain a better understanding 
of the effects of policy changes. Thus a comprehensive perspective can be 
gained, which may be influential in driving future policy changes in both 
national and international settings. 
8.5 The impact of anti-tobacco mass media campaigns in 
England and Wales 
8.5.1 Summary of findings  
Chapter 7 of this thesis was a much-needed study of the impact of 
anti-tobacco mass media campaigns in England and Wales. Recent cuts in 
government spending on tobacco control campaigns and the dearth of 
recent UK-specific evidence made this a particularly important and topical 
study. The study found that during the study period, on average, tobacco 
control advertising was significantly associated with an increase in calls to 
the NHS stop smoking helpline. NRT advertising had a positive effect on 
NRT sales, but this effect was markedly smaller than that seen for tobacco 
control TVRs on quitline calls.  
8.5.2 Implications of findings and avenues for future research 
The implications of these findings are that the recent cuts in 
advertising are likely to have reduced quitting behaviour. Further to this, it 
seems likely that it would be unwise to rely on corporate-funded 
advertising to influence quitting behaviour. This may also be the case for 
other areas of health behaviour where mass media campaigns are used.  
This is an important finding, but in order to maximise the impact of 
future anti-tobacco campaigns, extensive research is required to identify 
the types and characteristics of the most effective and cost-effective 
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campaigns using a variety of indicators of quitting behaviour and identify 
those that are most successful in reaching target groups with the highest 
smoking rates. 
I have been involved in developing a proposal for a project, which 
has received funding from the National Prevention Research Initiative, 
which will evaluate the impact of UK anti-tobacco mass media campaigns 
carried out since 2004 on a set of key indicators of adult smoking 
behaviours including smoking prevalence, cigarette consumption, quitting 
behaviour, smoking in the home, and smoking-related health outcomes 
using a combination of time series analysis and longitudinal data analysis 
approaches in existing national datasets. We aim to determine what types 
of campaign are most effective and cost-effective in terms of their 
immediate and longer term impacts, and their potential to reduce smoking-
related health inequality. The campaigns will be classified in terms of the 
channel of delivery (TV, radio, press and billboard campaigns), duration, 
their aims and target audience, informational and emotional content and 
style.  
Thus the proposed research will draw on many of the lessons 
learned through this PhD thesis to conduct a comprehensive evaluation of 
the impact of anti-tobacco mass media campaigns. It will use a range of 
study designs, data sources and outcome measures which, together, 
should provide comprehensive evidence as to the impact of mass media 
campaigns in the UK and the content of the most effective and cost-
effective campaigns, and in doing so will help to guide future policy on a 
local, national and international level. It is possible that this comprehensive 
evaluation design could also be used in other areas of public health. 
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8.6 Overall conclusions 
This thesis has provided an important illustration of the data and 
methods that are needed for robust tobacco control policy evaluation. It 
has highlighted time series analysis as a particularly good study design for 
policy evaluation, and has described a range of data from existing sources 
which provide information on smoking cessation behaviour in England. 
Although it has shown that there are significant gaps in the existing data 
available for tobacco control policy evaluation using time series analysis, 
there are some high quality time series data, which have been used to 
evaluate a group of tobacco control policies recently implemented in 
England. Overall, this thesis has highlighted the need for the regular 
collection of data on key indicators of quitting behaviour, and that the 
frequent use of time series analysis in policy evaluation can play a vital 
role in strengthening the evidence for the effectiveness of policies, both in 
tobacco control, and in other areas of public health. 
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9.1 Nottingham Tobacco Control Database variables and descriptions 
 Variable Description 
GLF/GHS Denominators 
 
Total number of individuals that completed the survey 
GLF/GHS  Current smokers Number of individuals DQVZHULQJ³\HV´WRWKHTXHVWLRQ³'R\RXVPRNH
DWDOOQRZDGD\V"´ 
GLF/GHS Want to quit 
 
1XPEHURILQGLYLGXDOVDQVZHULQJ³\HV´WRWKHTXHVWLRQ³'R\RXZDQWWR
TXLWVPRNLQJ"´ 
Omnibus Current smokers 1XPEHURILQGLYLGXDOVDQVZHULQJ³\HV´WRWKHTXHVWLRQV 
   ³'R\RXVPRNHFLJDUHWWHVDWDOOQRZDGD\V"´0RGXOH 
   ³'R\RXVPRNHFLJDUHWWHV"´0RGXOH 
Omnibus Denominators 
 
Total number of individuals that completed the survey. 
Omnibus GP stop smoking advice in the last 
5 years 
1XPEHURILQGLYLGXDOVDQVZHULQJ³\HV´WRWKHTXHVWLRQ³+DV\RXU*3
JLYHQ\RXDGYLFHDERXWVWRSSLQJVPRNLQJLQWKHODVW\HDUV´ 
Omnibus Over the counter NRT purchases in 
the last year 
Number of individuals reporting having paid for NRT in the last year 
(excluding chargeable prescriptions). 
Omnibus Prescribed smoking cessation 
medication in the past year 
Number of individuals reporting having obtained a prescription for a 
smoking cessation product in the last year. Broken down by medication 
type, but not by formulation (not asked about). 
Omnibus Quit attempts in the last year Number of individuals reporting having made at least one quit attempt 
(of unspecified duration) in the last year. 
Omnibus Want to quit 
 
1XPEHURILQGLYLGXDOVDQVZHULQJ³\HV´WRWKH TXHVWLRQ³'R\RXZDQWWR
TXLWVPRNLQJ"´ 
Health Survey for 
England 
Denominators 
 
Total number of individuals that completed the survey. 
 221 
 
Health Survey for 
England 
Current smokers 1XPEHURILQGLYLGXDOVDQVZHULQJ³\HV´WRWKHTXHVWLRQ³'R\RXVPRNH
at all QRZDGD\V"´ 
Health Survey for 
England 
Want to quit 
 
1XPEHURILQGLYLGXDOVDQVZHULQJ³\HV´WRWKHTXHVWLRQ³'R\RXZDQWWR
TXLWVPRNLQJ"´ 
Smoking Toolkit Denominators 
 
Total number of smokers that completed the survey. 
Smoking Toolkit Quit attempts in the last month Number of individuals reporting having made at least 1 quit attempt 
during the month immediately prior to the date on which they completed 
the survey. 
Smoking Toolkit Plan to quit Number of individuals reporting having made a plan to quit smoking in 
the future. 
Smoking Toolkit Want to quit 
 
Number of individuals indicating that they want to quit smoking. 
Smoking Toolkit Used smoking cessation clinic in 
last month 
Number of individuals reporting having visited a smoking cessation clinic 
during any quit attempt in the last month. 
Smoking Toolkit Used smoking cessation medication 
in the past month 
Number of individuals reporting having used a stop-smoking medication 
during any quit attempt in the last month. Broken down by medication. 
Quitline Quitline calls Total number of calls to the NHS Stop Smoking Helpline 
 
IRI Sales of OTC NRT Total number of NRT items sold at retail (over-the-counter and off-the-
shelf), broken down by formulation. This reflects the actual number of 
packets sold, rather than the number of purchases. 
ePACT Dispensed smoking cessation 
medication 
Total number of items dispensed. This reflects the number of items listed 
on the prescription form, rather than the actual number of packets 
issued (i.e. a prescription for 60 tablets counts as one item regardless of 
whether two packets of 30 were actually issued). 
THIN Denominators 
 
Total number of currently-registered living individuals enrolled in THIN.  
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THIN Brief stop smoking advice from GP Number of individuals to whom brief advice is given.  
 
THIN GP-prescribed smoking cessation 
medication 
Overall number of prescriptions issued in each class.  
THIN Current smokers Number of currently-registered individuals enrolled in THIN with a last 
smoking status recording indicating any current smoking.  
 
Adapted from ´135,'DWDVHWYData Format and Variable Descriptions´E\-DFN*LEVRQ
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9.2 Can primary care data be used to monitor regional smoking 
prevalence? An analysis of The Health Improvement Network 
primary care data 
This study formed part of a medical student project supervised by 
me and Sarah Lewis. I subsequently prepared the manuscript for 
publication. This study has been published in BMC Public Health.288 
9.2.1 Background 
Robust regional data on smoking prevalence are important for 
monitoring regional trends in smoking and evaluating the impact of 
national and regional tobacco control interventions. Currently, few large-
scale high-quality regional data on smoking prevalence in the UK are 
available. The main source of regional prevalence data in the United 
Kingdom (UK) is national survey data. The General Lifestyle Survey (GLF), 
WKH FXUUHQW µJROG VWDQGDUG¶ IRU PHDVXULQJ VPRNLQJ SUHYDOHQFH LQ *UHDW
Britain, has highlighted significant variation in smoking prevalence across 
the British regions.50 However, survey data tend to be infrequently 
collected or have small sample sizes, particularly at the regional level, and 
there is often a significant time lag between the collection and the release 
of the data.147, 184 Electronic primary care databases have the potential to 
provide a valuable source of regional data on smoking prevalence due to 
their size, availability of monthly data and continuity.  
The Health Improvement Network (THIN) (http://www.epic-
uk.org/thin.htm) is a database of UK electronic primary care records. The 
validity of THIN data has been demonstrated for major events.178-183 More 
recently, THIN data on smoking status have been validated at the national 
level. From 2006 onwards there was, despite the very different methods of 
obtaining prevalence estimates between the two data sources, generally 
good agreement between the prevalence of  current smoking recorded in 
 224 
 
THIN and smoking rates based on national survey data from the GLF, 
suggesting  that THIN may be an accurate means of monitoring smoking 
prevalence nationally.184 However, the validity of THIN data on smoking 
prevalence at the regional level, which may be less precise as a result of 
smaller sample sizes and reduced representativeness, has yet to be 
demonstrated.  
A validation study was therefore conducted comparing estimates of 
regional smoking prevalence from THIN with those from the GLF to assess 
whether THIN data can be used to monitor regional variation and trends in 
smoking prevalence.  
9.2.2 Methods 
The version of THIN used in this study contains the primary care 
records of approximately 8 million patients from 446 general practices in 
England, Scotland, Wales and Northern Ireland, of whom 3.2 million are 
currently registered with a practice and can be followed prospectively; 
retrospective data is available for the remaining patients who have since 
either died or transferred from THIN practices. Prospective medical records 
are recorded using the Vision general practice computer system software, 
and serve as the primary medical record for the practice. GPs are able to 
record diagnoses, demographic information, lifestyle characteristics (such 
as smoking status) and other medical information. The dataset represents 
approximately 6% of the UK population.227  
Currently, the main source of statistics for monitoring smoking 
prevalence in Britain is a national, annual survey, the GLF,51 formerly 
known as the General Household Survey (GHS). It collects information on 
a range of topics from around 16,000 adults aged 16+ living in private 
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households in England, Wales and Scotland each year. Topics include 
housing, employment, health, alcohol consumption and income as well as 
smoking, and data are available by age and sex. It uses a probability, 
stratified two-stage sample design and aims to interview all adults aged 16 
or over at each sampled address.158 In 2009 the response rate was 73%.50 
)RU WKLV VWXG\ WKH */)¶V PHDVXUH RI the prevalence of current cigarette 
smoking, which is obtained by asking respondents µGR \RX VPRNH
ciJDUHWWHV DW DOO QRZDGD\V¶, was used. The data were weighted for non-
response and also weighted to the population distribution of region, age 
group and sex. 
The GLF covers England, Wales and Scotland only; therefore, the 
validation of the regional THIN prevalence data did not include data from 
Northern Ireland. The GLF surveys people aged 16 and over only, and 
therefore under 16s were also excluded from this study. GLF data from 
2000 to 2008, stratified by government office region (GOR), were used in 
this study. 
For each year from 2000 to 2009 all live patients who were over the 
age of 16 and registered with a practice on an index date of 1st July of that 
year were identified from the THIN dataset and stratified by region. THIN 
data are regionally stratified by Strategic Health Authority (SHA). SHAs are 
coterminous with GORs, except that the South East region is divided into 
two: South Central and South East Coast. The THIN data for these two SHA 
regions were therefore combined. Patients who registered with a practice 
within the previous three months were excluded from this analysis (the GP 
contract requires that the smoking status of newly-registering patients is 
recorded within three months for this recording to be financially rewarded). 
The prevalence of smoking each year was calculated from the data 
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recorded in medical records. All records of smoking status, identified by 
relevant Read Codes (a hierarchical dictionary of medical nomenclature 
289), entered into a patient's notes on or after their registration date were 
extracted. Patients were classified as current smokers at a given index 
date if their most recent smoking-related entry in their medical records 
prior to this index date identified them as such. The percentage of patients 
with no smoking status recorded decreased during the study period, from 
36% in 2000 to 10% in 2009. A previous study has shown that the 
majority of patients with missing smoking records in THIN are ex or non-
smokers, and therefore all patients with no smoking formation were 
assumed not to be current smokers at that point in time.290  
The way in which estimates of smoking prevalence are obtained are 
clearly very different in THIN and the GLF; however, the previous 
validation of THIN smoking prevalence data also used the GLF as a 
comparator and found that the estimates were comparable from 2006, 
suggesting that it is appropriate to compare these two data sources.184  
The sampling method of the GLF is designed to produce regionally 
representative estimates of smoking prevalence.158 However, THIN 
comprises those GP practices in each region that have agreed to contribute 
their data to the database, and may not be regionally representative.  
Therefore the demographic structure of THIN at the regional level was 
initially compared with regional population estimates from the Office of 
National Statistics.193 THIN was found to be highly representative in terms 
of age and sex structure at the regional level. Population pyramids showing 
the representativeness of THIN by age and sex on a regional basis are 
presented as supplementary online material (Additional file 1, available at 
http://www.biomedcentral.com/1471-2458/11/773/additional). Since both 
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GLF and THIN are regionally representative, the prevalence of smoking 
was compared between these two data sources directly, without 
standardisation for age or sex.  To ensure that this assumption was 
appropriate, age and sex-standardised estimates were also calculated. 
These were calculated through indirect standardisation by applying age- 
and sex-specific smoking rates from the corresponding GLF data to the 
THIN population. These are extremely similar to the unstandardised 
estimates and are shown in additional file 2 (available at 
http://www.biomedcentral.com/1471-2458/11/773/additional). 
Annual estimates of smoking prevalence in the different regions 
based on THIN were compared graphically with point estimates, and 
confidence intervals around those estimates, from the GLF, to assess 
whether regional estimates of prevalence in THIN are similar to those from 
the GLF. Confidence intervals were not drawn for THIN as its much larger 
sample size results in precise estimates and very narrow confidence 
intervals which are not easily graphically distinguishable from the point 
estimates. These confidence intervals are shown in additional file 3 
(available at http://www.biomedcentral.com/1471-
2458/11/773/additional). 
The data used in this study form part of the recently-developed 
Nottingham Tobacco Control Database, a compilation of sources of 
smoking-related information at a national and regional level. All analysis 
was carried out in Stata Version 11.0 (Stata Corp, College Station, TX) and 
the analysis of THIN data for this study was approved by the Derbyshire 
Research Ethics Committee.  
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9.2.3 Results  
Table 9-1 below shows the sample sizes of the GLF and THIN by 
region in 2000 and 2008, demonstrating the much-reduced sample sizes in 
the regional data. The regional sample sizes in THIN remain extremely 
large, with over 100,000 people in each region in 2008. The regional GLF 
sample sizes are much smaller, ranging from 642 in the North East region 
to 2,082 in the South East in 2008. 
Table 9-1. Sample sizes of General Lifestyle Survey and THIN, 2000 
and 2008 
 GLF 2000 THIN 2000 GLF 2008 THIN 2008 
North East 686 99,054 642 109,322 
North West 1,701 286,949 1,691 316,195 
Yorkshire And 
Humber 
1,253 136,982 1,370 144,646 
East Midlands 997 130,418 1,222 140,882 
West Midlands 1,300 285,633 1,354 317,585 
East Of England 1,348 222,265 1,497 243,355 
London 1,504 293,421 1,207 338,859 
South East 2,062 525,110 2,082 704,886 
South West 1,303 290,763 1,420 350,742 
Wales 724 141,372 830 210,585 
Scotland 1,211 198,045 1,304 250,109 
Total 14,089 
 
2,703,864 
 
14,619 
 
3,245,031 
  
Figure 9-1. Smoking prevalence by region from THIN and GLF 
(2000-2008) shows the comparison of THIN and GLF smoking prevalence 
data by region from 2000 to 2008. The GLF data show the general 
decreasing trend in smoking prevalence in recent years in all regions. In 
most regions, prevalence estimates from THIN converged with those from 
the GLF over the years of the study, with good agreement between the 
data sources, and THIN estimates falling within the confidence intervals of 
the GLF, from 2006 onwards. 
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Figure 9-1. Smoking prevalence by region from THIN and GLF (2000-2008) 
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In three regions this convergence is not observed.  The data from 
the West Midlands did not converge during the study period, although the 
discrepancy between the two datasets fell, and the THIN estimate was 
within the confidence interval for the GLF estimate in the final year. The 
Yorkshire and Humber data converged during the study period, but the 
2008 THIN estimate did not fall within the GLF confidence interval. The 
data from Wales converged from 2001 to 2005, at which point prevalence 
as measured by both data sources was approximately 22%. In subsequent 
years the values moved apart again; however, the THIN estimates were 
within the confidence interval for the GLF in the final two years of the 
study.  
9.2.4 Discussion  
To our knowledge, this is the first study to validate primary care 
smoking data at the regional level. These results show that estimates of 
regional smoking prevalence from THIN are highly comparable to the 
corresponding estimates from the current main source of such data. In 
most regions, smoking prevalence based on THIN data was similar to that 
found by the GLF from 2006 onwards. Primary care data could therefore be 
used to help target tobacco control initiatives at the areas with the highest 
smoking prevalence and to monitor prevalence across regions. 
The main limitation of this study is that it was not possible to 
compare 7+,1GDWDZLWKWKHFRUUHVSRQGLQJGDWDIRUDOORIWKH8.¶VUHJLRQV
The GLF covers Great Britain only, and therefore it was not possible to 
validate prevalence data for Northern Ireland. However, the results were 
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generally consistent across all regions that were included, and it is likely 
that THIN smoking prevalence estimates for Northern Ireland are similarly 
accurate. Further to this, it was not possible to explore the comparability of 
THIN and GLF prevalence estimates beyond 2008. Estimates from these 
two data sources were similar in the final three years of the study only; 
further research will be required in the future to ascertain whether this 
agreement is maintained in subsequent years. 
A further limitation of this study is that the GLF and THIN may 
underestimate smoking prevalence, as both GLF respondents and general 
practice patients do not have their smoking status biochemically validated. 
However, the high costs associated with such validation mean that it is 
extremely difficult to obtain it for such large samples. In addition, because 
there is considerable variation in the completeness of recording between 
UK general practices, these results are not necessarily generalisable across 
all practices.  
A final limitation of this study is that the significantly diminished 
sample sizes of the GLF at the regional level mean that there may be 
significant error in its estimates. However, during the study period the GLF 
was the largest survey providing regional prevalence data for Great Britain, 
and is therefore the most appropriate comparator.  
Despite the diminished sample size of the THIN data at the regional 
level, the results of this study are broadly consistent with those of the 
previous validation study of these data carried out at the national level. As 
at the national level, prevalence estimates based on THIN from most 
regions were found to be similar to those based on the GLF from 2006.184 
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The convergence in prevalence estimates from THIN and the GLF is 
almost certainly a result of the voluntary, pay-for-performance general 
practice contract introduced in 2004.291 The contract requires GPs to record 
WKHLUSDWLHQWV¶VPRNLQJVWDWXVDWOHDVWHYHU\PRQWKVHYHU\PRQWKV
for patients with specified chronic diseases) and has been taken up by 
almost all GPs.117  
Convergence between the two datasets by 2006 was not observed 
in all regions; there was greater discrepancy between the data sources for 
the West Midlands, Yorkshire and the Humber and Wales. Regional GLF 
data are based on small sample sizes, with resultant higher sampling error, 
as demonstrated by the wide confidence intervals, and any discrepancy 
between THIN and GLF estimates may reflect uncertainty associated with 
the GLF data rather than inadequacy of estimates from THIN. Further to 
this, while this study confirmed that THIN is representative regionally in 
terms of age and sex, it did not assess representativeness in terms of 
other factors such as social class. This may also account for some of the 
discrepancy in the three aforementioned regions. That even in these 
regions, the THIN estimates in two of the final three years (Yorkshire and 
Humber), the final year (West Midlands) and the final two years (Wales) of 
the study were within the confidence intervals of the GLF estimates 
demonstrates that estimates from GLF and THIN for these regions may 
indeed be comparable. The discrepancy in the final year of data for 
Yorkshire and Humber may be due to young adults being underrepresented 
in the THIN population of this region in the final year of the study (as 
shown in additional file 1).  
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There are several advantages to using THIN prevalence data 
compared with the national survey data. THIN data are routinely collected, 
are released 3-4 times per year, and have a lag of only 3-8 months before 
data become available.184 A further advantage is its size; the standard 
HUURURI7+,1¶VVPRNLQJSUHYDOHQFHHVWLPDWHVLVVLJQLILFDQWO\VPDOOHUWKDQ
those of the GLF at a national level.184 At a regional level, GLF estimates 
are prone to more error due to much reduced sample sizes and confidence 
intervals are so wide, as demonstrated in Figure 9-1, that changes from 
year to year will be difficult to detect; therefore the large sample size in 
THIN is extremely valuable. Further to this, THIN provides monthly data, 
which is particularly useful in the evaluation of short term impacts of 
tobacco control initiatives.  
Based on the THIN data, it was found that in 2008 Scotland (24%), 
the North West (23.5%), and Northern Ireland (23.5%) had the highest 
smoking prevalence in the UK. The East of England (19%), the West 
Midlands (19%) and South East England (19%) had the lowest prevalence. 
There remains substantial variation in smoking prevalence between the 
regions, with higher prevalence often being observed in regions with the 
lowest per capita disposable income.292 Smoking is an important 
contributor to health inequalities.53, 137 Therefore, reducing regional 
differences in smoking prevalence will contribute to alleviating health 
inequalities in the UK. This study indicates that THIN may be a useful 
source of data for monitoring these regional differences. 
To our knowledge, the current study and that by Szatkowski et al. 
are the first to explore the possibility of using primary care data to monitor 
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smoking prevalence; these results indicate that primary care data are a 
potentially valuable source of such information.184 Previous research 
suggests that surveys which monitor smoking prevalence in EU Member 
States often have small sample sizes and are irregularly carried out.285 This 
suggests that the way in which smoking prevalence is monitored 
internationally has similar limitations to the way it is currently monitored in 
Britain. Future research exploring the possibility of using primary care data 
to monitor smoking prevalence in countries other than Britain may 
therefore be warranted. 
9.2.5 Conclusions  
It is important to monitor regional patterns of smoking prevalence 
to ensure tobacco control measures in the UK are targeted at the areas 
most in need and help to reduce the health inequality caused by smoking. 
THIN data on smoking prevalence at the regional level are comparable with 
the main source of UK data on this measure, and could therefore be used 
to monitor longitudinal regional trends in smoking prevalence. 
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9.3 Validation of THIN smoking cessation medication prescribing 
data 
Figure 9-2. Rates of prescribing of smoking cessation medication, 
England, based on THIN and ePACT, January 2004-July 2008 
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9.4 Stata commands for time series analysis 
9.4.1 General time series commands 
To declare data to be time series data: 
tsset timevar 
To draw a time plot of a series: 
tsline series 
To draw an autocorrelation function (ACF): 
ac series 
To draw a partial autocorrelation function (PACF): 
pac series 
To generate a new variable containing the first difference of a series: 
gen dseries = D1.series 
To generate a new variable containing the first seasonal difference of a 
series: 
gen sdseries = S12.series 
To generate a new variable containing the first differenced and seasonally 
differenced series: 
gen dsdseries = D1.S12.series 
To generate a new variable containing the natural logarithm of a series: 
gen logseries = ln(series) 
To generate a dummy variable indicating the presence of an intervention in 
a given month e.g. December 2006: 
gen intervention = 0 
recode intervention 0=1 if month==tm(2006-12) 
9.4.2 Commands to fit a segmented regression model in Stata 
To fit a simple linear regression: 
regress series time level slope 
 
To fit a Prais-Winsten regression: 
prais series time level slope 
9.4.3 Commands to fit an ARIMA model in Stata 
To fit an ARIMA model to a pre-intervention series: 
arima series if month<intervention_month, arima(p,d,q) sarima(P,D,Q,S) 
To draw a histogram of the residuals from an ARIMA model: 
predict residuals if timevar <= tm(2006,11), residuals 
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ac residuals if timevar <= tm(2006,11) 
hist residuals, normal 
To obtain the information criteria for a model: 
estat ic 
To estimate the impact of an intervention on a series: 
arima D1.S12.series intervention, arima(p,0,q) sarima(P,0,Q,S) 
N.B. If the series requires differencing (either first or seasonal) the prefix 
D1.S12, D1., or S12., must be placed before series variable on the left 
hand side of the command and d and D replaced by 0 on the right hand 
side. This is to ensure that the intervention variable is not itself differenced 
in the model estimation procedure. 
9.4.4 Commands to fit a dynamic regression model in Stata 
To check weak exogeneity assumption: 
var output input, lags(numlist) 
vargranger 
If weak exogeneity confirmed, specify preliminary model: 
arima output input l(numlist).input 
N.B. Drop lags one at a time if non-significant. 
9.4.5 Commands to fit a SVAR model in Stata 
To specify the matrices: 
matrix A = (1,0\.,1) 
matrix B = (.,0\0,.) 
 
N.B. The B matrix places restrictions on the error structure and usually 
takes the form above. 
 
To run preliminary SVAR model: 
svar input output, aeq(A) beq(B)  
 
N.B. variables in SVAR command have to be in same order as in A-matrix 
 
To work out lags required using information criteria:  
varsoc 
 
To include exogenous variables:  
svar input output, aeq(A) beq(B) lags(1/2) exog(exogvar) 
 
To check for autocorrelation in the model: 
varlmar 
 
N.B. Evidence of the presence of autocorrelation suggests a greater 
number of lags is needed. 
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To check stability (stationarity of the model): 
varstable 
 
To check whether model errors are normally distributed: 
varnorm 
 
To obtain tables and graphs of IRF and CIRF: 
matrix sig_var=e(Sigma) 
matrix list sig_var                                                               
matrix chol_var=cholesky(sig_var) 
matrix list chol_var 
 
irf set irf, replace 
irf create name, step(12) 
irf graph oirf, impulse(input) response(output)                    
irf table oirf, impulse(input) response(output) 
irf table coirf, impulse(input) response(output) 
irf graph coirf, impulse(input) response(output)  
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9.5 R code for segmented regression analysis 
To read in data: 
dat<- read.csv("/Volumes/data.csv") 
dat[1:100,] 
To draw time plot of data: 
par(mfrow=c(1,1)) 
plot(dat$time, dat$series,type="l") 
To fit linear model with predictors: time, level change, slope change: 
mod1<- lm(series ~(time + level + slope),data=dat) 
summary(mod1) 
To plot model residuals: 
hist(residuals(mod1), main="Model residuals") 
resi<- residuals(mod1) 
plot(dat$time,resi,type="b", main="Residuals over time") 
abline(h=0) 
To draw an autocorrelation function (ACF): 
acf(resi, main="Residual ACF") 
To draw a partial autocorrelation function (PACF): 
pacf(resi, main="Residual PACF") 
To model smooth seasonality with gam + time + level + slope: 
library(mgcv) 
mod2<- gamm(series~time+slope+s(month),data=dat) 
summary(mod2$gam) 
To model smooth seasonality with gam + time + level + slope + MA(2) 
errors: 
library(mgcv) 
mod2<- gamm(series 
time+level+slope+s(month),data=dat,correlation=corARMA(c(0.5, 
0.5),p=0,q=2)) 
summary(mod2$gam) 
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9.6 Results of sensitivity analyses for Chapter 5 
Table 9-2. Results of ARIMA time series analysis of the impact of 
varenicline on prescribing of smoking cessation medication using 
doubled rates of prescribing of varenicline 
 Change in prescribing 95% CI p-value 
Introduction of 
varenicline  
0.06 -4.07-
4.19 
0.977 
Publication of 
varenicline guidance 
-2.14 -7.15-
2.87 
0.403 
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Table 9-3. Results of ARIMA time series analysis of the impact of varenicline on prescribing of smoking 
cessation medication omitting the final months of the time series 
 NRT Bupropion 
Introduction of 
varenicline 
Publication of 
varenicline guidance 
Introduction of 
varenicline 
Publication of 
varenicline guidance 
End of 
time 
series 
Change in 
prescribing 
(%) 
p-value Change in 
prescribing 
(%) 
p-value Change in 
prescribing 
(%) 
p-value Change in 
prescribing 
(%) 
p-value 
Jul-07 3.80 0.013 - - 8.10 <0.001 - - 
Aug-07 2.90 0.056 -28.16 1 6.64 0.004 -40.75 1 
Sep-07 0.93 0.53 -29.17 0.805 3.55 0.097 -39.74 0.187 
Oct-07 1.54 0.382 -20.23 <0.001 -0.17 0.948 -27.61 <0.001 
Nov-07 -2.50 0.171 -16.99 <0.001 -1.96 0.477 -23.66 <0.001 
Dec-07 -2.83 0.119 -14.80 <0.001 -2.76 0.316 -20.20 <0.001 
Jan-08 -3.81 0.033 -13.55 <0.001 -3.88 0.155 -19.13 <0.001 
Feb-08 -3.29 0.055 -11.24 <0.001 -4.18 0.123 -17.59 <0.001 
Mar-08 -3.57 0.034 -10.67 <0.001 -4.19 0.117 -16.05 <0.001 
Apr-08 -2.39 0.148 -8.63 <0.001 -3.00 0.236 -13.29 <0.001 
May-08 -2.49 0.121 -7.56 <0.001 -3.93 0.090 -13.34 <0.001 
Jun-08 -2.70 0.086 -6.47 <0.001 -3.86 0.089 -12.99 <0.001 
Jul-08 -2.84 0.066 -6.24 <0.001 -3.97 0.071 -12.86 <0.001 
Aug-08 -2.42 0.112 -5.51 0.002 -2.87 0.175 -9.83 <0.001 
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 NRT Bupropion 
Introduction of 
varenicline 
Publication of 
varenicline guidance 
Introduction of 
varenicline 
Publication of 
varenicline guidance 
End of 
time 
series 
Change in 
prescribing 
(%) 
p-value Change in 
prescribing 
(%) 
p-value Change in 
prescribing 
(%) 
p-value Change in 
prescribing 
(%) 
p-value 
Sep-08 -1.11 0.491 -4.12 0.018 -1.76 0.373 -6.54 0.005 
Oct-08 -0.86 0.601 -3.59 0.041 -1.56 0.426 -5.30 0.022 
Nov-08 -0. 75 0.644 -3.62 0.036 -1.74 0.361 -5.06 0.028 
Dec-08 0.25 0.883 -2.34 0.104 -0.77 0.652 -3.29 0.102 
Jan-09 0.15 0.927 -2.51 0.067 -1.30 0.403 -3.69 0.045 
Feb-09 -0.27 0.864 -2.82 0.028 -1.09 0.474 -3.19 0.08 
Mar-09 0.25 0.870 -2.34 0.059 -0.88 0.552 -2.76 0.13 
Apr-09 -0.16 0.914 -2.26 0.066 -0.83 0.574 -2.55 0.163 
May-09 -0.25 0.861 -2.20 0.071 -1.19 0.399 -2.90 0.093 
Jun-09 -0.31 0.828 -1.78 0.159 -1.17 0.401 -2.80 0.108 
Figures in bold: Significant at the 5% level 
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9.7 Impact of media campaigns on smoking cessation activity: 
descriptive analysis 
This report was written for ASH UK, and informed the subsequent 
proposal for the study described in Chapter 7, which was funded by the 
Cancer Research UK Tobacco Advisory Group. 
9.7.1 Background 
International evidence has shown that anti-tobacco mass media 
campaigns can increase smoking cessation and reduce smoking 
prevalence.82-87 However, the existing studies are heterogeneous, in terms 
of both the nature and intensity of the media campaigns and the 
populations studied, and the quality of the studies is variable.293 Many 
studies have difficulty in distinguishing the impacts of media campaigns 
from those of other tobacco control policies that tend to occur 
concurrently, as well as other broad secular trends in smoking 
behaviour.293 Furthermore, very few peer-reviewed academic studies have 
looked at the effectiveness of mass media campaigns in the UK; as such 
there is a dearth of UK-specific evidence.173, 272-274 In the light of current 
public spending cuts, which threaten media spend on tobacco control, 
there is a need for evaluation of the effect of anti-tobacco advertising 
campaigns to be carried out in the UK.  
The two main types of anti-tobacco advertising campaigns in the UK 
are government- or charity-funded anti-tobacco campaigns and 
pharmaceutical company-funded campaigns advertising smoking cessation 
medication. Government-funded anti-smoking mass media campaigns in 
the UK have conveyed the dangers of smoking and secondhand smoke, the 
implementation of smokefree legislation and smoking cessation services, 
with the aim of changing smoking behaviour. Some are targeted directly at 
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encouraging people to quit and try to help to enable quit attempts by 
DGYHUWLVLQJ WKH VHUYLFHV DYDLODEOH WR VXSSRUW SHRSOH¶V TXLW DWWHPSWV
Advertisements for nicotine replacement therapy (NRT) provide 
information on different types of NRT with the primary aim of increasing 
sales of NRT. However, by also conveying the health benefits of quitting, 
these adverts may also increase the number of people who want to quit 
smoking and influence quitting behaviour. Cuts in government funding 
seem likely to place greater reliance on pharmaceutical company-funded 
campaigns, and it is therefore important to consider the relative impact of 
both types of spend.  
 The aim of this study is to carry out a descriptive analysis, 
comparing monthly changes in advertising and a range of measures of 
quitting behaviour, to explore the possible association between these two 
types of anti-tobacco mass media campaigns and indicators of quitting 
behaviour, including calls to the NHS quitline, prescribing and over-the-
counter (OTC) sales of nicotine replacement therapy (NRT), quit attempts 
and brief stop smoking advice given by GPs. This will guide and inform 
subsequent formal statistical work to model these associations by 
highlighting the measures of quitting behaviour most likely to be influenced 
by mass media campaigns. This work should not be considered to provide 
conclusive evidence of the effectiveness (or non-effectiveness) of anti-
tobacco campaigns, but as a vital precursor to subsequent work
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9.7.2 Aims and Objectives 
The aim of this report is to explore whether changes in the level of 
anti-tobacco campaigns may influence changes in smoking cessation 
behaviour in England. The specific objectives of this work are 
x to compare descriptively changes in measures of advertising 
reach of anti-tobacco campaigns funded by the Department of 
Health and changes in measures of quitting behaviour  
x to compare descriptively changes in measures of advertising 
reach of anti-tobacco campaigns funded by pharmaceutical 
companies and changes in measures of quitting behaviour  
9.7.3 Methods 
Exposure Data 
This study uses a standard broadcasting industry measure of the 
audience which views a television programme or advert, television ratings 
points (TVRs), as its measure of exposure to anti-tobacco mass media 
advertising and smoking cessation medication advertising. A TVR is defined 
as the percentage of a particular audience that has seen a commercial 
break. TVRs represent the total TVRs for a given area (such as the whole 
of the UK), and are calculated using population-weighted TVRs from each 
television region. They are therefore weighted for different levels of 
advertising in different regions. The measures of exposure to advertising 
are:  
x TVRs purchased for tobacco control campaigns by the Central 
Office of Information (COI), Cancer Research UK and the British 
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Heart Foundation each month from January 2002 to May 2010, 
and  
x TVRs purchased by pharmaceutical companies to advertise 
nicotine replacement therapy each month from January 2005 to 
December 2009.  
The data from COI used in this study includes all mass media 
campaigns related to smoking, including those targeting young people and 
related to smokefree legislation. 
Advertising spend data are also available. For this study, TVR data 
were selected over spend data, as these ought to provide a more accurate 
representation of exposure to campaigns. However, spend data were 
compared with TVR data to ensure that there would be no significant 
differences in the results depending on the exposure used. 
Due to devolved responsibilities for health promotion media 
campaigns in the UK, the COI TVR data cover primarily cover England only, 
with some overlap into other home nations through advertising in the 
press. The data used in this study are for England and Wales only; the 
TVRs overlapping into Scotland and Northern Ireland have been removed, 
but those for Wales cannot be removed, due to overlapping television 
regions. The pharmaceutical company TVR data are available for the whole 
of the UK but, to allow better comparison with the government-funded 
campaign data, only data on England and Wales have been used in this 
study. The TVRs for England and Wales have been calculated by summing 
population-weighted values of TVRs for each television region in England 
and Wales.  
Outcome data 
 247 
 
This study uses five outcome measures which seem likely to be 
sensitive to changes in advertising exposure. 
x Calls to the NHS quitline 
x Prescribing of NRT, based on primary care data 
x OTC sales of NRT 
x Quit attempts, based on survey data 
x Brief stop smoking advice given in primary care, based on 
primary care data 
Calls to the helpline and NRT prescribing and OTC sales appear to 
be the measures most likely to be sensitive to changes in anti-tobacco 
advertising and smoking cessation medication advertising respectively. 
However, in order to better compare the impact of both types of media 
campaigns, we will explore, descriptively, the effect of both types of 
advertising on each of these outcomes, as well as their effect on brief 
advice and quit attempts. 
The quitline calls and quit attempts data are available only for 
England. The primary care data are UK-wide, but, for consistency with the 
exposure variables, which cover England and Wales, we have identified and 
used prescribing data from within England and Wales. The OTC sales data 
cover England, Wales and Scotland; they are not available for Northern 
Ireland. They are broken down by region (although the sales in Wales 
cannot be separated from those in South West England), therefore we 
have used OTC NRT sales data on England and Wales for consistency with 
the exposure variables.  
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Quitline calls 
Quitlines have been shown to be effective in helping smokers quit, 
and quitline calls are therefore an important measure of smoking cessation 
activity.173-175 Many of the government funded mass media campaigns 
have included the NHS quitline number, and are therefore likely to have 
influenced calls to the quitline. This study uses the number of calls the NHS 
quitline per month from November 2004 to June 2010. 
Prescribing of NRT and brief stop smoking advice 
Both NRT and brief physician stop smoking advice have been shown 
to be effective in aiding smoking cessation.126, 186 The Health Improvement 
Network (THIN) is a database of UK primary care records including all 
diagnoses and prescriptions recorded on all patients in nearly 500 practices 
throughout the UK, including 367 practices in England. It contains 
smoking-related data including prescribing of smoking cessation 
medication and brief stop smoking advice. These data have been extracted 
on a monthly aggregate basis in the Nottingham Tobacco Control 
Database, a compilation of sources of smoking-related information at a 
national level. The denominator for each month is the total number of live 
individuals contributing data to the THIN database throughout each month. 
We assumed that those contributing data within each month provided one 
person-month of follow-up, and divided the numbers of prescriptions by 
the total person months to derive the rate of prescribing and brief advice 
giving per 100,000 of the population per month from January 2002 to June 
2009.  THIN NRT prescription data have been validated in a previous 
study.192 
NRT over-the-counter sales 
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OTC NRT has been used as an indicator of quitting activity and 
increases in sales may therefore increase the number of people quitting.135, 
164, 294 The OTC sales data used in this study are Electronic Point of Sales 
scanner data obtained from Information Resources Inc. (IRI, now 
Symphony IRI).166 It includes data from all stores except Boots stores. IRI 
data are supplied as 4-weekly summaries. To convert these to monthly 
equivalents, it was assumed that 1/28th of sales occur on each day in each 
4-week period. We graphically compared these data with confidential sales 
data from GSK to ensure validity. The monthly population denominators for 
these data were calculated using the Office for National Statistics mid-year 
population estimates for England and Wales for each year, increasing by 
one twelfth of the annual increase per month.193 We divided the unit sales 
each month by the monthly population denominators to obtain the rate of 
sales per 100,000 population per month from November 2003 to 
September 2008. 
Quit attempts 
Quit attempts are evidently a vital measure of smoking cessation 
behaviour, and finding an effect of mass media campaigns on quit 
attempts would clearly be very valuable in arguing for the importance of 
such campaigns. This study uses monthly quit attempts data from The 
Smoking Toolkit, a monthly survey of around 500 smokers in England, 
which provides estimates of the proportion of smokers who have made a 
quit attempt in the past month each month since November 2006. This 
study uses data from November 2006 to December 2009.  
Analysis 
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The monthly advertising exposure and monthly outcome measures 
were compared graphically to compare monthly changes and try to identify 
possible associations between anti-tobacco campaigns and smoking 
cessation behaviour. All analysis was carried out in Stata Version 11.0. 
9.7.4 Results 
Trends in exposures 
Figure 9-3 shows government-purchased TVRs from January 2002 
to December 2009 and pharmaceutical company TVRs from February 2005 
to December 2009. 
COI TVRs  
There was no discernible trend in government-purchased TVRs 
during the study period, with much fluctuation from one month to the 
next. There were few months with no advertising. Campaigns appear to 
have been of longer duration until 2005, after which there was more 
fluctuation and months of zero spend until the latter part of 2008. TVRs 
were highest in January 2005 and 2010.  
Pharmaceutical company GRPs and spend on NRT advertising 
Pharmaceutical company TVRs for NRT advertising were 
characterised by peaks and troughs throughout the period. Most peaks in 
TVRs came in January. The largest peak was in July 2007, when smokefree 
legislation was implemented in England.
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Figure 9-3. Advertising exposure variables, January 2002-December 2009 
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Trends in outcomes 
Figure 9-4 shows plots of each outcome measure for the study 
period. 
Quitline calls 
There was a very large peak in quitline calls in January and 
February 2005, with around 70000 calls. The number of calls then levelled 
off at between 10 and 30 000 for the rest of the period. Seasonal peaks 
generally occurred in January to March each year. 
NRT prescribing 
NRT prescribing increased until 2005, and appears to have 
decreased in 2007. In most years there was a clear peak in prescribing in 
the first three months of the year and a much smaller peak in October. 
NRT OTC sales 
The level of OTC NRT sales changed little during the study period, 
with seasonal peaks of a similar magnitude in January to March each year. 
Sales in January tended to be approximately 50% higher than in the 
summer months. In July 2007, however, when smokefree legislation was 
introduced in England, sales were higher than in any other month during 
the study period. 
Quit attempts 
In each year there was a peak in quit attempts in January, 
coinciding with the New Year. The largest peak in the proportion of 
smokers making quit attempts was in January 2007. There were also 
smaller peaks in April each year, following No Smoking Day in March. 
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GP stop smoking advice 
Recorded brief stop smoking advice increased between January 
2002 and the start of 2004, before levelling off. Subsequently, brief advice 
fluctuated between around 750 to 1000 per 100,000 per month, with small 
peaks in the autumn of each year and large peaks in early 2007 and in 
March 2009. 
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Figure 9-4. Quitting behaviour outcome variables, January 2002-January 2010 
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Descriptive comparisons 
Advertising and quitline calls 
Figure 9-5 below shows the number of government-purchased and 
pharmaceutical company TVRs purchased and quitline calls made in 
England each month from November 2004 to May 2010. During this 
period, there was no upward or downward trend in either of the series. In 
most years government-funded TVRs were high in the first three months of 
the year, especially in January, and similar seasonality is observed in the 
quitline calls. The time series seem to rise and fall, to a large extent, 
together. Furthermore, the number of calls appears to be particularly low 
when few or no TVRs are purchased.  
Pharmaceutical company TVRs and quitline calls tended to show 
similar seasonal peaks in the early months of the year, but tended not to 
move together outside of the January to March period. 
There was only a small peak in quitline calls in July 2007, when 
TVRs for both types of anti-tobacco campaign were high. 
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Figure 9-5. Comparison of trends: Anti-tobacco advertising and quitline calls, November 2004-December 2009 
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Advertising and NRT prescribing 
Figure 9-6 below shows the number of government-funded and 
pharmaceutical company TVRs purchased and rates of NRT prescribing 
each month. It is more difficult to identify a potential association between 
government-funded TVRs and prescriptions than between government-
funded TVRs and quitline calls (Figure 4). There is substantial movement 
together between the two time series; however, this is primarily seasonal 
variation and increased advertising and prescribing around the time of the 
introduction of smokefree legislation.  
The same is true for pharmaceutical company TVRs for NRT: there 
does not appear to be an increase in prescribing in months where there is 
more advertising, except those months associated with increased quitting 
behaviour. 
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Figure 9-6. Comparison of trends: Anti-tobacco advertising and NRT prescribing, January 2002-December 2009 
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Advertising and NRT OTC sales 
Figure 9-7 below shows the number of government-funded and 
pharmaceutical company TVRs purchased and monthly rates of OTC NRT 
sales. Government-funded TVRs and OCT NRT sales show similar seasonal 
trends, with peaks often in the early months of the year. In January 2006, 
there was no NRT advertising, yet a peak in sales comparable with those in 
other years. Aside from seasonal patterns and high TVRs and sales around 
the introduction of smokefree legislation, these variables tend not to rise 
and fall together. 
Pharmaceutical company TVRs and OTC NRT generally rise and fall 
together. There are peak in both January and July 2007, with frequent 
smaller peaks in both time series in other months. Sales are lowest in 
months with little or no advertising. 
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Figure 9-7. Comparison of trends: Anti-tobacco advertising and OTC NRT sales, November 2003-September 2009 
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Advertising and quit attempts 
Figure 9-8 below shows the number of government and 
pharmaceutical company-funded TVRs purchased and the proportion of 
smokers in England making quit attempts each month November 2006 to 
May 2010. Government-purchased TVRs and quit attempts both show 
seasonal peaks in January, and a peak around July 2007, when smokefree 
legislation was introduced. Over and above these similarities, these 
variables do not generally seem to move together. 
The results are very similar for pharmaceutical company advertising 
and quit attempts. 
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Figure 9-8. Comparison of trends: Anti-tobacco advertising and quit attempts, November 2006-December 2009 
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Advertising and brief advice 
 Figure 9-9 below shows the number of COI and pharmaceutical 
company TVRs purchased and the proportion of patients receiving brief 
stop smoking advice from their GP each month. There are similar 
fluctuations in the COI advertising and brief advice giving and low rates of 
advice giving in many of the months with little or no advertising spend. 
However, there was a low rate of brief advice in January 2005 despite a 
large peak in advertising, but in March 2009 there were large peaks in both 
advertising and brief advice. 
Pharmaceutical company TVRs and brief advice moved very closely 
together throughout the early part of the study period, until early 2008. 
More recently, peaks in brief advice have not occurred in months with high 
levels of advertising. In March 2009 there was a large peak in brief advice 
and no pharmaceutical company-purchased advertising. 
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Figure 9-9. Comparison of trends: Anti-tobacco advertising and brief advice giving, January 2002-June 2009 
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9.7.5 Discussion 
This report is the first step into important research exploring the 
effect of anti-tobacco mass media campaigns on smoking cessation 
behaviour. Mass media campaigns are an intervention which can reach 
whole populations at a low per capita cost, where small individual effects 
have the potential to have a substantial overall impact; therefore 
establishing their effects is important.81, 272 It is 10 years since the last 
peer-reviewed study of the effect of mass media campaigns on smoking 
behaviour in the UK was published.272 That study highlighted the sparsity 
of studies in this area, and yet there continues to be a dearth of UK-
specific evidence, although the literature on these campaigns in the USA 
and Australia has increased. This descriptive study is the first step in a 
study which will begin to fill the gap in the evidence for anti-tobacco mass 
media campaigns in the UK.  
Summary of results 
This study found that it seems likely that government-funded and 
pharmaceutical company-funded antismoking advertising have an impact 
on some aspects of quitting behaviour. All the outcomes displayed some 
similarities in trends to the exposures. For the most part, both outcomes 
and exposures were similar in terms of seasonality; the exposures and 
outcomes had comparable peaks in the early months of each year, when 
quitting behaviour has been shown to be highest.277 This may indicate an 
effect of advertising on quitting behaviour which is strongest in the early 
months of the year. However, it is possible that increased quitting 
behaviour in the early months of the year is independent of increased 
advertising. This means that where similarities in peaks and troughs of 
advertising and measures of quitting behaviour are only seasonal, there is 
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likely to be no true association between the aggregated measures of 
advertising used in this study and smoking cessation behaviour in England 
and Wales.   
It seems most likely that government-funded anti-smoking 
advertising has an effect on quitline calls and, possibly, brief advice giving 
by GPs, and that pharmaceutical company-funded advertising for NRT 
influences OTC NRT sales and again, possibly, brief advice giving, as these 
appear to demonstrate similarities in monthly fluctuations over and above 
seasonal peaks. 
Government anti-smoking advertising often contains the quitline 
number, and it is therefore unsurprising that quitline calls seems to be 
associated with advertising. Similarly, it is intuitive that NRT advertising 
should cause increases in OTC NRT sales and again, these are two time 
series that were similar. Perhaps more surprising, is the indication that 
brief advice may be influenced by advertising. If this is shown to be a true 
association, it perhaps indicates that some people obtain advice from their 
GP following advertising which has played a role in making them try to quit 
smoking. 
Study limitations 
This descriptive analysis is important, but has limitations which 
explain the need for detailed statistical analysis. The issues surrounding 
seasonality described above clearly highlight why descriptive analysis is 
not sufficient in exploring the effect of anti-tobacco advertising. It is not 
possible, using descriptive analysis, to adjust for seasonal effects (or 
confounders such as, for example, the introduction of smokefree legislation 
in July 2007, cigarette prices etc.), and it is therefore not possible to draw 
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conclusions as to the effect of mass media campaigns. It is therefore 
important to analyse these associations, particularly those which seem 
likely to be positive, using formal statistical analysis, which will enable us 
to adjust for these seasonal effects, as well as, to the extent that they can 
be accurately modelled, the effects of relevant confounders. Statistical 
analysis will also enable us to provide effect estimates, as well as exploring 
any lags in the effect of advertising on smoking cessation behaviour. 
Furthermore, due to a lack of detailed information as to the content 
of the various campaigns, it was not possible to explore the effects of 
different types of mass media campaigns in this study. It is important to 
consider that different mass media campaigns, particularly government-
funded ones, may differ substantially in their content. For example, they 
may aim to encourage smoking cessation or raise awareness of smokefree 
legislation or the dangers of passive smoking. These may have different 
effects on different measures of smoking cessation behaviour. The impact 
of such differences may be reflected in this analysis. For example, a peak 
in government-funded advertising did not coincide with a peak in brief 
advice in January 2005, but both were high in March 2009. The differential 
effects of different types of studies have been demonstrated in previous 
studies. For example, studies have shown that the number of quitline calls 
generated by advertising varied depending on the content of the 
adverts.278, 279, 295, 296 Furthermore, there may be differential effects of 
campaigns in different sociodemographic groups, different types of media 
channels and of adverts shown on different channels and different times of 
day, as suggested by existing evidence.278, 297 Both this study and the 
forthcoming statistical analyses of these data are likely to underestimate 
the effect of mass media campaigns in that they are unable to distinguish 
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between different types of campaigns, some of which may be more 
effective than others; if a positive effect of aggregated TVRs is found at 
this early stage, which seems likely, it will likely be obscuring a larger 
effect of particular campaigns. 
A further analysis which should be carried out is a study which 
examines the effect of mass media campaigns on a regional basis. 
Advertising intensity varies across the country, partly due to variations in 
smoking behaviour (e.g. smoking prevalence). Analysis on a national level 
cannot pick up regional variation in the impact of anti-smoking campaigns, 
and may obscure the impact of mass media campaigns due to the inclusion 
of regions with little advertising and hence, little impact on cessation 
behaviour. 
While this work, and subsequent statistical analyses of the data 
available, which will be carried out in 2011 in the context of the CRUK 
Tobacco Advisory Group-funded project, provide vital information, more 
detailed analysis exploring these differential effects in the future is crucial. 
Selection of outcomes 
An important public health outcome related to smoking and 
smoking cessation is smoking prevalence, and previous international 
evidence suggests that mass media campaigns can reduce this.82 Ideally, 
therefore, this study would have used smoking prevalence as an outcome. 
However, the outcome measures use in this study were selected based on 
their availability on a monthly basis, likely or demonstrated validity, and 
likely sensitivity to changes in anti-tobacco mass media campaigns. Based 
on this, it is not possible, to include smoking prevalence as an outcome 
measure. Monthly prevalence data are available from THIN, but are likely 
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to be unreliable on a monthly basis and insufficiently sensitive to monthly 
changes in advertising exposure. Annual prevalence estimates are 
available from the General Household Survey (the most frequently cited 
source of UK prevalence estimates) and THIN (valid from 2006).259 
However, there are substantial limitations to using annual prevalence data 
to answer this research question. It restricts the number of data points 
(making statistical models less robust) and makes it more difficult to take 
account of the many other factors that may affect changes in prevalence 
over time, such as tobacco advertising bans, health warnings and 
smokefree legislation. Further to this, annual data may not be able to 
detect small or transient impacts on smoking prevalence which are the 
result of interventions being implemented at varying intensities during the 
year, thus leading to underestimated effects of campaigns.82 This study 
and subsequent statistical analysis therefore have the disadvantage of not 
being able to study the impact of mass media campaigns on prevalence; 
however, by using other monthly outcomes, the impact of mass media 
campaigns can be more accurately explored, in terms of the lag time to 
impacts and the duration of impacts. 
Given that it is not possible to use smoking prevalence as an 
outcome measure in this study, quit attempts are a potentially crucial 
outcome. Quit attempts ought to be related to smoking cessation, and may 
be more sensitive to changes in advertising than smoking prevalence. 
Unfortunately, few monthly data on quit attempts in the UK are available. 
This study uses data from the Smoking Toolkit, and the descriptive 
analysis suggests that it is unlikely that aggregated TVRs of either 
pharmaceutical company or government-funded advertising will be shown 
to have an effect on this measure of quit attempts. However, this may be 
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due the limitations of the outcome data. The monthly sample size is small 
(around 500), and as such the monthly estimates are prone to substantial 
error, thus making them less accurate on a monthly basis. Furthermore, 
these data start in November 2006, when the imminent implementation of 
smokefree legislation may have influenced quit attempts. Due to the 
brevity of the time series and lack of pre-smokefree legislation data, it is 
unlikely to be possible to adequately take account of its effect. Due to 
these limitations, it is not appropriate to rely on these quit attempts data 
in investigating the effect of anti-smoking advertising. Proxy markers of 
quitting behaviour used in this study, such as prescribing and OTC sales of 
NRT, which may be more sensitive to changes in anti-tobacco advertising, 
are therefore extremely important.  
This is one of the reasons why this study included prescribing and 
OTC sales of NRT, brief stop smoking advice in primary care and quitline 
calls, as well as quit attempts, as outcome measures. Further to this, they 
are, as described in the methods section, important indicators of smoking 
cessation, and including multiple indicators can also help to elucidate 
pathways to quitting. The measures we have used come from large-scale 
data sources, and therefore confidence intervals around the monthly 
estimates ought to be narrow. The use of large-scale and population level 
data is particularly valuable for the evaluation of anti-tobacco mass media 
campaigns, as small effects may be expected at the individual level. Also, 
because these data are routinely collected, we have been able to obtain 
several years of monthly data. We therefore feel that we have selected 
measures which, though not ideal, are the best possible measures 
available for use in this type of study in the UK. 
Comparison with previous research  
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The most likely potential associations appear to be between 
government advertising and quitline calls and between pharmaceutical 
advertising and OTC NRT sales. This is unsurprising, as these are the 
outcomes most directly linked with these exposures. This is also consistent 
with existing evidence. Several studies have demonstrated an association 
between anti-smoking campaigns and calls to quitlines.173, 278-281, 296-302 
Studies have shown that pharmaceutical company advertising for NRT can 
have a positive effect on OTC NRT sales, although advertising did not 
increase demand for all products studied.82, 89 However, although studies 
have found increased sales of NRT, there is a moral hazard in NRT 
advertising which may counteract the benefits of increased NRT sales, and 
the effects of which may not be detected by looking at NRT sales alone. 
NRT advertising may lead people to the belief that quitting is easy, and 
may therefore encourage people to take up smoking, or encourage existing 
smokers to smoke more or delay quit attempts.303 This is reflected in a 
study which looked at the effect of NRT advertising on youth smoking.303 It 
found that although NRT advertising had no effect on the uptake of 
smoking (although this may have been due to both an increase in initiation 
of smoking and in cessation), it increased cigarette consumption in existing 
smokers, with an elasticity of 0.1. In the future it will be important to look 
at the differential effect of NRT advertising on different age groups, as its 
net effect on public health may be negative. 
Study implications 
The public health implications of this study then, are unclear; given 
the seasonal and policy factors influencing both exposures and outcomes, 
it is not possible to clearly gauge the effect of either government 
advertising campaigns or pharmaceutical company mass media campaigns 
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for NRT on any of the outcomes. It is highly likely, however, that there is 
an effect of government advertising on quitline calls and of pharmaceutical 
companies advertising on OTC NRT sales. It is therefore appropriate to 
focus on these as a next step, with a view to much more comprehensive 
analysis, taking into account all the issues mentioned above, in the future. 
9.7.6 Conclusions 
This descriptive analysis has demonstrated that it is highly likely 
that anti-smoking mass media campaigns have an effect on at least some 
indicators of smoking cessation behaviour. The statistical analysis funded 
E\&DQFHU5HVHDUFK8.¶V7$*JUDQWWREHFDUULHGRXWIURP0DUFKWKLV\HDU
will be helpful in using more robust statistical techniques to examine these 
relationships further. Together, these two pieces of work will be vital in 
increasing the evidence base for the effectiveness of anti-tobacco 
campaigns in the UK, and will, we hope, trigger further work in this 
complex and multi-faceted tobacco control policy area. 
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9.8 Validation of mass media TVR data against advertising spend 
data 
 
Figure 9-10. Comparison of tobacco control TVR and spend data 
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Figure 9-11. Comparison of pharmaceutical company TVR and 
spend data 
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9.9 Tobacco price, affordability and smoking prevalence in the 
UK 
The analysis for this study was conducted by Dr Casey Quinn, based 
on the procedure for SVAR modelling I have used in Chapter 7. Casey 
Quinn wrote the first draft, and I prepared the final manuscript which has 
now been submitted for publication. The following abstract has been 
accepted for presentation at the World Conference on Tobacco or Health 
2012. 
Background 
There is consistent evidence that increasing cigarette prices can 
reduce the prevalence of cigarette smoking. However, demand for tobacco 
products is only slightly responsive to price changes. The most recent 
peer-reviewed UK study examining the relationship between tobacco price 
and smoking found that men and women in lower socioeconomic groups 
were more responsive to changes in cigarette prices than higher 
socioeconomic groups. However, this study pre-dates significant tobacco 
pricing policies, notably the tobacco tax escalator that was implemented 
between 1993 and 2001. Given the recent re-introduction, in 2011, of 
above-inflation tobacco taxation in the UK, we re-examined the association 
between price and prevalence by sex and socioeconomic group before, 
during and after this policy was last in place. 
Methods 
We used Structural Vector Autoregressive (SVAR) modelling of time 
series data on adult smoking prevalence and different measures of tobacco 
affordability: a tobacco price index, a relative tobacco price index and a 
tobacco affordability index. We ran SVAR models for both sexes, manual 
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and non-manual groups, the three price and affordability indices and three 
time periods (1972-1992, 1993-2010 and 1972-2010). 
Results 
Our results from the 1972-1992 period are consistent with 
previously published studies. They show that tobacco prices are negatively 
associated with smoking prevalence, even though smoking overall is 
relatively inelastic with respect to price and income. Thus, while increases 
in price and decreases in affordability reduce prevalence, the effect is 
typically very small. The 1972-1992 period effects were not observed in 
the latter period; in most models, for the period 1993-2010, there was no 
statistically significant association between price and prevalence, indicating 
that elasticity has weakened further. 
Likely explanations for this are that individuals adapted to 
increasing tobacco prices by using other forms of cheaper tobacco such as 
hand-rolled tobacco or forms of illicit tobacco such as smuggled or 
counterfeit, which increased in prevalence in the 1990s. A comprehensive 
strategy introduced to reduce tobacco smuggling introduced by the UK 
government in 2000 and strengthened at intervals since then has resulted 
in the market share for illicit cigarettes reducing; the proportion of 
smokers using hand-rolled tobacco has, however, continued to increase. 
Conclusions  
Smoking behaviours should be monitored closely and in a timely 
manner to establish the response of smokers to the price increases that 
will result from the recently re-introduced tobacco tax escalator. Measures 
to control smuggling and counterfeit cigarettes must also be maintained to 
ensure that the expected health benefits are realised.
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9.10 Training 
Epidemiology of Tobacco Use and the Tobacco Industry, 01-05/02/2010 
(7.5 credits) 
Tobacco Control Interventions, 07-11/06/2010 (7.5 credits of which 2.5 
may contribute to postgraduate training programme) 
Faculty Postgraduate Research Forum (Medicine and Health Sciences 
Faculty), 16/06/2010 (4 credits) 
Creating and managing long documents in Microsoft Word, 25/10/2010 (2 
credits) 
Essential information skills for new researchers in Medicine and Health 
Sciences, 03/11/2010 (1 credit) 
What do I want to get out of a conference ± and how do I do it? 
16/11/2010 (1 credit) 
Using posters to communicate research, 25/11/2010 (1 credit) 
Getting going on your thesis, 07/12/2010 (2 credits) 
Finishing your thesis, 07/07/2011 (1 credit) 
Preparing for the viva, 16/11/2011 (1 credit) 
 
9.11 Grants 
Langley T (Principal Investigator), Lewis S, McNeill A, Arnott D, Sims M. 
The impact of media campaigns on smoking cessation activity.  Cancer 
Research UK Tobacco Advisory Group Project Grant. £15,428.33. March-
August 2011. 
 
9.12 Presentations 
Invited presentations 
Invited to give UK National Smoking Cessation Conference plenary 
SUHVHQWDWLRQHQWLWOHGµ0DVV0HGLD&DPSDLJQV¶%LUPLQJKDPth-19th June 
2012 
Conference presentations 
The use of primary care data to monitor smoking prevalence and supply of 
smoking cessation medication. Oral presentation, UK Society for 
Behavioural Medicine/National Prevention Research Initiative Annual 
Scientific Meeting, Southampton, 14th-15th December 2009.  
 
Prescribing of smoking cessation medication since the introduction of 
varenicline. Oral presentation, UK National Smoking Cessation Conference, 
Glasgow, 14th-15th June 2010.  
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Prescribing of nicotine replacement therapy in adolescents in England. Oral 
presentation, Society for Academic Primary Care Annual Scientific Meeting, 
Norwich, 7th-9th July 2010. 
 
Prescribing of smoking cessation medication in England since the 
introduction of varenicline. Poster presentation, Annual Meeting of the 
SRNT Europe, Bath, 6th-9th September 2010. 
 
Prescribing of smoking cessation medication in England since the 
introduction of varenicline. Oral presentation, UK Society for Behavioural 
Medicine/National Prevention Research Initiative Annual Scientific Meeting, 
Leeds, 14th-15th December 2010. 
 
Prescribing of nicotine replacement therapy in adolescents in England. Oral 
presentation, European Conference Tobacco or Health, Amsterdam, 
Netherlands, 28th-30th March 2011. 
 
The impact of anti-tobacco mass media campaigns: feedback from a 
VPRNHUV¶ SDQHO Oral presentation, UK National Smoking Cessation 
Conference, London, 13th-14th June 2011. 
 
Prescribing of nicotine replacement therapy to cardiovascular disease 
patients in England.  Poster presentation, Annual Meeting of the SRNT 
Europe, Antalya, Turkey 8th-11th September 2011. 
 
Regional smoking prevalence and quitting behaviour in the UK: Validation 
of The Health Improvement Network primary care data. Poster 
presentation, Annual Meeting of the SRNT Europe, Antalya, Turkey 8th-11th 
September 2011. 
 
Tobacco control or pharmaceutical companies ± Whose mass media 
campaigns have a bigger impact on quitting behaviour? Poster 
presentation, Annual Meeting of the SRNT Europe, Antalya, Turkey, 8th-11th 
September 2011. 
 
A comprehensive evaluation of the impact of English tobacco control policy 
on smoking cessation activities: Results and lessons learned. Poster 
presentation at 7th Annual Scientific Meeting of the UK Society for 
Behavioural Medicine, Stirling, 13th-14th December 2011. 
 
A comprehensive evaluation of the impact of English tobacco control policy 
on smoking cessation activities: Outcomes and lessons learned. Accepted 
for poster presentation at World Conference on Tobacco Or Health, 
Singapore, 20th-24th  March 2012.  
 
Tobacco control or pharmaceutical companies ± Whose mass media 
campaigns have a bigger impact on quitting behaviour? Accepted for oral 
presentation at World Conference on Tobacco Or Health, Singapore, 20th-
24th March 2012. 
 
Tobacco price, affordability and smoking prevalence in the UK. Accepted 
for poster presentation at World Conference on Tobacco Or Health, 
Singapore, 20th-24th March 2012. (senior author and presenting author) 
 
Using multiple time series analysis in public health research: An example 
using an evaluation of the impact of anti-tobacco mass media campaigns in 
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England and Wales. Accepted for oral presentation at Population Health ± 
Methods and Challenges Conference, Birmingham 24th-26th April 2012. 
 
 
Other presentations 
A comprehensive evaluation of the impact of English tobacco control policy 
on smoking cessation activities: Background and early findings, Tobacco 
research group monthly meeting, 12th April 2010 . 
A comprehensive evaluation of the impact of English tobacco control policy 
on smoking cessation activities: Background and early findings, UK Centre 
for Tobacco Control Studies postgraduate conference 2010, 20th April 
2010. 
Prescribing of nicotine replacement therapy to adolescents in England, UK 
Centre for Tobacco Control Studies postgraduate conference 2010, 21st 
April 2010 (poster presentation). 
Evaluating the impact of English tobacco control policies on quitting 
behaviour, Epidemiology and Public Health Divisional Seminar, 14th 
February 2011. 
Evaluating the impact of English tobacco control policies on quitting 
behaviour, Health Economics Research @ Nottingham (HER@N) seminar, 
15th March 2011. 
Impact of mass media campaigns on smoking cessation, UK Centre for 
Tobacco Control StudieV6PRNHUV¶3DQHO%DWKth March 2011 
Evaluating the impact of English tobacco control policies on quitting 
behaviour, UK Centre for Tobacco Control Studies Postgraduate Student 
Conference, 21st-22nd November 2011. 
 
9.13 Publications arising 
Langley T, Szatkowski L, Gibson J, et al. Validation of The Health 
Improvement Network (THIN) primary care database for monitoring 
prescriptions for smoking cessation medications. Pharmacoepidemiology 
Drug Safe 2010;196(6):586-90. 
 
Langley T, Huang Y, McNeill A, et al. Prescribing of smoking cessation 
medication in England since the introduction of varenicline. Addiction, 
2011;106(7):1319±24.  
 
Langley T, Huang Y, McNeill A, et al. Response to Kotz et al. (2011): 
Estimating the rate of usage of varenicline and other medication for 
smoking cessation. Addiction, 2001; 106(10):1869. 
 
Langley T, Huang Y, McNeill, et al. Prescribing of nicotine replacement 
therapy in adolescents in England. Addiction, 2011;106(8):1513-1519. 
 
Langley T, Szatkowski L, McNeill A, et al. Prescribing of nicotine 
replacement therapy to cardiovascular disease patients in England. 
Addiction (in print). 
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Langley T, McNeill A, Lewis S, et al. The impact of media campaigns on 
smoking cessation activity: a 
structural vector autoregression analysis. (submitted)
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